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ABSTRACT 
 
Canarium patentinervium Miq. belongs to the family of Burseraceae best known for 
producing resins of economic, medicinal, and cultural values such as frankincense, 
myrrh, and copal. This family consists of 18 genera and 700 species of trees. In the 
Asia-Pacific region, about 20 species of Burseraceae are used to treat haemorrhoids, 
heal wounds and to treat skin infections. This plant has been used to heal wounds 
amongst the indigenous people of Malaysia. Furthermore no pharmacological and 
phytochemical studies have been reported on this species. This study was undertaken 
to screen the phytochemical and pharmacological aspects of this plant. Qualitative 
phytochemical properties of the crude extract was determined for the presence of 
tannins, flavonoids, alkaloids, saponins or sterols. Phytochemical analysis of 
Canarium patentinervium Miq. revealed presence of tannins and flavonoids in the 
ethanol extract of leaves and barks. Bioassay guided fractionation led to isolation of 
eight secondary metabolites by chromatography which were identified by NMR 
techniques. Two coumarins (scopoletin and scoparone), five phenols (cynaroside, 
hyperin, (+)-catechin, lioxin and syringic acid) and a norsesquiterpene with 
cyclohexenone ring (vomifoliol). The latter three compounds were isolated for the 
first time from the genus Canarium. The plant and the isolated compounds were then 
subjected to six biological assays comprising of antibacterial, antioxidant, anticancer, 
anti-inflammatory, anti-acetylcholinesterase and anti-parasitic activities. Infectious 
diseases remain the leading cause of death worldwide and bacteria have become more 
resistant to conventional antibiotic and the search for novel antimicrobial agents from 
medicinal plants has become crucial. Antibacterial test was done using disc diffusion 
method, minimum inhibitory concentration (MIC), minimum bactericidal 
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concentration (MBC) and death kinetic assay with ampicillin as the positive control. 
The ethanol extract of leaves and the hexane extract of bark displayed remarkable 
antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria. 
All isolated compounds tested against S.aureus ATCC 11632 showed bacterial 
growth inhibition. Scopoletin, scoparone, hyperin, cynaroside and syringic acid had 
bactericidal effect <100 µg/ml. Only scopoletin had bactericidal effect and complete 
kill at MBC 50.00 µg/ml.  Bacterial infections have been known to generate extensive 
formation of free radicals which is becoming increasingly recognized in the 
pathogenesis of the many human diseases. The role of free radicals and active oxygen 
is becoming increasingly recognized in the pathogenesis of the many human diseases, 
including cancer, neurodegenerative diseases, ageing, and atherosclerosis. Five 
various antioxidant assays with different mode of action [2, 2-diphenyl-1-
picrylhydrazyl (DPPH) and 2, 2'-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) 
(ABTS), ferric reducing antioxidant power (FRAP), く-carotene bleaching assay and 
superoxide dismutase (SOD) assay] were used to test the antioxidant scavenging 
abilities of this plant. Vitamin C (L-ascorbic acid), quercetin and trolox were used as 
positive controls. The ethanol extract of leaves and barks displayed superior 
antioxidant capacities. The EC50 values of the samples were consistently low in SET 
methods (ABTS, DPPH and FRAP) superior to standard as opposed to HAT method 
*く-carotene bleaching assay). Hyperin and (+)-catechin exhibited the most consistent 
free radical scavenging capability across the five antioxidant assay. Hyperin and (+)-
catechin have significantly lower IC50 (0.75±0.03 µg/ml and 0.94±0.27 µg/ml 
respectively) compared to SOD enzyme (IC50 1.59±04 µg/ml). Scopoletin exhibited 
potent antioxidant activity compared to scoparone with significantly lower EC50 
values in ABTS (IC50 1.08±0.03 µg/ml) compared to ascorbic acid (EC50 1.54±0.03 
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µg/ml) and lower values in FRAP assay (FRAP value 49.00±0.64 µg/ml) than 
quercetin (FRAP value 86.00±0.24 µg/ml) and ascorbic acid (FRAP value 
347.00±0.23 µg/ml). Xqokhqnkqn" jcf" rqvgpv" く-carotene bleaching activity with IC50 
6.85±0.37 µg/ml. Infections and free radical generation are recognized in the 
pathogenesis of cancer. The ethanol and chloroform extract of barks showed 
significant anticancer activities with GI50 values of 34.40µg/ml and 23.44µg/ml. The 
most susceptible cell lines were found to be the breast cancer cell line, MDA 468. 
Scopoletin displayed potent anticancer effect against breast cancer cell line MDA 468 
(GI50 0.09±0.25 µg/ml) and colorectal cancer cell line HT-29 (GI50 0.17±0.05 µg/ml), 
the latter being more significant that positive control doxorubicin (GI50 0.66±0.60 
µg/ml). In recent years, roles have been identified for several inflammatory cells and 
for a large number of inflammatory mediators in important pathologies not previously 
linked to inflammation, such cu" Cn¦jgkogtÓu" fkugcug" cpf" ectfkqxcuewnct" fkuqtfgtu"
including atherosclerosis, as well as cancer. Recently, reports have appeared 
regarding so-ecnngf" Ðfwcn" kpjkdkvqtu.Ñ" cigpvu" vjcv" kpjkdkv" pqv" qpn{" cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2), but also 5-lipoxygenase (5-LOX). 
Chloroform extract of the barks had the lowest 5-LOX inhibition (IC50=29.53±0.0 
5たi1on+" yjgp" eqorctgf" vq" PFIC" (IC50=4;03;ł2024" たi1on+0" Ethanol extract of 
leaves had superior COX-1 inhibition (IC50 = 0.60±0.01µg/ml) compared to COX-2 
inhibition (IC50 = 1.07±0.01 µg/ml), whereas the barks had superior COX-2 inhibition 
(IC50 = 9.39±0.03 µg/ml) as opposed to COX-1 (IC50 = 11.41±0.03 µg/ml). All 
isolated compounds exhibited significantly lower 5-LOX inhibition than NDGA. 
Scopoletin and scoparone were potent inhibitors of 5-LOX recording lowest IC50 
values (IC50 0.34±0.01 µg/ml and 0.20±0.01 µg/ml respectively). However (+)-
catechin had a more comprehensive anti-inflammatory activity with dual inhibition of 
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5-LOX (IC50 16.10±0.03 µg/ml) and COX (COX-1; IC50 12.08±0.02 µg/ml, COX-2; 
IC50 83.89±0.03 µg/ml). Syringic acid exhibited potent 5-LOX inhibition (IC50 
1.38±0.03 µg/ml) and moderate COX-1 inhibition (IC50 34.89±0.02 µg/ml). 
Furthermore, oxidative and inflammatory processes are among the pathological 
features associated with the central pgtxqwu"u{uvgo"kp"Cn¦jgkogtÓu"fkugcug0"Vjgtg" ku"
evidence that acetyl cholinesterase (AChE) inhibitors have an anti-inflammatory role 
through action against free radicals and amyloid toxicity, as well as through 
decreasing release of cytokines from activated microglia in the brain and blood. 
Chloroform extract of the barks displayed the best activity (IC50 ?"::07;ł2036"たi1on+"
as opposed to positive control, galanthamine (IC50 = 0.74±0.28"たi1on+0"Vjg"gvjcpqn"
extract of barks and leaves follow through with IC50 ?"3:8022ł2037"たi1on"cpf"KE50 = 
423046ł2037"たi1on"tgurgevkxgn{. Only scopoletin, scoparone, vomifoliol and syringic 
acid showed AChE inhibition at IC50 <100 µg/ml. Syringic acid exhibited good AChE 
inhibition (IC50 29.53±0.19 µg/ml), lowest of all compounds tested. Choline is the 
precursor of phosphatidylcholine (PC), a main component of Leishmania 
promastigote membranes. Therefore, inhibition of choline formation may decrease 
Leishmania survival. This hypothesis can be tested by using inhibitors of the 
acetylcholinesterase enzyme (AChE), which catalyzes the hydrolysis of acetylcholine 
to choline and acetic acid, as leishmanicidal compounds. The hexane extract of leaves 
showed moderate antileshmanial activity with IC50 xcnwgu"qh"479062ł2052"たi1on0"Qpn{"
ethanol extracts showed activity against Giardia intestinalis and Entamoeba 
histolytica cv" eqpegpvtcvkqp" qh" 722" たi1on0" Ucopoletin was tested against all three 
parasite amd it was more potent against Leishmania donovani (IC50 163.30±0.32 
µg/ml) and MIC of >200 µg/ml for both Giardia intestinalis and Entamoeba 
histolytica. Six kinds of major biological effects were evident in the crude and 
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compounds namely, antioxidant, antibacterial, anti-inflammatory, anti-AChE, anti-
parasitic, and anticancer all of which were reported for the first time from this plant. 
Given the aforementioned evidence it is tempting to speculate that Canarium 
patentinervium Miq. represents an exciting scaffold from which to develop leads for 
treatment of inflammatory and oxidative stress related diseases. 
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CHAPTER 1 
 GENERAL INTRODUCTION 
 
1.1  Introduction 
 
Pharmacognosy is not a familiar term, even to many scientists which is defined as the 
study of crude drugs of plant and animal origin. The scope of pharmacognosy is also 
defined as the study of physical, chemical, biochemical and biological properties of 
drugs, drug substances, or potential drugs or drug substances of natural origin as well 
as the search for new drugs from natural origin as well as the search for new drugs 
from natural sources [1]. Natural products offer unmatched chemical diversity with 
structural complexity and biological potency. It is estimated about 100-fold higher hit 
rate for natural products over synthetic compounds. Natural products occupy different 
chemical space that is sometimes difficult to access compared with synthetic 
compounds. Not only do the natural product databases contain many more scaffolds, 
but an important proportion of the ring systems are not found at all in other drug 
databases. Such unexploited scaffolds represent promising new starting points in drug 
discovery.  
 
Natural products compounds not only serve as drugs or templates for drugs but lead to 
a better understanding of targets and pathways involved in disease process.  They also 
create opportunities for additional drug targets to be identified and exploited in these 
pathways. The elucidation of the anti-inflammatory mechanism of action of aspirin 
led to the discovery of the cyclooxygenase isozymes COX-1 and COX-2, which were 
used in the development of novel anti-inflammatory drugs [2]. Over half of the 
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yqtnfÓu"vqr"47"dguv-selling pharmaceuticals drugs in 1991 owed their origin to natural 
products. Higher plant-derived products represent around 25% of the total number of 
clinically used drugs and include the classical drugs atropine, codeine, digoxin, 
morphine and quinine [1].  
 
Number of drug molecules obtained and developed industrially from plants and used 
in modern medicines increased drastically from 121 in 1995, 130 in 1997, 143 in 2000 
and 166 in 2006. From 1981 and 2000, 61% of the small molecule- new chemical 
entities (NCE) that were introduced as drugs worldwide can be traced to or were 
inspired by natural products. Between 2001 and 2005, 23 new drugs derived from 
natural products were introduced for the treatment of bacterial and fungal infection, 
ecpegt." fkcdgvgu." f{unkrkfgokc." cvqrke" fgtocvkvku." Cn¦jgkogtÓu" fkugcug" cpf" igpgvke"
disease such as tyrosinaemia and Gaucher disease [3]. Table 1.1 lists the drugs 
derived from plants, their clinical uses and sources as well as recent plant-derived 
drugs in the global market. 
 
 
1.2 An ethnopharmacological research 
 
The study of plants used in traditional medicine requires the effective integration of 
information on chemical composition of extracts, pharmacological activities of 
isolated compounds, as well as indigenous knowledge of traditional healers. The 
acquisition of ethnobotanical information remains an empirical aspect in any such 
study [4]. There is a great need and ethical obligation to accurately document 
investigative findings on plants used for health purposes. This will also aid in the 
3 
 
efficient preservation and conservation of traditional knowledge which may 
potentially benefit society in general. 
 
 
1.3 An introduction to the family Burseraceae Kunth. and genus Canarium L. 
 
1.3.1 The family Burseraceae Kunth. 
 
The Burseraceae Kunth is one of the nine flowering plant families belonging to the 
order Sapindales Juss. ex Bercht. & J. Pearl that comprise the monophyletic group 
(5700 species), whose first known fossils appear in Europe 65 million years ago (Ma). 
The Burseraceae Kunth. consists of approximately 18 genera and 700 species. This 
family is divided into 3 tribes namely Canariceae, Protieae which are determined to be 
monophyletic and Burserae which was shown to be polyphyletic. The list of genera in 
the Burseraceae Kunth., approximate number of species, tribal and subtribal in the 
Burseraceae Kunth., approximate number of species, tribal and subtribal placement, 
and geographic range  of genera are shown in Table 1.2.  The family is distributed 
pantropically across a broad range of low-elevation, frost-free habitats including 
rainforest, dry deciduous forest and deserts [5]. The Burseraceae Kunth. are best 
known for producing resins of economic, medicinal, and cultural values such as 
frankincense, myrrh and copal [6]. 
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Table 1.1 : Drugs derived from plants, their clinical uses, sources and recent plant derived drugs in global market till 2004 [3][7]. 
Drug     Clinical Use/Action     Plant source 
Atropine    Anticholinergic      Atropa belladonna Linn. 
Colchicine    Antitumor, antigout agent    Colchicum autumnale L. 
Digitoxin    Cardiotonic      Digitalis purpurea L. 
Emetine    Emetic, amoebicide     Cephaelis ipecacuanha (Brot.) A. Rich. 
Morphine    Analgesic      Papaver somniferum L. 
Pilocarpine    Parasympathomimetic     Pilocarpus jaborandi (Holmes.) 
Quinine    Antimalarial      Cinchona ledgeriana (Howard) Bern. 
Apomorphine HCL   Potent dopamine receptor agonist    Papaver somniferum L.  
     *RctmkpuqpÓu"fkugcug+  
Tiotropium bromide   Longer-acting antibronchospasm   Atropa belladonna Linn. 
Nitisinone    For hereditary tyrosinaemia type-1   Callistemone citrinus (Curtis) Skeels. 
Galanthamine HBr   Selective acetylcholinesterase     Galanthus nivalis L. 
     Kpjkdkvqt"*Cn¦jgkogtÓu"fkugcug+ 
Arteether    Antimalarial       Artemisia annua L.  
5 
 
1.3.2 The genus Canarium L. 
 
The genus Canarium L. probably originated from the North American continent, not 
Gondwanaland [5]. This clade embraces 75 species of trees which are mainly found in 
tropical Asia and the Pacific, and a few species in tropical Africa [8], about 9 species 
were found in the Philippines [8]. The geographical centre of their genetic diversity is 
the Molucca Islands of eastern Indonesia, but their centre of cultivated diversity is 
undoubtedly western Melanesia. Twenty to 25 species are found in the South Pacific, 
of which 21 are in Papua New Guinea [9], eight in the Solomon Islands [10] and 3 or 
4 in Vanuatu [11]. The known Canarium species and their distribution are listed in 
Table 1.3.  
 
The word Canarium L. fgtkxgu" htqo" vjg" Ocnc{" pcog" ÒmcpctkÓ[8]. Canarium L. 
species often produce edible kernels, called canarium nut of commercial interest: 
Canarium indicum L., Canarium solomonense B.L.Burtt, Canarium harveyi Seem, 
Canarium odontophyllum Miq. and Canarium album L. Another economical interest 
of Canarium L. species, is the production of resins used in foods (Canarium 
luzonicum Miq.), in the making of incense and varnishing. In spite of these 
commercial potentials  of Canarium L., little attention has been given to the collection 
and conservation of Canarium L. species [12]. The genetic diversity thus derogates at 
an alarming rate. 
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Table 1.2: List of genera in the Burseraceae Kunth., approximate number of species, tribal 
and subtribal placement, and geographic range [5]. 
 
Bursereae 
Burserinae 
Bursera Jacq. ca. 100 spp. Caribbean, Mexico, Central, and S. America 
Commiphora Jacq. ca. 190 spp. Africa, India, S. America 
Boswelliinae 
Aucoumea Pierre 1 sp. W. Africa 
Beiselia Forman 1sp. SW Mexico 
Boswellia Roxb. ca. 30 spp. NE Africa, Arabia, India 
Triomma Hook. f. 1sp. W Malesian region 
Unnamed subtribe 
Garuga Roxb. 4 spp. India, SE Asia 
Canarieae 
Canarium L. ca. 105 spp. SE Asia, Malaysia, Africa 
Dacryodes Vahl 66 spp. Caribbean, Mexico, C. and S. America, SE Asia, Africa 
Haplolobus H.J. Lam 22 spp. E. Malaysia 
Pseudodacryodes R. Pierlot 1 sp. Central Africa 
Rosselia Forman 1 sp. Rossel Island, New Guinea 
Santiria Blume 24 spp. W. Malesian region, Philipines, Moluccas, New Guinea, 
Africa 
Scutinanthe Thwaites 2 spp. Sri Lanka, S. Myanmar, Celebes, Sumatra, Malay 
Peninsula,Borneo 
Trattinnickia Willd. 13 spp. C. and S. America 
Protieae 
Crepidospermum Hook. f. 6 spp. S. America 
Protium Burm. f. 150 spp. Mexico, C. and S. America, Africa, SE Asia 
Tetragastris Gaertn. 9 spp. Central and S. America 
Garuga was placed informally within the Bursereae by Harley and Daly (1995). 
 
 
 
 
 
 
 
 
 
 
7 
 
Table 1.3: Canarium L. species and their geographic distribution [13]. 
 
 
Species     Distribution       
C. acutifolium (DC.) Merr.   Moluccas, New Guinea, Central Celebes   
C. album (Lour.) Raeusch.  Annam, Tonkin, S. China, Hainan    
C. apertum H.J. Lam    Sumatra, Malay Peninsula, Borneo   
C. asperum Benth.    Solomon Is., Bawean and Kangean Is    
subsp. asperum Lesser    Sunda Is., Borneo, Philippines, 
subsp. papuanum (H.J. Lam)   Leenh. Celebes, Moluccas, New Guinea 
C. australianum F.v.M    N. Australia, SE New Guinea     
C. baileyanum Leenh.   Queensland, NS Wales      
C. balansae Engl.    Loyalty Is.       
C. balsamiferum Willd.    Celebes, Moluccas, New Guinea    
C. luzonicum (Bl.) A. Gray   Philippines       
C. macadamii Leenh.   New Guinea       
C. madagascariense Engl.   Madagascar, Tanganyika,     
subsp. Madagascariense  Mozambique 
subsp. Obtusifolium (S.Elliot) Leenh. 
C. maluense Laut.    Central Celebes, Moluccas, New Guinea 
subsp. maluense  
subsp. borneense Leenh. 
C. manii King     Middle and S. Andaman    
C. megacarpum Leenh.    W. New Guinea     
C. megalanthum Merr.    Sumatra, Malay Peninsula, Borneo    
C. merrillii H. J. Lam    Borneo       
C. muelleri F.M. Bailey   Australia (Queensland)      
C. odontophyllum Miq.   Sumatra, Borneo, Philippines     
C. oleiferum Baill.   New Caledonia       
C. oleosum (Lamk) Engl.   New Britain, Lesser Sunda Island.,  
N. Celebes, Moluccas, New Guinea    
C. ovatum Engl.   Philippines       
C. paniculatum (Lamk) Benth. ex Engl. Mauritius      
C. parvum Leenh.    Tonkin, N. Annam      
C. patentinervium Miq.   Sumatra, Malay Peninsula, Banka,    
Anambas Island., Borneo 
C. perlisanum Leenh.    Malay Peninsula     
C. piloso-sylvestre Leenh.   W. New Guinea      
C. pilosum Benn.    Sumatra, Malay Peninsula, Borneo    
subsp. pilosum 
subsp. borneensis Leenh. 
C. pimela Leenh.    S. China, Hainan, Tonkin, Laos,   
Annam, Cambodia 
C. polyphyllum K. Sch.    New Guinea       
C. pseudodecumanum Hochr.   Sumatra, Malay Peninsula, Borneo    
C. pseudopatentinervium   S. Sumatra, Banka, Borneo     
H.J. Lam 
C. pseudosumatranum Leenh.   Malay Peninsula      
C. rigidum (Bl.) Zipp. ex Miq.  New Guinea  
C. salomonense B.L. Burtt  Solomon Island., E. New Guinea   
subsp. salomonense 
subsp. papuanum 
C. samoense Engl.    Samoa       
C. schlecteri Laut.    New Britain, E. New Guinea     
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Table 1.3: Canarium L. species and their geographic distribution [13]. (continuation) 
 
Species     Distribution       
C. schweinfurthii Engl.    Trop. W and Central Africa   
C. smithii Leenh.    Fiji        
C. strictum Roxb.    SW Deccan, Sikkim, Assam, Upper Burm 
C. subulatum Guill.    S. China, Hainan, Tonkin, Laos,    
Annam, Cambodia 
C. sumatranum Boerl.    Sumatra, Malay Peninsula     
and Koord. 
C. sylvestre Gaertn.    Moluccas, New Guinea      
C. trifoliatum Engl.    New Caledonia       
C. trigonum H.J. Lam    Central Celebes     
C. vanikoroense Leenh.   New Hebrides, Fiji      
C. vitiense A. Gray    Fiji        
C. vrieseanum Engl.    Philippines, Central and N. Celebes    
C. vulgare Leenh.    Kangean and Bawean Island.,     
Lesser Sunda Island.,    Celebes, Moluccas 
C. whitei Guill.     New Caledonia       
C. zeylanicum (Retz.) Bl.  Sri Lanka       
 
 
1.3.3. Botanical features of Canarium L. 
 
The members of the genus Canarium L. consist of medium to large buttressed trees 
up to 40-50m tall, or rarely a shrub. The barks are greenish grey, fawn or light yellow 
brown that are usually smooth, scaly or dippled with many small lenticels. Outer bark 
are thin while the inner barks are pinkish brown or reddish brown, laminated, soft and 
aromatic with a clear sticky or rarely oily exudate. The stems are usually terete. The 
leaves are pinnate, spiral and stipulated. The rachis is terete flattened to channeled 
swollen at base, and bears 5-21 folioles. The folioles are oblique at base, entire, 
dentate or serrate at margin, often thick and acuminiate at apex. The secondary nerves 
are arching and joined near margin. The tertiary nerves are reticulate. The 
infloresence is an axillary or terminal panicle. The calyx is cupular. The corolla 
includes 3 creamy petals. The androecium comprises a whorl of 6 stamens. The disc 
within the stamens is 6 lobed. The gynaecium consist of 3 carpels united into a 3 
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lobular ovary. The drupes are seated on a persistent enlarged calyx and enclose a 
woody stone [14]. 
 
 
1.4 Traditional and medicinal uses of Canarium L. 
 
Elemi (British Pharmaceutical Codex, 1934) is an oleoresin exuded through the bark 
of Canarium luzonicum Miq. or Canarium commune L. which has been used in the 
form of an ointment as a stomach stimulant and as an expectorant [15]. The barks of 
Canarium indicum L. has been used for chest pains where else the oil has been 
patented for treatment of arthritis pain and the oleoresin of the tree is applied as a 
poultice for ulcerated wounds. The resin of Canarium tonkinense Engl. has been used 
as a stimulant, rubefacient and anti-rheumatic when applied externally. The oleoresin 
has been applied as ointment for ulcers [16]. The dried fruit of chinese olive or 
Canarium album (Lour.) Raeusch. is used in China and used to treat bacterial and 
viral infections, inflammation, poisoning and for detoxification [17]. 
 
 In Chinese folk medicine, the dried fruits of Canarium album (Lour.) Raeusch have 
been used for treatment of angina, dysentery, snake bites, cough-hematemesis, 
enteritis, diarrhoea, toxicosis from swellfish and alcohol [18]. Canarium 
schweinfurthii Engl. is used by traditional healers as a remedy for diabetes mellitus in 
southern Senegal [19] while in Congo and Central African Republic the plant is used 
in fever, as stimulant, emollient, in post-partum pain, constipation, malaria, diarrhoea, 
sexual infections and rheumatism [20]. In Indonesia, the bark of Canarium littorale 
Bl. is used to make a decoction taken to heal haemorrhoids [21]. 
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1.4.1 In vitro and in vivo pharmacological activities of Canarium L. 
 
Only 12 % of 75 species have been studied for their pharmacological activities. 
Extracts and pure compounds derived from Canarium L. were reported to have a 
variety of pharmacological activities of which antioxidant, antibacterial, antifungal, 
antitumor, anti-inflammatory, hepatoprotective, analgesic and anti-diabetic (Table 
1.4). 
 
i. Antioxidant 
 
Antioxidant activities were reported in Canarium album (Lour.) Raeusch, Canarium 
odontophyllum Miq. and Canarium schweinfurthii Engl.  A tonic soup made of 
Canarium album (Lour.) Raeusch used mainly in China displayed significant 
antioxidant activity by 1,1,-diphenyl-2-2-picrylhydrazyl (DPPH) and ferric reducing 
antioxidant power (FRAP) assay [22]. Tannins extracted from the leaves, twigs and 
stem barks of Canarium album (Lour.) Raeusch showed potent antioxidant activity in 
the DPPH radical scavenging activity  with IC50 values of 56.86 µg/ml, 62.31 µg/ml 
and 54.80 µg/ml respectively and ferric reducing power of 4.28, 3.74 and 4.49 mmol 
AAE/g equivalent of dried tannin [23]. Pure compounds from this species includes 
brevifolin, hyperin and ellagic acid which showed free radical scavenging activity in 
DPPH assay [24]. 
 
The essential oil of Canarium schweinfurthii Engl. was tested for the antioxidant 
cevkxkv{"ykvj" vjg"FRRJ"cuuc{"cpf"d{"く-carotene bleaching test. It exhibited highest 
antioxidant activity at 150 µg/ml activity in both assay [25]. The ethyl acetate fraction 
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of peel of Canarium odontophyllum Miq. exhibited 95±1.00% scavenging activity at 
the concentration of 40 µg/ml [26][27].  
 
ii. Antibacterial and antifungal activities 
 
Antibacterial activities were reported in Canarium schweinfurthii Engl. and Canarium 
patentinervium Miq. Dichloromethane extract of Canarium schweinfurthii Engl. had 
bactericidal activity against Gram-negative Vibrio cholerae with minimum inhibitory 
concentration (MIC) of 0.62 mg/ml while the ethylacetate extract was active against 
Gram-positive and Gram-negative bacteria namely Staphylococcus aureus and 
Proteus vulgaris with MIC values of 10 mg/ml and 5 mg/ml respectively. Ethanol 
extract was active against Gram-negative Vibrio cholerae and Proteus vulgaris with 
MIC values of 0.62 mg/ml and 10 mg/ml respectively [28]. In a separate disc 
diffusion assay, the essential oil of Canarium schweinfurthii Engl. abrogated the 
survival of Gram-negative Salmonella enterica, Gram-positive Streptococcus pyogens 
and Staphylococcus aureus with an inhibition zone of 27 mm, 25 mm and 18 mm 
respectively. However the author did not inform on the concentration of the extract 
per disc. The oil was also fungicidal against Candida albicans  with an inhibition 
zone of  23 mm [25]. 
 
iii. Hepatoprotective activities 
 
Hepatoprotective activity was exhibited in Canarium manii King. and Canarium 
album (Lour.) Raeusch. The biflavanoid agathisflavone from Canarium manii King. 
preserved the integrity of the liver cells membrane of rodents as evidenced by the 
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decrease in the CCl4-induced rise of glutamic oxaloacetic transaminase (GOT) and 
glutamic pyruvic transaminase (GPT) levels. GPT which is predominantly found in 
the liver showed a dose-dependent and significant reduction [29]. The triterpenes urs-
12-ene-5g.38く-diol, olean-12-ene-5g.38く-diol and urs-12-ene-5く.38く-diol from from 
Canarium album (Lour.) Raeusch markedly reduced the amount of alanine 
aminotransferase leakage from the primary cultured hepatocytes intoxicated with 0.2 
mM of D-galactosamine (D-GaIN) [30]. The phenols brevifolin and ellagic acid 
protected rat hepatocytes against D-GaIN-induced insults [24]. 
 
iv. Other Biological Activities 
 
The essential oil of Canarium schweinfurthii Engl. collected from the region of 
Cameroon inhibited the enzymatic activity of lipoxygenase with an IC50 value of 62.6 
ppm [31]. However in a separate study of the same species collected from central 
African region did not show any activity in the cotton pellet induced granuloma 
formation experiment [20]. This may suggest possible evidence of variety between 
secondary metabolites constituents according to regions. The essential oil of 
Canarium schweinfurthii Engl. at a dose of 1, 2 and 3 mg/kg i.p. displayed potent 
analgesic effect in the acetic acid-induced writhing and hot plate experiments [20].  
 
Anti-diabetic activity was reported in the methanol/methylene chloride extract of stem 
bark of Canarium schweinfurthii Engl. At a dose of 300 mg/kg there was 67.1 % 
reduction in blood glucose levels after a once daily subcutaneous injection on 
streptozotocin-induced diabetic male rats over 14 days, versus insulin that had 76.8 % 
reduction. Weight gain was only 6.6 % as opposed to untreated rats that had lost 14.1 
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% of body weight. There was also significant reduction in food and fluid consumption 
by 68.5 % and 79.7 %. These results showed the extract could reverse hyperglycemia, 
polyphagia and polydipsia provoked by streptozotocin, thus having anti-diabetic 
activity [19]. 
 
 
1.5 The phytochemistry of Canarium L. 
 
Isolation and structure elucidations of secondary metabolites in Canarium L. has been 
carried out since the 50Ós [32]. Majority of investigations include the resin and the 
fruit of the species.  To date about 96 compounds have been isolated from 9 species, 
which are Canarium schweinfurthii Engl., Canarium boivinii Engl., Canarium 
odontophllum Miq., Canarium manii King., Canarium album (Lour) Raeusch, 
Canarium zeylanicum (Retz.) Blume, Canarium commune L., Canarium muelleri 
F.M. Bailey and Canarium bengalense Roxb. The extensively researched species are 
Canarium schweinfurthii Engl. and Canarium album (Lour.) Raeusch 
[17][18][23][33][34]. 
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Table 1.4:  Biological and pharmacological activities (in vitro) of Canarium L. extracts and pure 
constituents 
Extract/Compound Species Pharmacological activity References 
 
Polymeric 
procyanidins(tannins) 
from leaves, twigs and 
stem bark 
Canarium album 
(Lour.) Raeusch 
 
Significant DPPH radical 
scavenging activity,                        
Ferric reducing antioxidant 
activity 
[23] 
Ethyl acetate fraction 
of the fruit peel 
Canarium 
odontophyllum 
Miq. 
Antioxidant activity with 
DPPH assay, FRAP assay and 
hemoglobin oxidation assay 
[26] 
Carotenoids from 
peel,pulp and seed 
extracts 
Canarium 
odontophyllum 
Miq. 
Significant antioxidant activity 
with beta-carotene bleaching 
assay, ABTS assay, DPPH 
assay and hemoglobin 
oxidation assay 
[27] 
Essential oil of resins Canarium 
schweinfurthii Engl. 
Bactericidal for Enterococcus 
faecalis, Listeria innocua, 
Salmonella enterica, 
Staphylococcus aureus, 
Staphylococcus camorum                     
Fungicidal for Candida 
albicans                      
Cpvkqzkfcpv"hqt"FRRJ"cpf"く-
carotene bleaching test 
[25] 
Essential oil of 
resins(monoterpenes 
hydrocarbon) 
Canarium 
schweinfurthii Engl. 
Significant anti-inflammatory 
activity via lipooxygenase 
method with IC50 of 62.6 ppm 
[31] 
Brevifolin, ellagic 
acid and hyperin 
Canarium album 
(Lour.) Raeusch 
 
Significant antioxidant activity 
and inhibitory effect on lipid 
peroxidation assay 
[24] 
Dichloromethane 
extract of barks 
Canarium 
schweinfurthii Engl. 
Antimicrobial activity against 
V.cholerae 
[28] 
Extract of whole plant Canarium album 
(Lour.) Raeusch 
 
Antioxidant activities in DPPH 
and FRAP assay 
 
[22] 
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Table 1.5:  Biological and pharmacological activities (in vivo) of Canarium L. extracts and pure 
constituents 
Extract/Compound        Species                        Pharmacological activity           References 
 
Agathisflavone 
(biflavanoid) 
Canarium manii 
King. 
Hepatoprotective activity 
against experimentally-induced 
carbon tetrachloride-
hepatotoxicity in rats and mice  
[29] 
urs-12-ene-5g."38く-
diol,           olean-12-
ene-5g."38く"fkqn"
(triterpene) 
Canarium album 
(Lour.) Raeusch 
 
Hepatoprotective activity in 
primary cultured rat 
hepatocytes intoxicated with D-
galactosamine 
[30] 
brevifolin, ellagic acid Canarium album 
(Lour.) Raeusch 
 
Reduction of carbon 
tetrachloride induced liver 
damage in mice. Reduction in 
elevated GPT and GOT levels 
after intraperitoneal 
administration 
[24] 
Essential oil of 
resins(composed 
mainly of nerolidol 
and octylacetate) 
Canarium 
schweinfurthii Engl. 
Significant analgesic effect 
using acetic acid-induced 
writhing and hot plate methods 
with swiss mice 
[20] 
Methanol/methylene 
chloride extract of 
stem barks 
Canarium 
schweinfurthii Engl. 
Anti-diabetic activity that 
reverses hyperglycemia, 
polyphagia and polydipsia in 
streptozotocin-induced diabetic 
rats. Significant reduction 69.9 
% reduction in blood glucose 
level after 14 days at 300 
mg/kg 
[19] 
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The isolation and separation technique is very much dependent on the type of 
fractions. Essential oils are analysed with gas chromatography (GC) and mass 
spectroscopy (MS) [20][31][35]. Other substances are separated with liquid 
chromatography using different solvent mixtures with silica gel [29][36], charcoal 
[37], sephadex [18] and multiple column packing  such as AB-8 adsorption resin, 
polyamide, and TSK Toyopearl HW-40(S). Other types of analytical techniques  
include thin layer chromatography (TLC) and high performance liquid 
chromatography (HPLC) [17][27][34][38][39].  
 
The structures are mainly established by mass spectroscopy (MS), ultra-violet 
spectroscopy (UV), infrared spectroscopy (IR) and 1H and/or 13C nuclear magnetic 
resonance (NMR). 1H and/or 13C spectroscopy is probably the most useful method in 
structure elucidation [29]. Among the secondary metabolites isolated from members 
of the genus Canarium L. are terpenes (monoterpenes, triterpenes, tetraterpenes like 
carotenoids, sesquiterpenes, cyclohexane and sterols), carboxylic acids, coumarins, 
furans, lipids and phenols (flavonoids, tannins, phenolic acids). The main secondary 
.metabolites isolated so far from the genus Canarium L. consists of terpenes with 58 
compounds and flavonoids with 11 compounds. The profile of all known secondary 
metabolites of Canarium L. as found in literature are included in Table 1.6 and their 
structures are included in Figure 1.1. 
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1.6 The commercial uses of Canarium L. produces 
 
Gngok" fgtkxgf" htqo" vjg" Ctcdke" ÒCn-ncokÓ" ku" c" eqnngevkxg" vgto" crrnkgf" vq" ugxgtcn"
oleoresins obtained from different plants of the family Burseraceae Kunth. The most 
important and widely known of these oleoresins is Manila Gum Elemi which exudates 
from the trunk of Canarium luzonicum Miq. or Canarium commune L. The natural 
constituent of elemi oil is elemicin. Variety of foodstuffs are flavoured with elemi oil 
and in Europe its used in spices and seasonings. In US elemi oil is also used in 
fragrances to approximately 1000 lb/year [40]. At present, at least 4 species of 
Canarium L. nuts are of economic importance.  Canarium ovatum Engl. (known 
nqecnn{" cu" ÒrknkÓ" cpf" ÒrkncwkÓ+" ku" vjg" oquv" korqtvcpv" pwv-producing species in the 
Philippines. Canarium luzonicum Miq. most commonly known in the Philippines as 
ÒrkucÓ" cpf" ÒdcukcfÓ." ku" korqtvcpv." pqv" cu" cp" gfkdng" pwv" dwv" hqt" kvu" qkn{" tgukp" *mpqyp"
nqecnn{"cu"ÒucjkpiÓ+."yjkej"ku"vcrrgf"htqo"vjg"vtwpm0"Yjgp"rtqeguugf."kv"ku"ecnngf"Òdtgc"
dncpecÓ*yjkvg" ritch) and is exported as Manila elemi Canarium indicum L. is an 
important nut-rtqfwekpi"urgekgu"kp"vjg"Uqnqoqp"Kuncpfu"*nqecnn{"ecnngf"ÒpicnkÓ+."Rcrwc"
Pgy"Iwkpgc"*nqecnn{"ecnngf"ÒicnkrÓ+"cpf"Xcpwcvw"*yjgtg"kv"ku"mpqyp"cu"ÒpcpickÓ+ [10]. 
Canarium album (Lour) Raeusch.."mpqyp"kp"Gpinkuj"cu"Ejkpgug"qnkxg."Òucoq"ejggpÓ"
kp"Vjckncpf"cpf"Òvtco"vtcpiÓ"kp"Xkgvpco."ku"korqtvcpv"kp"vjgug"eqwpvtkgu"hqt"kvu"gfkdng"
pulp and kernel [13]. 
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Table 1.6   Secondary metabolites of Canarium L. 
 
Compound name Species Chemical 
formula 
Structure 
number 
Plant part References 
 
CARBOXYLIC ACIDS 
Octyl acetate 
 
 
Canarium 
schweinfurthii Engl. 
 
 
 
C10H20O2 
 
 
1 
 
 
resin,oil 
 
 
[20] 
2,5-Dimethoxytoluene Canarium 
schweinfurthii Engl. 
 
C9H12O2 2 resin,oil [20] 
 
COUMARINS                       
Scoparone 
 
 
Canarium album 
(Lour.) Raeusch 
 
 
 
C11H10O4 
 
 
3 
 
 
fruit 
 
 
[41] 
Scopoletin Canarium album 
(Lour.) Raeusch 
 
C10H8O4 4 fruit [41] 
HETEROCYCLIC 
COMPOUNDS-FURANS     
2-acetylfuran 
 
 
 
Canarium 
schweinfurthii Engl. 
 
 
 
 
C6H6O2 
 
 
 
 
5 
 
 
 
resin,oil 
 
 
 
[20] 
n-octanol 
Canarium 
schweinfurthii Engl. 
 
C8H18O 
 
6 resin,oil [20] 
LIPIDS           
  Hexadecanoic acid 
 
 
 
Canarium 
schweinfurthii Engl. 
 
 
 
C16H32O2 
 
 
7 
 
 
fruit,oil 
 
 
[42] 
9-octadecenoic acid Canarium  
schweinfurthii Engl. C18H34O2 8 fruit,oil [42] 
6,9-octadecadienoic acid 
 
Canarium  
schweinfurthii Engl. 
 
C18H32O2 9 fruit,oil [42] 
9,12,15-octadecatrienoic 
acid 
Canarium 
schweinfurthii Engl. 
 
C18H32O4 10 fruit,oil [42] 
Oleic acid Canarium 
schweinfurthii Engl. 
 
C18H34O2 11 fruit,oil [43] 
Linoleic acid Canarium 
schweinfurthii Engl. 
 
C18H32O2 12 fruit,oil [43] 
n-decanol Canarium 
schweinfurthii Engl. 
 
C10H22O 13 resin, oil [20] 
n-dodecanol Canarium 
schweinfurthii Engl. 
 
C12H26O 14 resin,oil [20] 
 
PHENOLS- 
FLAVONOIDS            
Luteolin 
 
 
 
Canarium album 
(Lour.) Raeusch 
 
 
 
 
C15H10O6 
 
 
 
15 
 
 
 
fruit 
 
 
 
[18] 
Luteolin-7-O-く-D-glucoside Canarium album 
(Lour.) Raeusch 
 
C21H20O11 16 fruit [18] 
Quercetin Canarium album  C15H10O7 17 fruit [18] 
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Table 1.6   Secondary metabolites of Canarium L. (continuation) 
 
Compound name Species Chemical 
formula 
Structure 
number 
Plant part References 
 
 
Quercetin-3-O-く-D-
glucoside 
 
Kaempferol 
 
 
9.:.5Ó.6Ó-
tetrahydroxyflavanone 
 
Canarium album 
(Lour.) Raeusch 
 
Canarium album 
(Lour.) Raeusch 
 
Canarium album  
(Lour.) Raeusch 
 
C21H19O12 
 
 
C15H10O6 
 
 
C15H10O6 
 
 
 
18 
 
 
19 
 
 
20 
 
fruit 
 
 
fruit 
 
 
fruit 
 
[18] 
 
 
[18] 
 
 
[18] 
3,5,7,3'-tetrahydroxy-4'-
methoxyflavanonol 
Canarium album 
(Lour.) Raeusch 
 
C15H10O6 21 fruit [18] 
Hyperin/ 
Quercetin-3-galactoside 
Canarium album 
(Lour.) Raeusch 
 
C21H20O12 22 dried stem, 
leaf,fruit 
[24] 
[17] 
Kaempferol-3-glucoside Canarium album 
(Lour.) Raeusch 
 
C21H20O11 23 fruit [17] 
Amentoflavone Canarium album 
(Lour.) Raeusch 
 
C30H18O10 24 fruit [17] 
Agathisflavone Canarium manii King. C30H18O10 25 stem,bark [29] 
 
PHENOLIC ACIDS 
Sinapic acid 
 
 
Canarium album 
(Lour.) Raeusch 
 
 
 
C11H12O5 
 
 
26 
 
 
fruit 
 
 
[34] 
Corilagin  
 
 
Gallic acid 
 
 
Canarium album 
(Lour.) Raeusch 
 
Canarium album 
(Lour.) Raeusch 
 
C27H22O18 
 
 
C7H6O5 
 
 
27 
 
 
28 
fruit 
 
 
fruit 
[41] 
 
 
[17] 
Ellagic acid Canarium album 
(Lour.) Raeusch 
 
C14H6O8 29 dried 
stem,leaf 
[24] 
Brevifolin carboxylic acid Canarium album 
(Lour.) Raeusch 
 
C13H8O8 30 fruit [34] 
3-O-galloyl quinic acid 
butyl ester 
Canarium album 
(Lour.) Raeusch 
 
C18H24O10 31 fruit [33] 
3,4-dihydroxybenzoic acid 
ethyl ether 
Canarium album 
(Lour.) Raeusch 
 
C9H10O4 32 fruit [18] 
2-hydroxybenzoic acid Canarium album 
(Lour.) Raeusch 
 
C7H6O3 33 fruit [18] 
TANNINS 
Ethyl gallate 
 
Canarium album 
(Lour.) Raeusch 
 
 
C9H10O5 
 
34 
 
fruit 
 
[18] 
[17] 
Methyl gallate Canarium album 
(Lour.) Raeusch 
 
C8H8O5 35 fruit [17] 
Elemicin Canarium commune L. C12H16O3 36 fruit 
 
[40] 
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Table 1.6   Secondary metabolites of Canarium L. (continuation) 
 
Compound name Species Chemical 
formula 
Structure 
number 
Plant part References 
 
 
SAPONINS- 
HYDROXY ACIDS 
Elemadienonic acid 
 
 
 
 
 
 
 
 
 
 
Canarium boivinii 
Engl. 
 
Canarium 
schweinfurthii Engl. 
 
 
 
C30H46O3 
 
 
C30H46O3 
 
 
 
 
 
 
 
37 
 
 
37 
 
 
 
resin 
 
 
resin 
 
 
 
[44] 
 
 
[32] 
 
TERPENES- 
CYCLOHEXANE 
Limonene 
 
 
 
 
 
 
 
 
Furfuryl butanoate 
 
 
 
Canarium 
schweinfurthii Engl. 
 
Canarium boivinii 
Engl. 
 
Canarium zeylanicum 
(Retz.) Blume 
. 
Canarium 
schweinfurthii Engl. 
 
 
 
C9H12O3 
 
 
 
 
 
 
 
 
C9H12O3 
 
 
 
38 
 
 
 
 
 
 
 
 
39 
 
 
 
resin,oil 
 
 
resin 
 
 
oleoresin 
 
 
resin, oil 
 
 
 
[20] 
 
 
[36] 
 
 
[44] 
 
 
[20] 
 
 
MONOTERPENES 
g-pinene 
 
 
 
Canarium album 
(Lour.) Raeusch 
 
 
 
C10H16 
 
 
40 
 
 
resin 
 
 
[35] 
く-Pinene Canarium album 
(Lour.) Raeusch 
 
C10H16 41 resin [35] 
Myrcene Canarium album 
(Lour.) Raeusch 
 
C10H16 42 resin [35] 
g-Fenchene Canarium album 
(Lour.) Raeusch 
 
C10H16 43 resin [35] 
p-1-Menthene Canarium album 
(Lour.) Raeusch 
 
C10H18 44 resin [35] 
Ä-3-Carene Canarium album 
(Lour.) Raeusch 
 
C10H16 45 resin [35] 
g-Terpinene Canarium album 
(Lour.) Raeusch 
 
C10H16 46 resin [35] 
cis-Sabinene hydrate Canarium album 
(Lour.) Raeusch 
 
C10H18O 47 resin [35] 
Terpinolene Canarium album 
(Lour.) Raeusch 
 
C10H16 48 resin [35] 
Linalool Canarium album 
(Lour.) Raeusch 
 
Canarium 
schweinfurthii Engl. 
 
 
C10H18O 49 resin 
 
 
resin,oil 
[35] 
 
 
[20] 
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Table 1.6   Secondary metabolites of Canarium L. (continuation) 
 
Compound name Species Chemical 
formula 
Structure 
number 
Plant part References 
 
 
cis-p-Menth-2-en-1-ol 
 
Canarium album 
(Lour.) Raeusch 
 
 
C10H18O 
 
50 
 
resin 
 
[35] 
trans-p-Menth-2-en-1-ol Canarium album 
(Lour.) Raeusch 
 
C10H18O 51 resin [35] 
Terpinen-4-ol Canarium album 
(Lour.) Raeusch 
 
C10H18O 52 resin [35] 
g-Terpineol Canarium album 
(Lour.) Raeusch 
Canarium 
schweinfurthii Engl. 
C10H18O 53 resin 
 
 
resin,oil 
 
[35] 
 
 
[20] 
 
cis-Piperitone Canarium album 
(Lour.) Raeusch 
 
C10H16O2 54 resin [35] 
Isobornyl acetate Canarium album 
(Lour.) Raeusch 
 
C12H20O2 55 resin [35] 
1,8-cineole Canarium 
schweinfurthii Engl. 
 
C10H18O 56 reisn,oil [20] 
Citronellyl acetate Canarium 
schweinfurthii Engl. 
 
C12H22O2 57 resin,oil [20] 
Neryl acetate Canarium 
schweinfurthii Engl. 
 
C12H20O2 58 resin,oil [20] 
Decyl Acetate Canarium 
schweinfurthii Engl. 
 
C12H24O2 59 resin,oil [20] 
a-pinene/ 
g-pinene 
Canarium boivinii 
Engl. 
Canarium zeylanicum 
(Retz.) Blume 
 
C10H16 40 Resin 
 
Oleoresin,   
timber 
[36] 
 
[44] 
Carvone Canarium zeylanicum 
(Retz.) Blume 
 
C10H14O 60 oleoresin [36] 
g-phellandrene Canarium zeylanicum 
(Retz.) Blume 
 
C10H16 61 oleoresin,  
bark,timber 
[36] 
く-phellandrene Canarium zeylanicum 
(Retz.) Blume 
 
C10H16 62 oleoresin, 
bark,timber 
[36] 
Terpineol Canarium zeylanicum 
(Retz.) Blume 
 
C10H18O 63 oleoresin,  
bark 
[36] 
TRITERPENES         
 g-amyrin/ a-amyrin/ 
 (urs-12-en-5く-ol) 
 
Canarium  album 
(Lour.) Raeusch 
 
Canarium boivinii 
Engl. 
 
Canarium zeylanicum 
(Retz.) Blume 
 
 
C30H50O 
 
64 
 
dried stem, 
leaf 
 
Resin, 
oleoresin,  
 
bark,timber 
 
[30] 
 
 
[36] 
 
 
[44] 
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Table 1.6   Secondary metabolites of Canarium L. (continuation) 
 
Compound name Species Chemical 
formula 
Structure 
number 
Plant part References 
 
 
く-amyrin(olean-12-en-5く-
ol) 
 
 
 
 
Canarium  album 
(Lour.) Raeusch 
 
 
Canarium boivinii 
Engl. 
 
Canarium zeylanicum 
(Retz.) Blume 
 
 
C30H50O 
 
65 
 
dried stem, 
leaf 
 
 
Resin 
 
 
oleoresin, 
bark,timber 
 
[30] 
 
 
 
[36] 
 
 
[44] 
 
 
3-epi-g-amyrin Canarium  album 
(Lour.) Raeusch 
 
C30H50O 66 dried stem, 
leaf 
[30] 
3-epi-く-amyrin Canarium  album 
(Lour.) Raeusch 
 
C30H50O 67 dried stem, 
leaf 
[30] 
g-Amyrenone  
(urs-12-en-3-one) 
Canarium zeylanicum 
(Retz.) Blume 
 
C30H48O 68 oleoresin [36] 
く-Amyrenone  
(olean-12-en-3-one) 
Canarium zeylanicum 
(Retz.) Blume 
 
C30H48O 69 oleoresin [36] 
Taraxerol Canarium zeylanicum 
(Retz.) Blume 
 
C30H50O 70 bark [36] 
 
urs-12-ene-5g."38く-diol Canarium album 
(Lour.) Raeusch 
 
C30H50O2 71 dried 
stem,leaf 
[30] 
olean-12-ene-5g."38く"fkqn Canarium album 
(Lour.) Raeusch 
 
 
C30H50O2 72 dried stem, 
leaf 
[30] 
TETRATERPENES 
CAROTENOIDS            
All-trans-lutein 
 
 
Canarium 
odontophyllum Miq. 
 
 
 
C40H56O2 
 
 
73 
 
 
peel,pulp, 
seed 
 
 
[26] 
9-cis-lutein Canarium 
odontophyllum Miq. 
 
C40H56O2 74 peel,pulp, 
seed 
[26] 
13-cis-lutein Canarium  
odontophyllum Miq. 
C40H56O2 75 peel,pulp, 
seed 
 
[26] 
15-cis-く-carotene Canarium 
odontophyllum Miq. 
C40H56 76 peel,pulp, 
seed 
 
[26] 
9-cis-く-carotene Canarium 
odontophyllum Miq. 
C40H56 77 peel,pulp,  
seed 
 
[26] 
All-trans-く-carotene Canarium 
odontophyllum Miq. 
C40H56 78 peel,pulp,  
seed 
[26] 
 
 
SESQUITERPENES             
 g-Cubenene 
 
Canarium album 
(Lour.) Raeusch 
 
 
C15H24 
 
79 
 
resin 
 
[35] 
g-Copaene Canarium album 
(Lour.) Raeusch 
 
C15H24 80 resin [35] 
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Table 1.6   Secondary metabolites of Canarium L. (continuation) 
 
Compound name Species Chemical 
formula 
Structure 
number 
Plant part References 
 
 
く-Cubebene 
 
Canarium album 
(Lour.) Raeusch 
 
 
C15H24 
 
81 
 
resin 
 
[35] 
Canaric acid Canarium muelleri 
F.M. Bailey 
 
Canarium zeylanicum 
(Retz.) Blume 
C30H48O2 82 oleoresin [36] 
 
 
[37] 
 
 
(E)-く-Caryophyllene Canarium album 
(Lour.) Raeusch 
 
C15H24 83 resin [35] 
g-Humelene Canarium album 
(Lour.) Raeusch 
 
C15H24 84 resin [35] 
Germacrene D Canarium album 
(Lour.) Raeusch 
 
C15H24 85 resin [35] 
Spathulenol Canarium album 
(Lour.) Raeusch 
Canarium 
schweinfurthii Engl. 
 
C15H24O 86 Resin 
 
resin,oil 
[20] 
 
[35] 
 
Viridiflorol Canarium 
schweinfurthii Engl. 
C15H26O 87 resin, oil [20] 
 
 
Caryophyllene epoxide Canarium album 
(Lour.) Raeusch 
 
C15H24O 88 resin [35] 
(E)- Nerolidol Canarium 
schweinfurthii Engl. 
 
C15H26O 89 resin,oil [20] 
Elemene Canarium zeylanicum 
(Retz.) Blume 
 
C15H24 90 oleoresin,  
bark 
[36] 
Elemol Canarium zeylanicum 
(Retz.) Blume 
 
C15H26O 91 oleoresin,   
bark 
[36] 
Brevifolin Canarium album 
(Lour.) Raeusch 
 
C10H12O4 92 dried stem, 
leaf 
[24] 
h-Elemene Canarium album 
(Lour.) Raeusch 
 
C15H24 93 resin [35] 
STEROLS         
 Sitosterol 
 
Canarium zeylanicum 
(Retz.) Blume 
 
C29H50O 
 
94 
 
oleoresin,   
bark,timber 
 
[36] 
 
 
く-sitosterol Canarium benglense 
Roxb. 
 
C29H50O 95 bark [45] 
Pgqkngzqpqn"*5く-
Hydroxyurs-12-en-11-one) 
Canarium zeylanicum 
(Retz.) Blume 
 
C30H48O2 96 oleoresin,  
bark 
[36] 
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In Melanesia, marketing operations for Canarium indicum L. and Canarium harveyi 
Seem. range from private and community based production, processing, and 
marketing of kernel oil for cosmetic and medicinal use, to government-backed 
nationwide purchasing of kernels for sale as confections and oil. Canarium 
solomonense B.L. Burtt in the Solomons islands are used as general-purpose timber 
[46]. Because of the potential of Canarium L. as a high-value export crop for nuts (for 
confections) and/or oil extraction, some research is being done on its taxonomy, 
production and marketing. Additional research needs include selection, evaluation, 
and improvement of promising varieties for timber production, investigation of 
cultural aspects, phenological studies, and vegetative propagation [47]. 
 
 
1.7 Selection of plant material  
 
The selection of plant material for the screening of biological activity can be based on 
a random selection or based on ethnopharmacology, where existing knowledge of the 
particular healing properties have been handed down from generation to generation 
especially amongst traditional healers. An additional mechanism for the identification 
of the plants for the study of its chemical constituents is based on chemotaxonomy. 
Chemotaxonomy is a science focusing on the correlation between related plant 
species and the occurrence of similar secondary metabolites. 
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1.7.1. The selection of Canarium patentinervium Miq. 
 
Despite reasonable traditional use of Canarium L. species, as well as extreme 
botanical diversity, the Canarium species in the Malaysian region have neither been 
the subject of pharmacological nor extensive phytochemical studies. Claims of the 
traditional usage to heal wounds [12] therefore requires validation and accurate 
documentation. For this purpose, this study was initiated as a basis for scientific 
verification regarding the traditional use of Canarium patentinervium Miq. . The 
leaves and barks of Canarium patentinervium Miq. were collected from one 
individual tree in April 2010 from Bukit Putih, Selangor, Malaysia (3°5'24 "N 
101°46'0"E). The plant was identified by Mr. Kamaruddin (Forest Research Institute 
of Malaysia). A herbarium sample (PID 251210-12) has been deposited in the Forest 
Research Institute of Malaysia. 
 
1.7.2 The selection of bioassays performed 
 
The origin and design of a screening process incorporates knowledge attained in 
ethnomedicine, traditional uses of the plant species, phytochemical evaluation and 
correlation to specific biological targets as well as the use of natural product libraries 
and general or targeted literature review. Stable standardized crude extracts are 
prepared and assayed for the claimed activities for which the particular plant species 
is traditionally used. The present study is focused on antioxidant, anti-inflammatory, 
anti-acetylcholinesterase, antimicrobial, antiparasitic and anticancer activities. 
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1.8 Aims of study 
 
This study is undertaken to extract and to isolate and purify active constituents from 
plants by phytochemical techniques and to characterize, elucidate and identify the 
structure of the pure compound and to assay isolated plant active constituents for 
antibacterial, antiparasitic, antioxidant, anti-inflammatory, anti-acetylcholinesterase 
and anticancer activities (Figure 1.2). 
 
 
1.9 Objectives of the study 
 
i. Extraction of leaves and barks of plant with solvents of different polarity to 
obtain crude extracts. 
ii. Investigation of the secondary metabolites present in the crude extracts of  
leaves and barks by qualitative phytochemical analysis. 
iii. Investigation of the antioxidant activity of the crude extracts of both leaves 
and barks using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging 
assay, ferric reducing ability of plasma (FRAP) assay, 4.4Ó-Azino-bis (3-ethyl-
benzthiazoline-6-sulfonic acid) (ABTS) assay, く-carotene bleaching assay and 
superoxide dismutase assay (SOD). 
iv. Investigation of the anti-inflammatory potential of the crude extracts against 5-
lipoxygenase (5-LOX) and cycloxygenase (COX) systems in vitro. 
v. Investigation of the anti-acetylcholinesterase (AChE) potential of the crude 
extracts in vitro.  
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vi. Investigation of the in vitro antibacterial activity of the crude extracts of leaves 
and barks using the disc diffusion assay and determination of minimum 
inhibitory concentration, minimum bactericidal concentration and death kill 
rate against four ATCC bacterial strains namely Gram-positive bacteria 
Staphylococcus aureus, Bacillus cereus, methicillin-resistant Staphylococcus 
aureus and Gram-negative Pseudomonas aeruginosa and nine clinical strain 
bacteria. 
vii. Investigation of the in vitro antifungal activity of the crude extracts of leaves 
and barks using the disc diffusion assay against three clinical strain fungi 
namely, Candida parapsilosis, Candida glabrata and Candida albicans. 
viii. Investigation of the anticancer activity of the crude extracts of the leaves and 
barks against human derived cell lines [HCT 116,colon cancer cell line and 
MCF-7 (ER+), MDA 468 (ER-) breast carcinoma] using MTT assay. 
ix. Investigation of the in vitro anti-parasitic activity of the crude extracts of 
leaves and barks against Leishmania donovani promastigotes, Entamoeba 
histolytica and Giardia intestinalis. 
x. Isolation and identification of the chemical compounds responsible for the 
antibacterial and antioxidant activity in the most active extract through 
bioassay-guided fractionation using liquid-liquid extraction or solvent 
partioning, column chromatography, thin layer chromatography (TLC) and 
nuclear magnetic resonance (NMR).  
xi. Bioactivity screening of all isolated compounds using the same bioassay as 
mentioned in iii-viii. 
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Leaves and barks of 
Canarium patentinervium 
Miq. 
  
Succesive maceration 
extraction with solvent 
hexane, chloroform and 
ethanol 
Hexane 
extract 
 
Chloroform extract 
 
Ethanol 
extract 
Bioassay ( in vitro) 
Most active extract 
 
 
 Preliminary fractionation 
with solvent partioning and 
column chromatography 
Bioassay ( in vitro)  
Active fraction(s) 
Different 
chromatographic 
techniques for isolation 
and purification of 
compound(s) guided by in 
vitro bioassay 
 
Active compound (s) 
 
 
Structure determination 
by NMR 
Bioassay of pure compound (s) 
using different concentrations 
to determine potency 
 
 
 
 
 
 
 
 
 
Figure 1.2: A diagrammatic summary of steps in the study of Canarium patentinervium 
Miq. evaluating the phytochemistry and pharmacological activities 
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CHAPTER 2 
PLANT COLLECTION AND EXTRACTION 
 
2.1 Brief introduction to Canarium patentinervium Miq. 
 
Canarium patentinervium Miq. is fairly widespread species which occurs in lowland 
primary and secondary mixed dipterocarp forest and kerangas forest. It is recorded as 
a common understorey tree0"KvÓu"c"uocnn"vq"ogfkwo-sized tree reaching a height of 50-
60 feet. The bark is grey brown that is smooth to cracking with many small lenticels 
and often inconspicuous hoop marks. The inner bark is reddish brown and loosely 
fibrous with clear resinous exudate. The sapwood is whitish with strong resinous 
smell from slash. Stipules are caduceus, inserted at the junction of twigs and rachis. 
Leaves are about 6-15 inches long and thickened at both ends, blade ovate to oblong 
lanceolate. Apex is gradually to rather shortly and bluntly acuminate. Fruits are 
ellipsoid to obovoid, rounded with a stone triangular in cross section. ItsÓ strongly 
glaucous and strongly aromatic (Figure 2.1). Tree flowers mainly from November to 
May and fruits from September to April [14].  
 
 
2.2 Plant collection and extraction 
 
The leaves and barks of Canarium patentinervium Miq. were collected from one 
individual tree in April 2010 from Bukit Putih, Selangor, Malaysia (3°5'24 "N 
101°46'0"E). The plant was identified by Mr. Kamaruddin (Forest Research Institute 
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Figure 2.1: Fresh and dried herbarium sample of Canarium patentinervium Miq.
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of Malaysia). A herbarium sample (PID 251210-12) has been deposited in the Forest 
Research Institute of Malaysia. The leaves and barks were air dried at ambient 
temperature (25 oC) in the laboratory for about 15 days. Thereafter the leaves were 
separated from the barks and any fruit present were removed and stored separately. 
The plant material was crushed to a fine powder using an industrial grinder.  
 
Extraction was performed with maceration that involves leaving the pulverized plant 
to soak in a suitable solvent in a closed container at room temperature [48]. Dried and 
grinded sample of leaves (2.8 kg) and barks (1.7 kg) were soaked in hexane with the 
ratio of 1:3 parts of sample to solvent for 2 hr in a 60 oC water bath, then filtered and 
concentrated with a rotary evaporator (Buchi, R-200 Switzerland). This was repeated 
3 times. Thereafter the leaves and barks were left to air dry completely for 3 days 
before repeating the whole process with chloroform and then ethanol respectively. 
The yield for the hexane, chloroform and ethanol extract of leaves were 1.25 %, 1.11 
% and 6.45 % respectively. The yield for the hexane, chloroform and ethanol extract 
of barks were 1.04 %, 0.40 % and 2.61 %. Crude extracts were kept at -20 oC until 
further use. 
 
 
 
 
 
 
 
 
50 
 
CHAPTER 3 
PHYTOCHEMICAL METHODS 
 
3.1 Introduction 
 
Phytochemical screening is basically done to detect the types of secondary 
metabolites that may be present in the plant extract.  A positive reaction should not be 
taken as proof of presence of a certain type of secondary metabolite because other 
compound types may give false-positive reactions. Despite this caveat, these detection 
methods are often effective for generating hyphotheses about what types of secondary 
ogvcdqnkvgu" oc{" dg" rtgugpv" kp" c" okzvwtg" qh" ÐwpmpqypuÑ" cpf" qh" oqpkvqtkpi" vjg"
presence of compounds of interest [48]. Qualitative phytochemical analysis of the 
crude extract was determined as outlined below. 
 
 
3.2 Phytochemical assay protocol 
 
Qualitative phytochemical analysis of the crude extract was determined as outlined 
below [48][49]. 
 
i. Alkaloids test 
200 mg of the extract was dissolved in 10 ml of methanol and heated on a 
boiling water bath with 2M HCl (5 ml). After cooling, the mixture was 
filtered and the filtrate was divided into two equal portions. One portion 
was treated with a few drops of Mayer's reagent and the other with equal 
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amounts of Wagner's reagent. The samples were then observed for the 
presence of turbidity or precipitation. A (+) score was recorded if the 
reagent produced only a slight opaqueness; a (++) score was recorded if a 
definite turbidity, but no flocculation was observed and a (+++) score was 
recorded if a definite heavy precipitate or flocculation was produced. 
 
Oc{gtÓu"tgcigpv"eqpukuvu"qh"4"uqnwvkqpu"fguetkdgf"jgtg"cu"uqnwvkqp"K"cpf"uqnwvkqp"KK0 
Solution I:  1.36 g HgCl2 was dissolved in 60 ml water. Solution II: 5 g KI was 
dissolved in 10 ml water. Both solutions are combined and diluted with water to 100 
ml. If alkaloids are present a white to yellowish precipitate will appear. Wagner 
reagent consists of 1.27 g I2 (sublimed) and 2 g KI was dissolved in 20 ml water and 
water is made up to 100 ml. A brown precipitate indicates the presence of alkaloids. 
 
ii. Flavonoids test 
40 mg plant material was dissolved in 2 ml ethanol and filtered. The 
filtrate was treated with a few drops of concentrated HCl and magnesium 
turnings (0.5 g). The presence of flavonoids was indicative if pink or 
magenta-red color developed within 3 min.  
 
iii. Saponins test 
 About 2.5 g of the plant material was extracted with boiling water. After 
cooling, the extract was shaken vigorously to froth and was then allowed 
to stand for 15-20 min and classified for saponin content as follows: (no 
froth = negative; froth less than 1 cm = weakly positive; froth 1.2 cm high 
= positive; and froth greater than 2 cm high = strongly positive). 
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iv. Tannins test 
 About 10 mg of extract was dissolved in 6 ml of hot distilled water and 
filtered. The solution is divided in three test tubes. To the first 0.9 % 
sodium chloride solution was added, to the second 0.9 % sodium chloride 
and 1 % gelatine solution was added and to the third ferric chloride (FeCl3) 
was added. Formation of a precipitate in the second treatment suggests the 
presence of tannins, and a positive response after addition of FeCl3 to the 
third portion which will result in a characteristic blue, blue-black, green or 
blue-green color supports this inference.  
 
v. Sterols (Salkowski reaction) test.  
40mg of extract was dissolved in 2 ml of chloroform and filtered. The 
filtrate was then added to 1 ml of concentrated H2SO4. The presence of 
sterols was indicated by the 2 phase formation with a red color in the 
chloroform phase.  
 
 
3.3 Results 
 
Phytochemical analysis results exhibits the presence of flavonoid, tannin and sterols 
in the respective leaves and barks extracts as shown in Table 3.1. Presence of 
flavonoid and tannin was shown in the leaf and bark extract of ethanol (Figure 3.1 and 
3.2). Steroids were present in all extracts except leaf extract of hexane and chloroform 
(Figure 3.3 and Figure 3.4). 
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3.4 Discussion 
 
Phytochemical analysis of Canarium patentinervium Miq.(Table 3.1) revealed 
presence of tannins and flavonoids  in the ethanol extract of leaves and barks. 
Triterpenoids can be divided into at least four groups of compounds namely true 
triterpenes, steroids, saponins and cardiac glycosides [50]. Steroids were detected in 
the ethanol extract of leaves and all tested bark extracts.  
 
 
3.5 Conclusion 
 
Results from our phytochemical analysis revealed that the ethanol extract of leaves 
and barks of Canarium patentinervium Miq. accumulate substantial amounts of 
flavonoids and tannins which could be possibly result in antioxidant or antibacterial 
activity [51]. 
 
 
 
 
 
 
 
 
 
54 
 
Table 3.1: Preliminary phytochemical analysis of the crude extract of Canarium patentinervium Miq 
Sample Alkaloids Flavonoids Saponins Tannins Steroids 
LH - - - - - 
LC - - - - - 
LE - +++ - +++ +++ 
BH - - - - +++ 
BC - - - - ++ 
BE - +++ - +++ +++ 
LH-leaf hexane extract, LC- leaf chloroform extract, LE-leaf ethanol extract, BH- bark hexane extract, BC- bark chloroform 
extract, BE- bark ethanol extract 
-:negative, +:trace, ++:positive, +++: strongly positive 
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Figure 3.1: Positive flavonoid result for leaf ethanol extract (left) against blank and and bark ethanol extract (right) against blank. 
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Figure 3.2: Positive tannin result for ngch"gvjcpqn"gzvtcev"octmgf"cu"vguv"vwdg"Ò56LEÓ"*nghv+ cpf"dctm"gvjcpqn"gzvtcev"octmgf"cu"vguv"vwdg"ÒUÓ"*tkijv+" against 
blank  (-), positive standard tannic acid(+) and ferric chloride . 
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Figure 3.3: Positive sterol test for leaf ethanol extract (left) and bark ethanol extract (right) against blank. 
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Figure 3.4: Positive sterol test for bark hexane extract (left) and bark chloroforml extract (right) against blank. 
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CHAPTER 4 
THE ANTIOXIDANT ACTIVITY 
 
4.1 Introduction 
 
4.1.1 Free radicals and their mechanism of action 
 
Oxygen is important for life processes to occur, however, an excess of oxygen could 
result in oxidative damage, which may even lead to death. The damage is not due to 
the presence of oxygen, but rather due to its role in the reduction of certain products 
to toxic free radicals as natural by products of cell metabolism [52]. These free 
tcfkecnu"ctg"rtqfwegf"ykvjkp" nkxkpi"egnnu"cpf"ctg"rctv"qh" vjg"egnnÓu normal metabolic 
processes, including detoxification processes and immune system defences. Free 
radicals may either be oxygen derived (ROS, reactive oxygen species) or nitrogen 
derived (RNS, reactive nitrogen species) [53]. The oxygen derived molecules are O2- 
(superoxide), HO (hydroxyl), HO2 (hydroperoxyl), ROO (peroxyl), RO (alkoxyl) as 
free radical and H2O2 oxygen as non-radical. Nitrogen derived oxidant species are 
mainly NO (nitric oxide), ONOO (peroxy nitrate), NO2 (nitrogen dioxide) and N2O3 
(dinitrogen trioxide) [54]. 
 
In normal cell, there are appropriate oxidant and antioxidant balance. However this 
balance can be shifted, when the production species is increased or when levels of 
antioxidants are diminished. This stage is called oxidative stress [53]. Oxidative stress 
results in the damage of biopolymers including nucleic acids, proteins, 
polyunsaturated fatty acids and carbohydrates. Oxidative stress causes serious cell 
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fcocig"ngcfkpi"vq"c"xctkgv{"qh"jwocp"fkugcugu"nkmg"Cn¦jgkogtÓu"fkugcug."RctmkpuqpuÓu"
disease, atherosclerosis, cancer, liver disease, inflammation, diabetes, AIDS, arthritis, 
immunological incompetence, neurodegenerative disorders and etc [55][56]. 
 
In aerobic organisms, the defence system against these free radicals is provided by 
free radical scavengers which act as anti-oxidants. Antioxidants are defined as a 
molecule capable of slowing or preventing the oxidation of other molecules, whereas 
c"dkqnqikecn"cpvkqzkfcpv"jcu"dggp"fghkpgf"cu"Ðcp{"uwduvcpeg"vjcv."yjgp"rtgugpv"cv"nqy"
concentrations compared to those of an oxidizable substrate, significantly delays or 
rtgxgpvu"qzkfcvkqp"qh"vjcv"uwduvtcvgÑ"[56] . There are at least four general sources of 
antioxidants: (1) enzymes, for example super oxide dismutase, gluthathione 
peroxidase and catalse; (2) large molecules (albumin, ceruloplasmin, ferritin, other 
proteins); (3) small molecules [ascorbic acid, glutathione, uric acid, tocopherol, 
carotenoids, (poly)phenols]; and (4) some hormones (estrogen, angiotensin, 
melatonin, etc) [54][56]. 
 
Mechanisms of antioxidant action include serving as (1) physical barriers to prevent 
ROS generation or ROS access to important biological sites, eg UV filters, cell 
ogodtcpgu=" *4+" ejgokecn" vtcru1ukpmu" vjcv" ÐcduqtdÑ" gpgti{" cpf" gngevtqpu." swgpejkpi"
ROS, eg carotenoids and anthocyanidins; (3) catalytic systems that neutralize or divert 
ROS, eg SOD (superoxide dismutase), catalse and gluthathione peroxidase; (4) 
binding/inactivation of metal ions to prevent generation of ROS, eg ferritin, 
ceruloplasmin, catechins; and (5) chain breaking antioxidants which scavenge and 
destroy ROS, eg ascorbic acid (vitamin C), tocopherols (vitamin E), uric acid, 
gluthathione, flavonoids [57]. 
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4.1.2 Natural antioxidants 
 
The term, antioxidant is used to describe a component that can function to decrease 
tissue damage by reactive oxygen. Defence provided for by the anti-oxidant systems 
is crucial to survival and can operate at different levels within the cells through the 
prevention of radical formation, intercepting formed radicals, repairing oxidative 
damage, increasing the elimination of damaged molecules, and recognition of 
excessively damaged molecules, which are not being repaired but rather eliminated to 
prevent mutations from occurring during replication [58].  Non-enzymatic anti-
oxidants are classified as being either water-soluble or lipid-soluble, depending on 
whether they act primarily in the aqueous phase or in the lipophilic region of the cell 
membranes [51].  
 
The hydrophilic anti-oxidants include vitamin C (ascorbic acid) and certain 
polyphenol flavonoid groups, while the lipophilic anti-oxidants include ubiquinols, 
retinoids, carotenoids, apocynin, procyanidins, certain polyphenol flavonoid groups 
and tocopherols [59]. Other non-enzymatic anti-oxidants include antioxidant enzyme 
cofactors, oxidative enzyme inhibitors and transition metal chelators such as ethylene 
diamine tetra-acetic acid (EDTA) [58]. 
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4.1.3 Therapeutic potential of phenolic substances 
 
The establishment of an inverse correlation between the intake of fruits and 
vegetables and the occurrence of diseases such as inflammation, age-related disorders, 
cancer and cardiovascular disease is derived from clinical trials and epidemiological 
studies [58][59]. Phenolic substances, which are known to possess high antioxidative 
activity, are actually common phytochemicals in fruits and leafy vegetables. Plants 
containing phenolic compounds have been reported to possess strong antioxidant 
properties. Most of these phenolics are classified into two principal groups of phenol; 
carboxylic acids and flavonoids, the latter being the most significant [58]. Phenolic 
compounds are found abundantly in all parts of the plant, such as wood, bark, stems, 
leaves, fruit, root, flowers, pollen and seeds. Antioxidative activity of phenolic 
compounds is based on their ability to donate hydrogen atoms to free radicals. Many 
phenolic compounds, particularly flavonoids, exhibit a wide range of biological 
effects, including antioxidant activity, antibacterial, antiviral, anti-inflammatory, 
antiallergic, anticancer, anti-thrombotic, vasodilatory actions and the ability to lower 
the risk of coronary heart diseases [58]. 
 
Knowledge of the potential antioxidant compounds present within a plant species 
does not necessarily indicate its antioxidant capacity, as the total anti-oxidant effect 
may be greater than the individual antioxidant activity of one compound, due to 
synergism between different anti-oxidant compounds. Methods to measure the anti-
oxidant activity in plant material generally involve both the generation of radicals 
(and their related compounds), and the addition of anti-oxidants, the latter resulting in 
the reduction of the radical and its consequent disappearance [60][61]. The role of 
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free radicals and active oxygen is becoming increasingly recognized in the 
pathogenesis of the many human diseases, including cancer, neurodegenerative 
diseases, ageing and atherosclerosis [62].  
 
Free radicals can also cause lipid peroxidation in foods that leads to their 
deterioration. Synthetic antioxidants, such as butylated hydroxyanisole (BHA) and 
butylated hydroxytoluene (BHT), have restricted use in food as they are suspected of 
carcinogenicity and of hormonal perturbation [63][64]. In search for sources of novel 
anti-oxidants with low toxicity, medicinal plants have over the past few years been 
studied extensively for their radical scavenging activity [65]. As plants produce a 
large number of anti-oxidants to control the oxidative stress caused by sunbeams and 
oxygen, it is clear that plants may represent a source of new compounds with 
antioxidant activity [66]. 
 
4.1.4 Antioxidant potential of Canarium L. 
 
Antioxidant activities were reported in Canarium album (Lour.) Raeusch, Canarium 
odontophyllum Miq. and Canarium schweinfurthii Engl. A tonic soup made of 
Canarium album (Lour.) Raeusch used mainly in China displayed significant 
antioxidant activity by 1,1,-diphenyl-2-2-picrylhydrazyl (DPPH) and ferric reducing 
antioxidant power (FRAP) assay [22].  Tannins extracted from the leaves, twigs and 
stem barks of Canarium album (Lour.) Raeusch showed potent antioxidant activity in 
the  DPPH radical scavenging activity  with IC50 values of 56.86 µg/ml, 62.31 µg/ml 
and 54.80 µg/ml respectively and ferric reducing power of 4.28, 3.74 and 4.49 mmol 
AAE/g equivalent of dried tannin [67]. Pure compounds from this species includes 
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brevifolin, hyperin and ellagic acid which showed free radical scavenging activity in 
DPPH assay [24]. The essential oil of Canarium schweinfurthii Engl. was tested for 
vjg" cpvkqzkfcpv" cevkxkv{" ykvj" vjg" FRRJ" cuuc{" cpf" d{" く-carotene bleaching test. It 
exhibited highest antioxidant activity at 150 µg/ml activity in both assay [25]. The 
ethyl acetate fraction of peel of Canarium odontophyllum Miq. exhibited 95±1.00% 
scavenging activity at the concentration of 40 µg/ml [26][68].  
 
 
4.2 Materials and methods 
 
4.2.1 Antioxidant determination assays 
 
Major antioxidant capacity methods have been generally divided into two categories: 
(1) hydrogen atom transfer (HAT) reaction and (2) single electron transfer (SET) 
reaction-based method. SET and HAT almost always occur together with the balance 
determined by antioxidant structure and pH. Bond dissociation energy (BDE) and 
ionization potential (IP) are two major factors that determine the mechanism and the 
efficacy of the antioxidants. HAT-based methods measure the classical ability of an 
antioxidant to quench free radicals by hydrogen donation. Relative reactivity in HAT 
methods are determined by the BDE of the H-donating group in the potential 
antioxidant and IP. Most HAT-based methods monitor competitive reaction kinetics 
and are rapid. 
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Z̋"-"CJ   ZJ"-"C̋ 
SET-based methods detect the ability of a potential antioxidant to transfer one 
electron to reduce any compound, including metals, carbonyls and radicals. 
                                          Z̋"-"CJ"         X- -"CJ̋ 
Relative reactivity is based on deprotonation and IP of the reactive functional group 
so SET is pH dependent. In general, IP decrease with increasing pH, reflecting 
increased electron-donating capacity with deprotonation. At acidic conditions, the 
reducing capacity may be restrained due to protonation on antioxidant compounds, 
whereas in basic conditions, proton dissociation of phenolic compounds would 
increase samples reducing capacity. SET methods can be relatively slow and involve 
two components, antioxidant and oxidant (probe). 
 
Probe (oxidant) + e (from antioxidant) reduced probe + oxidised antioxidant 
 
Huang et al. [69] broadly classified antioxidant capacity assays based on the reaction 
mechanisms as follows : SET [Folin-Ciocalteu (Folin-C), 1,1-diphenyl-2-
picrylhydrazine (DPPH) radical scavenging, trolox equivalent antioxidant capacity 
(TEAC), ferric reducing ability of plasma (FRAP)]; and HAT [oxygen radical 
absorbance capacity (ORAC), く-carotene/linoleic acid model system and inhibition of 
phospholipid peroxidation]. Prior et al. [70] classified DPPH, TEAC and Folin-C 
antioxidant assays into a category that utilises both SET and HAT reaction 
mechanisms, though predominantly based on electron transfer [70][53]. 
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4.2.2 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay 
 
4.2.2.1 Principle of the assay 
 
The antioxidant activity of each of the plant extracts was determined using the 
colorimetric DPPH assay, as described by Juan Badaturuge [71], was employed to 
determine the radical scavenging activity of the plant extracts. In DPPH radical-
scavenging assay, antioxidants react with DPPH, and convert it to yellow coloured 
g.g-diphenyl-く-picryl hydrazine. The degree of discolouration indicates the radical-
scavenging potential of the antioxidant activities [72] (Figure 4.1). The hydrogen 
donating capacity of test samples is quantified in terms of their ability to scavenge the 
relatively stable, organic free radical DPPH and by consequent reduction thereof. The 
absorption of the deep violet DPPH solution is measured at 550 nm, after which 
absorption decreases due to decolourisation to a yellow-white colour, in the event of 
reduction [73]. This decrease in absorption is stoichiometric according to the degree 
of reduction. The remaining DPPH is measured at a time interval of 30 min after the 
addition of the DPPH, which corresponds inversely to the radical scavenging activity 
of the sample extract or anti-oxidant. 
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FIOH Î flavonoid compound, FIO. Î flavonoid having donated a hydrogen 
Figure 4.1: Diagrammatic representation of chemical reaction of the reaction of DPPH in the presence of an electron donating antioxidant [74]. 
DPPH relatively 
stable 
organic radical Î deep 
violet colour 
DPPH reduced in 
presence of anti-
oxidant 
Î yellow-white colour 
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4.2.2.2 Colorimetric spectrophotometric assay 
 
Aliquots of plant extract dissolved in dimethyl sulfoxide (DMSO, R&M) were plated 
out in triplicate in a 96-well microtiter plate at different concentrations, prepared as 
serial dilutions ranging from 10 µg/ml to 0.3125 µg/ml. The 0.1 mM DPPH solution 
(AldrichR) was added to alternating columns of the test samples and methanol for 
control of test samples, in the remaining columns. The plate was shaken for 2 min and 
incubated for 30 min in the dark. The percentage decolourisation was obtained 
spectrophotometrically at 550 nm using the Thermo Scientific Varioskan Flash 
microtiter plate reader, linked to a computer equipped with (SkanIt Software 2.4.3). 
Percentage decolourisation was plotted against the concentration of the sample and 
the EC50 values were determined using Prism 5.00 software. Vitamin C (l-ascorbic 
acid), quercetin and trolox was used as positive control. At least three independent 
tests were performed for each sample. The DPPH absorbance decreases with an 
increase in DPPH radical scavenging activity. This activity is given as percent DPPH 
radical scavenging, which is calculated with the equation: 
DPPH radical scavenging activity (%) = [(Abscontrol - Abssample)]/ (Abscontrol)] x 
100 
Abscontrol is the absorbance of DPPH radical + methanol; 
Abssample is the absorbance of DPPH radical + sample extract /standard. 
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4.2.3 4.4Ó-Azino-bis(3-ethyl-benzthiazoline-6-sulfonic acid) (ABTS) assay 
 
4.2.3.1 Principle of the assay 
 
The antioxidant activity of each of the plant extracts was determined using the 
colorimetric ABTS assay, as described by Miller et al. [75], Rice-Evans [76] and 
Roberta et al. [77] was employed to determine the radical scavenging activity of the 
plant extracts. The ABTS anti-oxidant assay, also known as the Trolox equivalent 
anti-oxidant capacity (TEAC) assay, assesses the total radical scavenging capacity of 
the plant extracts. This is determined through the ability of these extracts to scavenge 
the long-lived specific ABTS radical cation chromophore in relation to that of Trolox, 
the water-soluble analogue of vitamin E [78].  The generation of the ABTS+ 
blue/green chromophore occurs through the oxidation of ABTS diammonium salt in 
the presence of potassium persulfate (Figure 3.4), with the absorption maxima 
occurring at wavelengths 645 nm, 734 nm and 815 nm. Anti-oxidants will reduce the 
pre-formed radical cation to ABTS, and in so doing bring about the decolourisation of 
ABTS+ to a colourless product [76]. The extent of this decolourisation is a measure of 
the ABTS+ radical cation that has been scavenged, after a fixed time period, and is 
relative to the Trolox standard. 
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Figure 4.2: Diagrammatic representation of the formation of the ABTS radical after the addition of potassium persulphate. 
 
 
ABTS radical 
relatively stable 
organic radical- deep 
turquoise green 
ABTS- transparent 
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4.2.3.2 Colorimetric spectrophotometric assay 
 
Aliquots of plant extract dissolved in dimethyl sulfoxide (DMSO, R&M) were plated 
out in triplicate in a 96-well microtiter plate at different concentrations. At least three 
independent tests were performed for each sample. Trolox (6-hydroxy-2,5,7,8-
tetramethylchromon-2-carboxylic acid, Sigma-Aldrich) Vitamin C (l-ascorbic acid) 
and quercetin was used as positive control and  prepared in ethanol and serial 
dilutions of this positive control were also prepared. Ethanol was used as the negative 
control. The stock solution included 7 mM ABTS solution and 2.4 mM potassium 
persulfate solution. The working solution was then prepared by mixing the 2 stock 
solutions in equal quantities. This solution was then stored in the dark for 12 - 16 
hours in order to stabilise it before use. It remains stable for 2 - 3 days in the dark.  
 
The concentrated ABTS+ solution was diluted with cold ethanol shortly before 
conducting the assay, to a final absorbance of 0.70 ± 0.01 at 734 nm at 37 °C, in a 3 
cm cuvette. The total scavenging capacity of the extracts was quantified through the 
addition of 100 たn"CDVU-"to 100 たn"qh"rncpv"gzvtcev0"Vjg"uqnutions were heated to 37 
°C for 7 min, after which the absorbance was read at 734 nm on a spectrophotometer 
(Thermo Scientific Varioskan Flash microtiter plate reader, linked to a computer 
equipped with SkanIt Software 2.4.3). All experiments were done in triplicate. The 
percentage decolourisation was calculated using equation below and the extent of 
inhibition of the absorbance of the ABTS+ was plotted as a function of the 
concentration.  
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This activity is given as percent ABTS radical scavenging, which is calculated with 
the equation: 
ABTS radical scavenging capacity (%) = [(Abscontrol - Abssample)]/ (Abscontrol)] x 
100 
Abscontrol is the absorbance of ABTS radical +ethanol; 
Abssample is the absorbance of ABTS radical + sample extract /standard. 
 
4.2.4. Ferric reducing ability of plasma (FRAP) assay 
. 
4.2.4.1 Principle of assay 
 
The antioxidant activity of each of the plant extracts was determined using the 
colorimetric FRAP assay, as described by Benzie & Strain [79] with slight 
modifications. The mechanism associated with this method is shown in Figure 4.3. 
This method was first developed to quantitate ascorbic acid in serum or plasma. When 
a Fe3+-TPTZ complex is reduced to the Fe2+ form by an antioxidant under acidic 
conditions, an intense blue color with maximum absorption develops at 593nm. 
Therefore, the antioxidant effect (reducing ability) can be evaluated by monitoring the 
formation of a Fe2+-TPTZ complex with a spectrophotometer. The FRAP assay gives 
fast and reproducible results. 
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!
!
Figure 4.3: Formation of (Fe2+-TPTZ) complex from (Fe3+-TPTZ) complex by antioxidant. 
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4.2.4.2 Colorimetric spectrophotometric assay 
 
Aliquots of plant extract dissolved in dimethyl sulfoxide (DMSO, R&M) were plated 
out in triplicate in a 96-well microtiter plate at different concentrations. Vitamin C (l-
ascorbic acid), quercetin and trolox were used as positive control. At least three 
independent tests were performed for each sample. The working FRAP reagent was 
prepared just before assay by mixing 300 mM of acetate buffer (pH 3.6), 10 mM of 
2,4,6-tripyridyl-s-triazine (TPTZ) and 20 mM of FeCl3.6H2O in ratio of 10:1:1.  
 
Briefly 180 µl of the FRAP reagent was mixed with 20 µl of the test sample so that 
the final dilution of the test sample in the reaction mixture was 1/10. After 30 
minutes, the absorbance of the coloured product (ferrous triphridyltriazine complex) 
was recorded using a spectrophotometer (Thermo Scientific Varioskan Flash 
microtiter plate reader, linked to a computer equipped with SkanIt Software 2.4.3). Fe 
(II) concentrations in the range of 1 µM-100 µM (FeSO4.7H2O) was used as standard 
for calibration curve and equation of linearity is determined (y=ax+b). From the 
linearity equation, concentration of sample that produced same absorbance as 1mM of 
Fe (II) was determined (y of sample filled in equation to obtain x). The antioxidant 
activity was calculated as Ferrous Equivalents, the concentration of samples which 
produced an absorbance value equal to that of 1 mM FeSO4. 
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4.2.5 く-carotene bleaching assay 
 
4.2.5.1 Principle of assay 
 
Vjg"く-carotene bleaching assay was conducted according to the method described by 
Habtemariam et al. [80] with some modifications. Kv" jcu" nqpi" dggp" mpqyp" vjcv" く-
ectqvgpg"tgcevu"ykvj"vjg"rgtqz{"tcfkecn"vq"rtqfweg"vjcv"く-carotene epoxides. Therefore 
that く-carotene has received attention as a radical scavenger or antioxidant. Later an 
cpvkqzkfcpv" cuuc{" wukpi" vjcv" く-carotene combined with lipids such as linolenic acid 
was established [80]. As shown in Figure 4.4, lipids such as linolenic acid forms as 
rgtqz{"tcfkecn"*NQQ̋+"kp"rtguence of the ROS and O2. This peroxy radical reacts with 
く-carotene to form a stable く-ectqvgpg"tcfkecn"uwdugswgpvn{."vjg"coqwpv"qh"く-carotene 
reduces in the testing solution. If an antioxidant is present in the testing solution, it 
reacts competitively with the peroxy radical. Therefore, antioxidant effects are easily 
monitored by the bleaching of the colour of a test solution with a spectrophotometer at 
470 po."yjkej"ku"vjg"v{rkecn"cduqtdcpeg"d{"く-carotene [56]. 
 
く-carotene    NQQ̋1"く-carotene adduct 
    NQQ̋ 
 
Antioxidant    NQQ̋1"く-carotene adduct 
 
Figure 4.4: Hqtocvkqp"qh"cffwevu"htqo"d{"く-carotene and antioxidant with lipid 
peroxide radical. 
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4.2.5.2 Colorimetric spectrophotometric assay 
 
Aliquots of plant extract dissolved in dimethyl sulfoxide (DMSO, R&M) were plated 
out in triplicate in a 96-well microtiter plate at different concentrations. Vitamin C (l-
ascorbic acid), quercetin and trolox were used as positive control. Dtkghn{."3"on"qh"c"く-
carotene solution in chloroform (2 mg in 10 ml) was pipetted into a round bottom 
flask containing 40 µl of linoleic acid and 500 µl of Tween 20. After the removal of 
chloroform using a rotary vacuum evaporator at 45 oC, 100 ml of deionised water 
were added with vigorous agitation. 180 µl of the emulsion was added to 20 µl of test 
samples at varying concentrations in 96-well microtitre plate. The absorbance was 
measured at 470 nm immediately against a blank consisting of the emulsion without 
く-carotene and after 3 hr of incubation at 50 oC using a spectrophotometer (Thermo 
Scientific Varioskan Flash microtiter plate reader, linked to a computer equipped with 
SkanIt Software 2.4.3). All determinations were carried out in triplicates. 
 
The antioxidant activity of test agents was evaluated in terms of bleaching qh" く-
carotene using the following formula:  
Antioxidant activity AA (%) = [1- (A0-At)/(Aoガ"-Atガ+_z"322 
A0 and Aoガ" ctg"absorbances measured at zero time of incubation for the test sample 
and control, respectively; At and Atガ"ctg"the absorbances measured in the test sample 
and control, respectively, after incubation for 3 hr. 
 
 
 
 
77 
 
4.2.6 Superoxide dismutase assay 
 
4.2.6.1 Principle of assay 
 
This assay was conducted with Sigma SOD assay kit [81].  SOD Assay Kit-WST 
cnnqyu" xgt{" eqpxgpkgpv" UQF" cuuc{kpi" d{" wvknk¦kpi" FqlkpfqÓu" jkijn{" ycvgt-soluble 
tetrazolium salt, WST-1 (2-(4-Iodophenyl)- 3-(4- nitrophenyl)-5-(2,4-disulfophenyl)- 
2H-tetrazolium, monosodium salt) that produces a water-soluble formazan dye upon 
reduction with a superoxide anion. The rate of reduction with oxygen is linearly 
related to the xanthine oxidase (XO) activity, and is inhibited by SOD. Therefore, the 
IC50 (50% inhibition activity of SOD or SOD-like materials) can be determined by a 
colorimetric method. Since the absorbance at 450 nm is proportional to the amount of 
superoxide anion, the SOD activity as an inhibition activity can be quantified by 
measuring the decrease in the colour development at 450 nm.  
 
4.2.6.2 Colorimetric spectrophotometric assay  
 
Twenty microliters of sample was plated at different concentrations in a 96-well 
microtiter plate. Then, 200 µl of WST solution and 20 µl of enzyme was added and 
incubated for 20 mins at 37 oC. Absorbance was then recorded at 450nm using 
Thermo Scientific Varioskan Flash microtiter plate reader, linked to a computer 
equipped with (SkanIt Software 2.4.3) and SOD inhibition rate was determined. SOD 
enzyme (Nacalai Tesque) was used as standard control. 
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4.2.7 Total phenolic content determination 
 
4.2.7.1 Principle of assay 
 
The total phenolic content of the crude extract and fractions was determined with the 
FolinÎCiocalteu reagent, following the modified method of Singleton and Rossi [82]. 
The Folin-Ciocalteu reagent is sensitive to reducing compounds including 
polyphenols, thereby producing a blue colour upon reaction. This blue colour is 
measured spectrophotometrically, thus determining the total phenolic content. 
 
4.2.7.2 Colorimetric spectrophotometric assay 
 
Briefly, 20 µl of test samples dissolved in methanol (1 mg/ ml) were added to 100 µl 
of FolinÎCiocalteu reagent and 1.58 ml of deionised water. After allowing the mixture 
to stand at room temperature for 5 min, 300 µl of 20% (w/v) sodium carbonate were 
added. Reaction mixtures were further incubated at room temperature for 30 mins, 
following which absorbance at 765 nm was read against a blank, using a Jenway 6305 
UVÎVis spectrophotometer (Jenway Ltd., Essex, UK). The standard calibration curve 
was plotted using gallic acid (50-250 µg/ml), from which total phenolic content was 
expressed as gallic acid equivalents (mg/g extract). 
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4.2.8 Total flavonoid content determination 
 
4.2.8.1 Principle of assay 
 
The total flavonoid content of the crude extract and fractions was determined with the 
aluminium chloride colorimetric method of Froehlicher et al. [83]. The principle of 
this assay is that aluminium chloride forms acid stable complexes with the C-4 keto 
group and either the C-3 or C-5 hydroxyl group of flavones and flavonols. In addition, 
aluminium chloride forms acid labile complexes with the orthodihydroxyl groups in 
the A- or B- ring of flavonoids [84]. 
 
4.2.8.2 Colorimetric spectrophotometric assay 
 
Briefly, 0.5 ml of test samples dissolved in methanol (1 mg/ ml) were added to 1.5 ml 
of 2% methanolic solution of aluminium chloride in sealed tubes and kept in dark for 
15 mins. Absorbance was then read at 430 nm using UV-vis spectrophotometer 
against blank of methanolic aluminium chloride solution. The standard calibration 
curve was plotted using quercetin (50-250 µg/ml), from which total flavonoid content 
was expressed as quercetin equivalents (mg/g extract). 
 
4.2.9 Statistical analysis 
 
ConcentrationÎresponse curves were calculated using the Prism software package 
5.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com (GraphPad, San Diego, USA) and data were reported as mean 
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and SD values obtained from a minimum of three determinations. Non linear best fit 
was plotted with SD and 95% confidence interval. All data were expressed as mean ± 
standard deviation. SD was computed but values were not shown in the graphs via 
this software. Data were analyzed using one way Anova followed by Tukey test using 
GraphPad Prism5 software. A significant difference was considered at the level of P < 
0.01. 
 
 
4.3 Results 
 
4.3.1 DPPH assay 
 
In this test the ethanol extract of leaves and barks exhibited profound antioxidant 
activities (Figure 4.5). The antioxidant activities were highest for ethanol extract of 
barks (77.80±0.01 %) followed by the ethanol extract of leaves (65.80±0.01 %), the 
hexane extract of leaves (38.90±0.02 %), the chloroform extract of barks (8.00±0.02 
%), the hexane extract of barks (5.00±0.01 %) and the chloroform extract of leaves 
(3.00±0.01 %) against standard ascorbic acid which was 97.90±0.00 % at the dose of 
10 µg/ml (Table 4.1). The EC50 (µg/ml) for the ethanol extract of barks (2.33 µg/ml) 
and leaves (2.93 µg/ml) were as good as ascorbic acid (1.88 µg/ml) as shown in 
Figure 4.6 and Table 4.2. 
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Figure 4.5: DPPH test result with 96 well microtiter plate results for bark (left) and leaf 
(right) ethanol extract. 
 
4.3.2   ABTS assay 
 
In this test the ethanol extract of leaves and barks exhibited good antioxidant activities 
(Figure 4.7). The EC50 (µg/ml) for the ethanol extract of barks (0.93±0.01 µg/ml) and 
leaves (2.28±0.01 µg/ml. The EC50 for ethanol extract of bark was significantly lower 
than ascorbic acid (1.54±0.06 µg/ml) (Table 4.2). 
 
4.3.3 FRAP assay 
 
The FRAP values are represented  in terms of concentration of sample that produced 
same absorbance as 1 mM of Fe (II) was determined (y of sample filled in equation to 
obtain x). The antioxidant activity was calculated as Ferrous Equivalents, the 
concentration of samples which produced an absorbance value equal to that of 1 mM 
FeSO4.  
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Table 4.1:  DPPH radical scavenging activity  at 10 µg/ml of extract 
 
Extracts % DPPH radical scavenging 
LH 38.90±0.02 
LC 3.00±0.01 
LE 65.80±0.01 
BH 5.00±0.01 
BC 8.00±0.02 
BE 77.80±0.01 
AA 97.90±0.00 
 
LH-leaf hexane extract, LC- leaf chloroform extract, LE-leaf ethanol extract 
BH- bark hexane extract, BC- bark chloroform extract, BE- bark ethanol extract 
AA- ascorbic acid 
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Figure 4.6: DPPH scavenging activity (%) of Canarium patentinervium Miq. 
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Figure 4.7: ABTS scavenging activity (%) of Canarium patentinervium Miq. 
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Linear regression curve for all samples and positive controls are shown in Figure 4.9-
4.17. From the standard graph of ferrous sulphate (Figure 4.8), the values for six 
extracts were determined using the standard formula (Table 4.2). The FRAP activity 
was calculated from regression equation of ferrous sulphate calibration curve 
(y=0.0105x+0.0136, r2- 0.9817).  The ethanol extract of bark showed significant 
FRAP activity of 67.00±0.32 µg/ml compared to quercetin and ascorbic acid. The 
ethanol extract of the leaves showed significant FRAP activity of 200.00±0.07 µg/ml 
compared to ascorbic acid. The poorest activity was shown by hexane extract of barks 
that correlates with the low r2 in its regression equation (Figure 4.12). 
 
4.3.4 く-carotene bleaching assay 
 
The く-carotene decolourisation (Figure 4.18) was most prominent in ethanol extract 
of leaves and barks with EC50 (µg/ml) of 6.04±0.02 µg/ml and 7.04±0.04 µg/ml 
respectively (Table 4.2) 
 
4.3.5 Superoxide dismutase assay 
 
The ethanol extract of the leaves shows highest SOD-like activity with IC50 of 
5027ł2023"たi1on0"*Vcdng"604+. 
 
4.3.6 Total phenolic content determination 
 
The total phenolics in the extracts was determined with the Folin-Ciocalteu assay, 
calculated from regression equation of calibration curve of gallic acid 
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(y=0.1762x+0.0047, r2- 0.9994) (Figure 4.19) and is expressed as gallic acid 
equivalents, GAE (mg/g). The highest phenolic content was in ethanol extract of 
leaves followed by barks (Table 4.2). 
 
4.3.7 Total flavonoid content determination 
 
The total flavonoids in the extracts was determined with the aluminium chloride 
assay, calculated from regression equation of calibration curve (y=0.09330x+0.0023, 
r2-0.9992) (Figure 4.20) of quercetin and is expressed as quercetin equivalent, (mg/g). 
The highest flavonoid content was in ethanol extract of leaves followed by barks 
(Table 4.2). 
 
4.3.8 The antioxidant values, total phenolic and flavonoid content and their 
correlations 
 
The total antioxidant activity investigated with the relevant total phenolic and 
flavonoid content are summarized in table 4.3. 
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Figure 4.8:  Fe (II) calibration curve in FRAP assay. 
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Figure 4.9:  Leaf hexane (LH) extract calibration curve in FRAP assay. 
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Figure 4.10:  Leaf chloroform (LC) extract calibration curve in FRAP assay. 
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Figure 4.11:  Leaf ethanol (LE) extract calibration curve in FRAP assay. 
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Figure 4.12:  Bark hexane (BH) extract calibration curve in FRAP assay. 
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Figure 4.13:  Bark chloroform (BC) extract calibration curve in FRAP assay. 
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Figure 4.14:  Bark ethanol (BE) extract calibration curve in FRAP assay. 
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Figure 4.15:  Ascorbic acid (AA) calibration curve in FRAP assay. 
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Figure 4.16:  Trolox (TRO) calibration curve in FRAP assay. 
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Figure 4.17:  Quercetin (QC) calibration curve in FRAP assay. 
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Figure 4.18<"く-carotene decolourisation (%) of Canarium patentinervium Miq. 
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Figure 4.19: Gallic acid calibration curve in Folin-Ciocalteu assay. 
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Figure 4.20: Quercetin calibration curve in total flavonoid content determination. 
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Table 4.2: Antioxidant values of Canarium patentinervium Miq. 
  
Extracts 
Total phenolic 
content, Gallic 
acid equivalent 
(mg/g) 
Total flavonoid 
content, Quercetin 
equivalent (mg/g) 
ABTS assay, 
EC50 *たi1on+ 
DPPH assay, 
EC50 *たi1on+ 
FRAP assay, 
FRAP value
 *たi1on+ 
く-carotene 
bleaching 
assay, EC50 *たi1on+ 
Superoxide 
dismutase 
assay 
IC50*たi1on+ 
LH 6.61±0.01 18.99±0.02 27.30±0.01 17.45±0.03 2845.00±0.15 9.39±0.05 80.54±0.03 
LC 14.28±0.03 12.57±0.04 31.10±0.02 134.00±0.04 1329.00±0.18 21.81±0.04 26.84±0.03 
LE 204.97±0.05 125.32±0.03 2.28±0.01 2.93±0.00B 200.00±0.07 6.04±0.02 3.05±0.01 
BH 5.19±0.01 1.55±0.02 521.00±0.01 1857.00±0.01 3531.00±0.14 125.00±0.08 238.00±0.04 
BC 13.99±0.03 12.14±0.02 34.90±0.02 87.80±0.05 1242.00±0.19 50.40±0.03 20.13±0.02 
BE 100.26±0.01 24.57±0.02 0.93±0.01A 2.33±0.02 67.00±0.32 7.04±0.04 8.51±0.07 
AA NA NA 1.54±0.06 1.88±0.01 347.00±0.23 NA NA 
QC NA NA 0.88±0.03A 2.88±0.02B 86.00±0.24 1.64±0.04C NA 
TRO NA NA 0.68±0.02 4.77±0.04 33.00±0.54 1.65±0.03C NA 
SOD NA NA NA NA NA NA 1.59±0.04 
LH: leaf hexane extract, LC: leaf chloroform extract, LE: leaf ethanol extract, BH: bark hexane extract, BC: bark chloroform extract, BE: bark 
ethanol extract, AA: ascorbic acid, QC:quercetin, TRO: trolox and SOD: superoxide dismutase 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same capital  letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
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Table 4.3: The mean r2 values for correlation between total phenolics contents, total flavonoid contents and antioxidant activities (EC50) 
 
 
ABTS DPPH FRAP BC 
Total phenolic contents 0.1410 0.1285 0.5246 0.2287 
Total flavonoid contents 0.1388 0.1319 0.3179 0.2146 
ABTS na 0.9977*** 0.5398 0.9008** 
DPPH 0.9977*** na 0.5029 0.8977** 
FRAP 0.5398 0.5029 na 0.4770 
BC 0.9008** 0.8977** 0.4770 na 
** significant with p<0.01 
   
*** significant with p<0.0001, na- not applicable 
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4.4 Discussion 
 
In vitro antioxidant capacity can be determined by hydrogen atom transfer (HAT) 
method and single electron transfer (SET) method [56]. HAT based methods measure 
the ability of an antioxidant to scavenge free radical by hydrogen donation to form a 
stable compound. SET  based methods detect the ability of the antioxidant to transfer 
one electron to reduce compound including metals, carbonyls and radicals [70][85]. く-
carotene bleaching assay involves HAT method, FRAP assay involves SET method 
while DPPH and ABTS assay involves both method predominantly via SET method 
[55][57]. 
 
FRAP is the ferric reducing power of antioxidants by the reduction of the ferric ions 
to the ferrous ions, which form a blue colored ferrous-tripyridyltriazine complex 
(ferric TPTZ) which is detected at 593 nm. Deeper blue colour indicates higher 
antioxidant potential [86]. The samples absorbance equivalent to 1 mM FeSO4 was 
calculated from equation of linearity of individual sample. Total FRAP value was 
determined from the absorbance obtained from samples above using the standard Fe 
(II) calibration curve equation (y=0.0105x+0.0136, r2=0.9817). Ethanol extract of 
barks displayed significant (p< 0.01) FRAP value (89022ł2054" たi1on+ compared to 
ascorbic acid (569022ł2045"たi1on+"cpf"swgtegvkp"*:8022ł2046"たi1on+0 
   
Kp" vjg" く-carotene/linoleic model, linoleic acid reacts with ROS and O2 to form an 
wpuvcdng"rgtqz{"tcfkecn0"く-carotene being an antioxidant will react with this radical to 
form stable epoxide causing the bleaching of yellow solution. Competition reaction 
occurs with the presence of another antioxidant (sample) to react with the peroxy 
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radical resulting in slower bleaching of solution detected at 470 nm 
spectrophotometrically [87]. Ethanol extract of leaves and barks displayed best EC50 
value of 8026ł2024" たi1on" cpf" 9026ł2026" たi1on" tgurgevkxgn{0 Our results are in 
agreement to the previous reports which pointed out that ascorbic acid did not show 
its antioxidant activity under similar assay [88] Such phenomenon was termed as 
Ðrqnct" rctcfqzÑ"yjgtgd{" rqnct" cpvkqzkfcpvu" tgockpkpi" kp" vjg" cswgqwu" rjcug" qh" vjg"
emulsion are more diluted in lipid phase and thus, they are less effective [89]. 
 
ABTS assay involves the reduction of the blue-green 2,2-azino-bis(3- 
thylbenzothiazoline-6- uwnhqpcvg+" tcfkecn" ecvkqp" *CDVU┳-+" d{" cpvkqzkfcpvu" vq" kvu"
original colourless ABTS form. Greater discolourisation results in lower absorbance 
at 734 nm indicating higher antioxidant capacity [75][76]. Ethanol extract of the bark 
displayed significant (p<0.01) EC50 (20;5ł2023" たi1on) compared to ascorbic acid 
(3076ł2028"たi1on).  
 
The DPPH radical has a deep purple colour and absorbs strongly at a wavelength of 
550 nm, whereas the yellowish reduction product DPPH2 does not. In DPPH assay 
(another SET method), ethanol extract of leaves and barks displayed significantly 
lower EC50 value of 40;5ł2022"たi1on"cpf"4055ł2024"たi1on"tgurgevkxgn{"eqorctgf"vq"
trolox (EC50 = 6099ł2026"たi1on+"[90]. The radical scavenging potential against DPPH 
organic radical directly depends on the number of hydroxyl groups present in ring B 
of flavonoids, with an increase in the number of hydroxyl groups resulting in an 
increase in radical scavenging activity [91]. Phenols, amino and thiophenol groups are 
commonly known to be the active groups for DPPH scavenging. The mechanism by 
which DPPH is scavenged, aids in elucidating the structure-activity relationship 
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(SAR) of the antioxidant and in doing so, may be beneficial in the rational design of 
novel flavonoid-derived antioxidants with improved pharmacological profiles [92]. 
 
The DPPH and ABTS assays have the same mechanism of action, but, in most cases, 
the results obtained from the ABTS assay are higher than those from DPPH assay. It 
has been documented that results reported for the ABTS assay do not only take into 
account the activity of the parent compound, but also the contribution of reaction 
products and other individual compounds on the activity, which is not the case in the 
DPPH assay [93][94]. 
 
SOD which catalyses the dismutation of the superoxide anion (O2-) into hydrogen 
peroxide and molecular oxygen, is one of the most important anti-oxidative enzymes. 
Preventive antioxidants, such as SOD are described either as preventing introduction 
of initiating radicals or as inhibiting the rate which new chains are set up. The 
analytical methods for determination of O2- scavenging capacity employ enzymatic or 
nonenzymatic O2- generation systems. In this study the enzymatic system that uses 
xanthine oxidase (XOD) to generate O2- radicals was used [57]. XOD was used for 
formation of O2- that is the reduced to oxygen by SOD-like activities in samples. The 
WST-1 is used as a probe that undergoes competitive reaction with SOD-like samples 
to reduce O2- to oxygen forming a formazan coloured dye. Thus higher rate of SOD 
activity results in less dye formation and less absorbance. The ethanol extract of the 
leaves shows highest SOD-like activity with IC50 qh"5027ł2023たi1on0 
 
In the above experiments, the ethanol extract of leaves and barks displayed superior 
antioxidant capacities. The EC50 values of the samples were consistently low in SET 
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methods (ABTS, DPPH and FRAP) superior to standard as opposed to HAT method 
*く-carotene bleaching) assay. The present study demonstrates that Canarium 
patentinervium Miq.  is a potent source of antioxidants that exhibits its antioxidant 
activity predominantly  via the SET method. Several reports emphasized on the fact 
that there is a positive relationship between total phenolic contents and antioxidant 
activity [95][96]. Our study demonstrated the existence of a low positive correlation 
between the total phenolic contents and the FRAP values (y = -0.0125x + 2.2564, r2 = 
0.5246) and total phenolic contents and く-carotene bleaching values (y = -0.2747x + 
52.42, r2 = 0.2287), respectively. Therefore, one could draw an inference that non 
phenolic by itself or in synergy with the phenolics and flavonoids impart Canarium 
patentinervium Miq its antioxidant properties. 
 
4.5 Conclusion 
 
The present study demonstrates that Canarium patentinervium Miq.  is a potent 
source of antioxidants that exhibits its antioxidant activity predominantly  via the SET 
method. Pronounced radical scavenging activity has been reported in plants with 
phenolic moieties, the presence of which is common in natural antioxidants. These 
phenolic moieties include substances such as tannins, flavonoids, phenolic acids, 
tocopherol, and cathecheses. Tannins are, at least in part, responsible for the free 
radical scavenging activities working synergistically with other antioxidant substances 
[86]. 
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CHAPTER 5 
ANTI-INFLAMMATORY ACTIVITY 
 
5.1 Introduction 
 
5.1.1 Inflammation and arachidonic system 
 
Over the last 10 years, a significant body of evidence has emerged indicating that 
chemically diverse classes of naturally-occurring substances derived from higher 
plants are of potential interest for therapeutic interventions in several inflammatory 
diseases [97]. Inflammation response is a critical protective reaction to irritation, 
injury, or infection, characterised by redness, heat, swelling, loss of function and pain. 
Redness and heat result from an increase in blood flow, swelling is associated with 
increased vascular permeability, and pain is the consequence of activation and 
sensitisation of primary afferent nerve fibres. In normal conditions, these changes in 
inflamed tissue serve to isolate the effects of the insult and thereby limit the threat to 
the organism [97]. 
 
In recent years, roles have been identified for several inflammatory cells and for a 
large number of inflammatory mediators in important pathologies not previously 
nkpmgf" vq" kphncoocvkqp." uwej" cu" Cn¦jgkogtÓu" fkugcug" cpf" ectfkqxcuewnct" fkuqtfgtu"
including atherosclerosis, as well as cancer [98]. These findings have significantly 
increased the importance of understanding the cellular and molecular mechanisms 
forming the basis of the inflammatory process and in identifying new targets for the 
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development of innovative and safe therapeutic strategies for the management of 
inflammatory diseases. Most plant-derived secondary metabolites are known to 
interfere directly or indirectly with the following molecules and/or mechanisms 
[98][99]: 
1. various inflammatory mediators (eg arachidonic acid metabolites, peptides, 
cytokines, excitatory amino acids etc). 
2. the production and/or action of second messengers ( such as cGMP, cAMP, 
various protein kinases, and calcium among others). 
3. the expression of transcription factors such as AP-1, NF-┏D." cpf" rtqvq-
oncogenes (c-jun, c-fos, and c-myc), 
4. the expression of key pro-inflammatory molecules such as inducible NO 
synthase (iNOS), cyclooxygenase (COX-4+." e{vqmkpgu" *KN?3く." VPH-g" gve+."
neuropeptidases and proteases.  
 
In this study we reviewed and investigated the contribution of naturally occurring 
substances from higher plants acting on the arachidonic acid pathway. Inflammation 
in injured cells is both initiated and maintained by the overproduction of 
prostaglandins and leukotrienes, which are produced by separate enzymatic pathways, 
viz. the cyclo-oxygenase (COX) and lipoxygenase (LOX) pathways, respectively. 
Both the prostaglandins as well as the leukotrienes are biosynthesised on demand 
from arachidonic acid, which is a 20-carbon fatty acid, derived from the breakdown of 
cell membrane phospholipids by any number of phospholipase A2 (PLA2) isoforms 
[100] (Figure 5.1). 
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Figure 5.1: Arachidonic acid metabolites and inflammation [101]. 
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Arachidonic acid is normally stored in membrane-bound phospholipids and released 
by the action of phospholipases. Enzymatic conversion of released arachidonic acid 
into biologically active derivatives proceeds through one of several routes [99]. 
Cyclooxygenase converts arachidonic acid to unstable cyclic endoperoxides from 
which prostaglandins, prostacyclin and thromboxanes are derived. Formation of the 
leukotrienes from arachidonic acid is initiated by the action of 5-lipoxygenase 
producing leukotriene A4. Hydrolysis of leukotriene A4, or the incorporation of 
glutathione results in the formation of leukotriene B4 and C4, respectively [102]. In 
addition, 12- and 15-lipoxygenase can catalyse arachidonic acid conversion and 
lipoxins A and B are amongst the possible products. Many of these metabolites of 
arachidonic acid feature prominently in the development of inflammation. 
Prostaglandin E2 and prostacyclin are potent vasodilators, while leukotriene D4 causes 
cellular adhesion, chemotaxis of neutrophils and degranulation. Leukotrienes C4, D4 
and E4 contribute to inflammation by increasing vascular permeability. Leukotrienes 
are also believed to play an important pathophysiological role in allergic broncho-
constriction of asthma [103]. 
 
Through pharmacological intervention in the arachidonic acid cascade various anti-
inflammatory agents have been developed. These include aspirin-like drugs, which 
inhibit cyclo-oxygenase. Corticosteroids appear to indirectly inhibit phospholipases 
thus preventing release of arachidonic acid. Future progress in this field is likely to 
produce drugs which antagonise arachidonic acid derivatives or inhibit the enzymes 
involved in their synthesis with greater specificity [99][103]. 
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5.1.2 The lipoxygenase system 
 
5-LOX presents either in the cytosol or the nucleus of a resting cell (depending on the 
cell), as a soluble enzyme. Upon cellular stimulation, 5-LOX and cytosolic 
phospholipase A2 (cPLA2) co-migrate to the nucleus. It is here that cPLA2 liberates 
arachidonic acid from the membrane phospholipids [104] (Figure 5.2). Arachadonic 
acid is the main substrate for the lipoxygenase enzyme, and is presented to 5-LOX for 
metabolism by the 5-lipoxygenase activating protein (FLAP). The metabolism of 
arachidonic acid produces leukotrienes and lipoxins via the LOX pathway [105]. 5-
LOX, catalysing the oxidation of arachidonic acid, produces 5(S)- 
hydroxyperoxyeicosatetraenoic acid (5-HPETE), a hydroperoxide intermediate, which 
undergoes dehydration, resulting in the formation of leukotriene A4 (LTA4). 
Enzymatic hydrolysis of LTA4, as well as conjugation with other substances, leads to 
the formation of inflammatory mediators [106]. These inflammatory mediators are 
responsible for the powerful chemo-attractive effects on the eosinophils, neutrophils 
and macrophages, as well as the increased release of pro-inflammatory cytokines by 
macrophages and lymphocytes. 
 
Two other pathways in the LOX system, 15-LOX and 12-LOX, are responsible for 
the production of lipoxins, the latter having the potential to counteract the pro-
inflammatory effects of the leukotrienes. 5-Lipoxygenase is inhibited by quinones, 
hydroxyquinones, and a variety of phenolic compounds, including certain flavonoids 
such as, quercetin, kaempferol, morin, myricetin and cirsiliol [107].  At the onset of 
the inflammatory process, arachidonic acid is converted to eicosanoids and 
leukotriene B4 (LTB4) by LOX [104], which is coupled with the production of 
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prostaglandins and thromboxanes by cyclooxygenase (COX). The leukotrienes 
present at the onset of inflammation are also responsible for the maintenance thereof.  
Leukotrienes have been identified as mediators of a number of inflammatory and 
allergic reactions [103]..  
 
These include rheumatoid arthritis, inflammatory bowel disease,  atopic dermatitis, 
psoriasis, chronic urticaria, asthma [108] and allergic rhinitis [109][103]. The 5-LOX 
pathway has also recently been linked to the development of atherosclerosis, 
osteoporosis and certain types of cancers [105]. As a result of the pathophysiological 
implications of 5-LOX products and the potential benefits of anti-leukotriene therapy, 
different strategies have been employed (targeting PLA2, 5-LOX, FLAP, LTA4 
hydrolase and leukotriene C4 (LTC4) synthase with 5-LOX being the ideal and most 
promising target [105]. 
 
5.1.3 The cyclooxygenase system 
 
Cyclooxygenase (COX) is a key enzyme that catalyzes the transformation of 
arachidonic acid to several biologically active eicosanoids, such as prostaglandins 
(PGs), thromboxane (e.g., TxA2), and prostacyclin (e.g., PGI2). This enzyme actually 
catalyzes two major reactions, as shown in Figure 5.3. Arachidonic acid, the most 
important physiological precursor of eicosanoids biosynthesis, can be released from 
the membrane phospholipid by activation of phospholipase A2 (PLA2) and/or 
phospholipase C (PC). Cyclooxygenase then catalyzes the addition of molecular 
oxygen at the C-11 of arachidonic acid to form the 11-peroxy intermediate, following 
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by rearrangement to a cyclic endoperoxide and introduction of a second molecule of 
oxygen at C-15 to form prostaglandin G2 (PGG2).  
 
        Ligand  
 
           
        Receptor  
 
   
 
 
 
Figure 5.2: The translocation of 5-lipoxygenase and cytosolic phospholipase A2, upon 
cellular stimulation, to the nuclear membrane, followed by substantial generation of 
leukotrienes [105]. 5-LOX = 5-lipoxygenase, cPLA2 = cytosolic phospholipase A2, FLAP = 
5-lipoxygenase activating protein, PKA = protein kinase A, cAMP = cyclic adenosine 
monophosphate, MK2 = kinases, ERK1,2 = extracellular signal-regulated kinase 1,2. 
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The hydroperoxidase activity reduces PGG2 to generate PGH2 which is the immediate 
precursor for production of eicosanoids, such as PGD2, PGE2, PGF2a, PGI2, and TxA2, 
through corresponding synthase activities. These arachidonic acid metabolites derived 
from PGH2 are important mediators of inflammatory responses, immunological 
effects, and tumour development [100]. 
 
Cyclooxygenase (COX) exist as three isoforms: cyclooxygenase-1 (COX-1), 
expressed in most cells constitutively, inducible cyclooxygenase-2 (COX-2), triggered 
by pro-inflammatory stimuli, and COX-3, present mainly in the cerebral cortex and 
human heart [110][111] . COX-1 is a constitutive form of the enzyme that has been 
linked to the production of physiologically important prostaglandins that may play a 
role in homeostasis (gastric, renal, etc). COX-2 exists in a constitutive form in kidney 
and brain and is inducible by cytokines and growth factors. Induction of the COX-2 is 
linked to inflammatory cell types and tissues and COX-2 is believed to be the target 
for the anti-inflammatory actions of NSAIDs. Thus there is an on-going effort to 
identify compounds that will inhibit COX-2 in preference to COX-1 since such an 
agent may be safer and perhaps more efficacious [112].  
 
Despite of the undesired side effects such as increased cardiovascular risk of COX-2-
selective inhibitors, much research spanning many years has been focused on finding 
COX-2 selective inhibitors, owing to the remarkable reduction of adverse 
gastrointestinal and renal effects associated with conventional non-steroidal anti-
inflammatory drugs (NSAIDs) as well as to their potential therapeutic benefits in 
several diseases, including certain types of cancer [113]. Thus, it is of value to study 
cyclooxygenase inhibitors. 
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Figure 5.3: Cyclooxygenase and arachidonic acid metabolism. 
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5.1.4 Dual inhibitors  
 
Conventional pharmacological management of inflammatory disease like 
osteoarthritis involves treatment with non-steroidal anti-inflammatory drugs 
(NSAIDs) or selective COX-2 inhibitors that block the formation of PGs without 
modulating 5-LOX enzyme activity. Inhibition of one or both of the COX enzymes 
oc{"ÐujwpvÑ"CC"ogvcdqnkuo"fqyp"vjg"7-LOX pathway, which can aggravate toxicity 
associated with the lack of PGs and excess production of LTs. For example, NSAID-
induced gastric ulcers have been shown to have high concentrations of LTB4 in their 
walls, which attracts leukocytes to the stomach and may contribute to ulceration 
[114][115]. 
 
Recently, reports have appeared regarding so-ecnngf" Ðfwcn" kpjkdkvqtu.Ñ" cigpvu" vjcv"
inhibit not only COX-1 and COX-2, but also 5- LOX [116][117][118][119]. These 
agents with anti-oxidative properties may be particularly effective for managing the 
metabolic processes underlying inflammatory conditions and reducing both gastric 
and cardiovascular side effects by balancing AA metabolism in the body. This dual 
inhibition activity will be investigated for this plant. 
 
5.1.5 Anti-inflammatory potential of Canarium L. 
 
The essential oil of Canarium schweinfurthii Engl. collected from the region of 
Cameroon inhibited the enzymatic activity of lipoxygenase with an IC50 value of 62.6 
ppm [19]. However in a separate study of the same species collected from central 
African region did not show any activity in the cotton pellet induced granuloma 
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formation experiment [13]. This may suggest possible evidence of variety between 
secondary metabolites constituents according to regions. The essential oil of 
Canarium schweinfurthii Engl. at a dose of 1, 2 and 3 mg/ kg i.p. displayed potent 
analgesic effect in the acetic acid-induced writhing and hot plate experiments [13]. 
 
 
5.2 Materials and methods 
 
5.2.1 Anti-inflammatory determination assays 
 
The anti-inflammatory activity of the plant extracts was determined using the in vitro 
5- LOX assay. This assay measures the inhibitory activity against the 5-LOX enzyme, 
which is a key enzyme in the metabolism of arachidonic acid that is responsible for 
the formation of leukotrienes (which play a pivotal role in the pathophysiology of 
chronic inflammatory and allergic diseases) as first determined by Sircar et al. [120] 
and later modified by Evans [121]. 
 
There are three ways to measure COX activity, one is to measure the final product of 
the reaction, PGE2; another is to measure directly the oxygen uptake that occurs 
during the first step of the reaction using the oxygen sensor and third is to measure the 
second reaction (peroxidase function) spectrophotometrically [112]. The peroxidase 
co-substrate oxidation assay can detect cyclooxygenase inhibitors which may directly 
interfere with enzyme activity or scavenge the free radical intermediates to block the 
reaction process. However, the oxygen consumption assay is mainly reflective of 
inhibitors which block the interaction of enzyme and arachidonic acid. We currently 
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describe a peroxidase co-substrate oxidation assay system adapted to a 96-well plate 
format. This requires less enzyme and reaction material and yields savings in time and 
money. The peroxidase co-substrate oxidation assay is useful as a pre-screening 
method [100][112]. 
 
5.2.2 The 5-LOX inhibition assay 
 
5.2.2.1 Principle of the assay 
 
The 5-LOX assay was conducted according to the method described by Baylac & 
Racine [122] with some modifications. Lipoxygenases (LOX) are dioxygenases that 
catalyse the addition of molecular oxygen to polyunsaturated fatty acids containing a 
1,4-pentadiene group. The 5-LOX enzyme thus converts its substrate, arachidonic 
acid, to the conjugated diene product 5-hydroxy- 6,8,11,1-eicosatetraenoic acid (5-S-
HETE), which, in turn, is converted to LTA4, and then to LTB4, by LTA4 hydrolase. 
For the purposes of this experiment, linoleic acid was used as the substrate, as it 
shares a high degree of structural similarity to arachidonic acid (containing the 1,4-
pentadiene group in question), it is far easier to handle as well as having a stronger 
affinity for the 5-LOX enzyme resulting in greater UV absorbance readings [123].  
 
The experiment specifically determines increases in absorbance at 234 nm as a result 
of the formation of conjugate double bonds in linoleic acid hydroperoxide (from a 
1,4-diene to a 1,3-diene), as used in the biochemical evaluation of the LOX pathway 
of soybean plants submitted to wounding [124]. 
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 5.2.2.2 Protocol 
 
5-LOX enzyme (human recombinant from Calbiochem) was used. Ice-cold buffer 
(potassium phosphate) at 4 oC was mixed with 100 U of the thawed enzyme. Twenty 
microliters of samples dissolved in DMSO was plated out in triplicate in a 96-well 
microtiter plate at different concentrations, followed by 160 µl of 0.1 M potassium 
phosphate buffer (pH 6.3) maintained at 25 oC and 20 µl of enzyme solution. Mixture 
was agitated and 10 µl of linoleic acid was added and incubated for 10 mins at 25 o C. 
Absorbance was recorded at 234 nm using Thermo Scientific Varioskan Flash 
microtiter plate reader, linked to a computer equipped with (SkanIt Software 2.4.3). 5-
Lipoxygenase is known to catalyse oxidation of unsaturated fatty acids containing 1-4 
diene and the modification of linoleic acid (1-4-diene into 1- 3-diene) can be detected 
at 234 nm. Percentage inhibition of enzyme was determined by comparison of rates of 
reaction of samples relative to blank sample using the formula (E-S)/E x 100, where E 
is the activity of enzyme without test sample and S is the activity of enzyme with test 
sample. The experiments were done in triplicate. Nordihydroguaiaretic acid (NDGA) 
was used as positive control. 
 
5.2.3 The peroxidase endpoint assay for COX-1 and COX-2 
 
5.2.3.1 Principle of the assay 
 
The COX-1 and COX-2 peroxidase endpoint assay was conducted according to 
method described by Gierse et al. [112]. The peroxidase endpoint assay system is 
based on sequential reactions of the cyclooxygenase (generating PGG2) and the 
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peroxidase (converting PGG2 to PGH2) activities. Its success relies on the peroxidase 
co-substrate being transformed to a comparatively stable chromophore in a 
predictable stoichiometric relationship to the reduction of PGG2. N,N,NÓ,NÓ-
tetramethyl-p-phenylenediamine (TMPD) is a convenient co-substrate for use in the 
assay. 
 
5.2.3.2 Protocol 
 
COX-1 and COX-2 enzyme from Calbiochem was used. Twenty microliters of 
sample dissolved in DMSO was plated in triplicates at different concentrations in a 
96-well microtiter plate followed by 20 µl of enzyme solution. Then, 160 µl of 
endpoint assay mix was added and incubated for 10 mins at room temperature. 
Absorbance was recorded at 611 nm using Thermo Scientific Varioskan Flash 
microtiter plate reader, linked to a computer equipped with (SkanIt Software 2.4.3). 
Percentage inhibition of enzyme was determined by comparison of rates of reaction of 
samples relative to blank sample using the formula (E-S)/E x 100, where E is the 
activity of enzyme without test sample and S is the activity of enzyme with test 
sample. Indomethacin was used as positive control. 
 
5.2.4 Statistical analysis 
 
ConcentrationÎresponse curves were calculated using the Prism software package 
5.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com (GraphPad, San Diego, USA) and data were reported as mean 
and SD values obtained from a minimum of three determinations. Non linear best fit 
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was plotted with SD and 95% confidence interval. All data were expressed as mean ± 
standard deviation. SD was computed but values were not shown in the graphs via 
this software.  Data were analyzed using one way Anova followed by Tukey test 
using GraphPad Prism5 software. A significant difference was considered at the level 
of P < 0.01. 
 
 
5.3 Results 
 
5.3.1 The 5-LOX inhibition assay 
 
In the 5-LOX assay, chloroform extract of the barks displayed potent enzyme 
inhibition (IC50=29.53±0.03 µg/ml) which was close to nordihydroguaiaretic acid 
(IC50=29.19±0.02 µg/ml). Ethanol extract of leaves and barks follow through with 
IC50=49.66±0.02 µg/ml and IC50=59.06±0.07 µg/ml respectively. Thus the potency of 
activity against 5-LOX was BC > LE > BE (Table 5.1.). According to the 5-LOX 
enzyme inhibition activity measurement guide by Kamatou et al. [94], [IC50 <30 
µg/ml: good activity; 30 < IC50 <80 µg/ml : moderate activity; IC50 >80 µg/ml : poor 
activity] chloroform extract of barks of Canarium patentinervium Miq  displays good 
5-LOX enzyme inhibition activity followed by moderate activity by ethanol extract of 
leaves and barks. 
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5.3.2 The peroxidase endpoint assay for COX-1 and COX-2 
In the COX assay, only ethanol extract of leaves and barks exhibited IC50 below 100 
µg/ml. Ethanol extract of leaves had superior COX-1 inhibition (IC50 = 0.60±0.01 
µg/ml) compared to COX-2 inhibition (IC50 = 1.07±0.01 µg/ml) (Figure 5.5) whereas 
the barks had superior COX-2 inhibition (IC50 = 9.39±0.03 µg/ml) as opposed to 
COX-1 (IC50 = 11.41±0.03 µg/ml) (Figure 5.4) .  
 
5.4 Discussion 
These assay measures the inhibitory activity against 5-LOX and COX enzymes. At 
the onset of the inflammatory process, arachidonic acid is converted to eicosanoids 
and leukotriene B4 (LTB4) by LOX [104], which is coupled with the production of 
prostaglandins and thromboxanes by cyclo-oxygenase (COX). 5-LOX is the key 
enzyme in the metabolism of arachidonic acid that is responsible for the formation of 
leukotrienes which play a pivotal role in the pathophysiology of chronic inflammatory 
and allergic diseases. Lipoxygenase catalysing the oxidation of arachidonic acid, 
produces 5(S) - hydroxyperoxyeicosatetraenoic acid (5-HPETE), a hydroperoxide  
intermediate, which undergoes dehydration, resulting in the formation of leukotriene 
A4 (LTA4). Enzymatic hydrolysis of LTA4, as well as conjugation with other 
substances, leads to the formation of inflammatory mediators [106]. These 
inflammatory mediators are responsible for the powerful chemo-attractive effects on 
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Figure 5.4: COX inhibition by BE. 
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Figure 5.5: COX inhibition by LE. 
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Table 5.1.Anti-inflammatory values of Canarium patentinervium Miq.  
 
Extracts Anti-inflammatory 
assay 5-LOX, IC50 *たi1on+ 
COX-1 inhibition 
assay IC50*たi1on+ 
COX-2 inhibition 
assay IC50*たi1on+ 
COX-1/COX-2 
ratio 
LH 206.00±0.02 >100 >100 NA 
LC 104.69±0.04 >100 >100 NA 
LE 49.66±0.02 0.60±0.01 1.07±0.01 0.56 
BH 110.07±0.04 >100 >100 NA 
BC 29.53±0.03 >100 >100 NA 
BE 59.06±0.07 11.41±0.03 9.39±0.03 1.22 
NDGA 29.19±0.02 NA NA NA 
INDO NA 0.29±0.04 0.26±0.03 1.11 
LH: leaf hexane extract, LC: leaf chloroform extract, LE: leaf ethanol extract, BH: bark hexane extract, BC: bark 
chloroform extract, BE: bark ethanol extract, AA: ascorbic acid, QC: quercetin, TRO: trolox and INDO: 
indomethacin.  
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± 
SD. Values with the same capital letter are not significantly different (P<0.01) according to Tukey multiple comparison 
test. 
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the eosinophils, neutrophils and macrophages, as well as the increased release of pro-
inflammatory cytokines by macrophages and lymphocytes [104].  
 
Other inflammatory mediators such as histamine and immunoglobulin E, cause 
spasms in the smooth muscle of bronchi and blood vessels, playing an eminent role in 
asthmatic attacks. As leukotrienes thus play a major role in the pathophysiology of 
chronic inflammatory diseases, it has been suggested that 5-LOX inhibitors may thus 
be useful in the treatment of various conditions [125]. The 5-LOX pathway has also 
been implicated in cardiovascular disease, including atherosclerosis, stroke, 
myocardial infarction and the weakening of large artery walls and the formation of 
aneurysms [126][105]. The presence of the 5-LOX pathway, the production of 
leukotrienes and presence of the enzymes concerned, as well as leukotriene receptors 
is expressed in diseased tissue. Genetic studies have been carried out on mice linking 
the 5-LOX pathway to atherosclerosis, and population genetic studies involving 
humans, correlates genotypes of 5-LOX, FLAP and LTA4 hydrolase to cardiovascular 
disease, as shown in studies by Dwyer et al. [127]  and Helgadottir et al.  
[128][129][130]. 
  
The results obtained from the leaves and barks of the plant indicate good anti-
inflammatory activity via 5-LOX inhibition cascade in the chloroform extract of the 
barks (IC50=29.53±0.0 5たi1on+"yjgp"eqorctgf" vq"PFIC" (IC50=29.19±0.02 たi1on+0"
Moderate activity was shown in  BE and LE while poor activity was depicted in LH 
and BH in accordance with measure of activity by Kamatou et al. [94], [IC50 <30 
µg/ml: good activity; 30 < IC50 <80 µg/ml : moderate activity; IC50 >80 µg/ml : poor 
activity].   
  
126 
 
 
 
COX (prostaglandin H2 synthase) inhibition is the mechanism of action of most 
NSAIDS. COX-1 is a constitutive form of the enzyme that has been linked to the 
production of physiologically important prostaglandins that may play a role in 
homeostasis (gastric, renal, etc). COX-2 is a form of the enzyme that is inducible by 
cytokines and growth factors. Induction of COX-2 is linked to inflammatory cell 
types and tissues. There is an ongoing effort to identify compounds that might inhibit 
COX-2 in preference to COX-1 since such an agent may be safer and perhaps more 
efficacious. In this study, COX activity is measured by utilizing peroxidase activity 
and the electron donor TMPD, which turns blue upon reduction as a co-substrate. 
Arachidonic acid is used as a substrate which must first be converted to 
hydroperoxide thus yielding an indirect measure of COX activity. This assay has been 
noted to be a high-thorough put method [112]. 
 
In this study, only the ethanol extract of leaves and barks showed inhibition against 
COX-1 and COX-2 enzymes with IC50 below 100 µg/ml. Ethanol extract of leaves 
had superior COX-1 inhibition (IC50 = 0.60±0.01µg/ml) compared to COX-2 
inhibition (IC50 = 1.07±0.01 µg/ml) whereas the barks had superior COX-2 inhibition 
(IC50 = 9.39±0.03 µg/ml) as opposed to COX-1 (IC50 = 11.41±0.03 µg/ml). 
 
In order to determine the inhibitory selectivity on COX-1 and COX-2 enzymes, the 
COX-1/COX-2 ratio was applied. According to Burnett et al. [131], A COX-1 
selective inhibitor will have ratio <1, whereas a COX-2 selective inhibitor will have 
ratio of  > 1. In this study ethanol extract of bark was COX-2 selective (ratio 1.22) 
while the leaves were COX-1 selective (ratio 0.56). The COX-2 selective behaviour 
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of the ethanol extract of the barks was similar to positive control indomethacin (ratio 
1.11). This indicates the presence of lead compound that would have a more potent 
COX-2 selectivity than indomethacin in the ethanol extract of barks. In view of dual 
inhibition activity, the ethanol extract of barks seemed to have moderate inhibition 
against 5-LOX and good inhibition against COX enzymes (selective COX-2). 
Chloroform extract of the bark though had good 5-LOX inhibition but did not have 
activity against COX enzymes below 100 µg/ml.  
 
 
5.5 Conclusion 
 
A combination of anti-inflammatory and antioxidant activity constitutes a good 
indication on potential anti-inflammatory activity of a drug [132][133]. Keeping this 
in mind the ethanol fraction of the plant warranted further studies. The pathway 
mechanism of the dual inhibition of the fraction against 5-LOX and COX needs to be 
investigated.  However it would be interesting to investigate the bioactive component 
of the chloroform extract of barks as it exhibited an activity similar to our positive 
control. The clinical significance of these data is quite clear that they support a role 
for Canarium patentinervium Miq. (Burseraceae Kunth.) as a source of lead 
compounds in the management of inflammatory diseases. 
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CHAPTER 6 
ANTI-ACETYLCHOLINESTERASE ACTIVITY 
 
6.1 Introduction 
 
6.1.1 Pathophysiology of Cn¦jgkogtÓu"fkugcug 
 
Neurodegenerative disease is a term applied to a variety of conditions arising from a 
chronic breakdown and deterioration of the neurons, particularly those of the central 
nervous system [134]0" Cn¦jgkogtÓu" fkugcug" *CF+" ycu" hktuv" fguetkdgf" kp" 3;28" d{" c 
Bavarian neuropsychiatrist Alois Alzheimer [135]. It is a complex, multifactoral, 
progressive, neurodegenerative disease primarily affecting the elderly population and 
is estimated to account for 50 Î 60 % of dementia cases in persons over 65 years of 
age [136]. The pathophysiology of AD is complex and involves several different 
biochemical pathways.  
 
The first neurotransmitter defect discovered in AD involved acetylcholine (ACh), 
which plays an important role in memory and learning. In the CNS, ACh stimulation 
of the nicotinic receptors appears to be associated with cognitive function. Normally, 
ACh is stored in the nerve terminals, in structures called vesicles and is released from 
the nerve endings when the nerve terminal is depolarized, thereby entering the 
synapse and binding to the receptor [137]. However, in patients with AD, the ACh 
which is released has a very short half-life due to the presence of large amounts of the 
enzymes; acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which are 
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both present in the brain and are detected among neurofibrillary tangles and neuritic 
plaques [138][139]. These enzymes hydrolyse the ester bond in the ACh molecule, 
leading to loss of stimulatory activity. Approaches to enhance cholinergic function in 
AD have included stimulation of cholinergic receptors or prolonging the availability 
of ACh released into the neuronal synaptic cleft by use of agents which restore the 
level of acetylcholine through inhibition of both AChE and BChE. 
 
Recently, Hodges [140] demonstrated that the inhibition of AChE holds a key role not 
only to enhance cholinergic transmission in the brain but also to reduce the 
ciitgicvkqp" qh" く-amyloid and the formation of the neurotoxic fibrils in AD. 
Therefore, AChE and BChE inhibitors have become remarkable alternatives in 
treatment of AD [139]. Existing anticholinesterase drugs (example, tacrine, donepezil, 
physostigmine, galantamine and heptylphysostigmine) for the treatment of dementia 
are reported to have several dangerous adverse effects such as hepatotoxicity, short 
duration of biological action, low bioavailability, adverse cholinergic side effects in 
the periphery and a narrow therapeutic window [141][142].  This necessitates the 
interest in finding better AChE inhibitors from natural resources. 
 
The history of drug discovery has shown that plants contain active compounds that 
have become new sources to investigate for the pharmaceutical industry. Plant 
constituents may not only act synergistically with other constituents from the same 
plant but may also enhance the activity of compounds or counteract toxic effects of 
compounds from other plant species [143]. In traditional practices, numerous plants 
have been used to treat cognitive disorders, including neurodegenerative diseases and 
different neuropharmacological disorders [144]. 
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6.1.2 Acetylcholine and its functions 
 
Acetylcholine (ACh), a neurotransmitter in the brain plays a critical role in the 
function of learning and memory. ACh is synthesized from acetyl-CoA and choline 
by choline acetyltransferase, and is released into the synaptic cleft which then is 
hydrolyzed by AChE to become choline and acetic acid (Figure 6.1). Choline is taken 
up again into the presynaptic neurons for use in ACh synthesis. Free choline within 
the nerve terminal is acetylated by a cytosolic enzyme, choline acetyltransferase 
(CAT), the source of the acetyl groups being acetyl-CoA [141].   
 
The rate-limiting process in the Ach synthesis appears to be the choline transport, the 
activity of which is regulated according to the rate at which ACh is released. ACh has 
functions both in the peripheral nervous system (PNS) and in the central nervous 
system (CNS) as a neuromodulator [141]. Its receptors have very high binding 
constants. In the peripheral nervous system, acetylcholine activates muscles, and is a 
major neurotransmitter in the autonomic nervous system. In the central nervous 
system, ACh and the associated neurons form a neurotransmitter system, the 
cholinergic system, which tends to cause anti-excitatory actions. Cholinesterase is 
present in the presynaptic nerve terminals and Ach is continually being hydrolysed 
and re-synthesised [145][146]. 
 
6.1.3 Distribution and function of cholinesterase 
 
There are two distinct types of cholinesterase both belonging to the family of serine 
hydrolases, namely acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), 
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related closely in molecular structure but differing in their distribution, substrate 
specificity and functions [145]. 
 
AChE is widely distributed in the central nervous system (CNS) and the peripheral 
nervous system AChE is one of the most efficient enzymes of the nervous system 
which is bound to the basement membrane in the synaptic cleft at cholinergic 
synapses, where its function is to hydrolyse the released transmitter. AChE is quite 
specific to acetylcholine (Ach). BChE has a widespread distribution, being found in 
tissues such as liver, skin, brain and gastrointestinal smooth muscles, as well as 
soluble form in the plasma. It is not particularly associated with cholinergic synapses 
and has broader substrate specificity than AChE. It hydrolyses butyrylcholine more 
rapidly than ACh [145][147]. 
 
6.1.4 Cholinesterase inhibitors 
 
The most important drugs that enhance cholinergic transmission act either by 
inhibiting cholinesterase or by increasing acetylcholine release by AChE. The choline 
released in the process is reused in synthesizing new ACh. Inhibition of AChE increases the 
amount of ACh available for neurotransmission. 
There are three main effects of cholinesterase inhibition: 
‚ effects on autonomic cholinergic synapses 
‚ effects on neuromuscular junction 
‚ effects on the central nervous system (CNS) 
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Figure 6.1: Cholinergic neurotransmission. The neurotransmitter Ach is synthesised in 
presynaptic cholinergic neurons by choline acetyltransferase (CAT or ChAT). The process 
entails transfer of an acetyl group from acetyl-coenzyme A to choline. Until needed, the ACh 
molecules are stored in discrete vehicles at the ends of the presynaptic neurons. Arrival of a 
nerve impulse triggers the release of Ca2+ ions, which activate actin microfilaments that in 
turn pull the storage vesicles into position for ACh release. In a single event the vesicles 
empty their contents into the synaptic cleft. Most of these molecules bind to cholinergic 
receptors on adjacent postsynaptic neurons. Any that remain unbound are rapidly hydrolysed 
by AChE. The choline released in the process is reused in synthesizing new ACh. Inhibition 
of AChE increases the amount of ACh available for neurotransmission. 
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Autonomic effects include bradycardia, hypotension, excessive secretions, 
bronchoconstriction, gastrointestinal hypermotility and decrease of intraocular 
pressure. This inhibition can be useful in the treatment of glaucoma that has increased 
intraocular pressure. Drugs that have been used for this condition are physostigmine 
and ecothiopate as eye drops. Neuromuscular action causes muscular fasciculation 
and increased twitch tension and can produce depolarisation block [147] . 
 
 The clinical uses of this action would be in myasthenia gravis where transmission 
fails due to too few ACh receptors due to immunological reasons, and cholinesterase 
inhibition improves transmission. Drugs targeting this action would be neostigmine 
and pyridostigmine taken orally. Cholinesterase inhibition at CNS has been used to 
alleviate the cholinergic deficiency associated with Alzheimers disease (AD). 
Although the overall AChE activity is reduced, it is increased in the neuritic plaque 
and neurofibrillary tangles at the early stages of a AD patient brain [146]. It has been 
uwiiguvgf" vjc{" CEjG"oc{" rtqoqvg" ciitgicvkqp" qh" Cdgvc" *く-amyloid) into a more 
toxic amyloid form. Thus inhibiting AChE activity might increase ACh 
neurotransmission in the synaptic cleft of the brain and diminish the Abeta burden 
resulting in improved cognitive function and alleviating the process of amyloid 
deposition. Among several existing hypotheses explaining the origin of AD, including 
the cholinergic, tau and amyloid theories [148][149], the cholinergic one is most 
studied. Majority of drugs on the market are thus AChE inhibitors like donepezil, 
tacrine, rivstigmine and galathamine [147].  
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6.1.5 Plants as potential anticholinesterase inhibitors 
 
In traditional practices, numerous plants have been used to treat cognitive disorders, 
including neurodegenerative diseases and different neuropharmacological disorders. 
Ethnopharmacological approach and bioassay-guided isolation have provided a lead 
in identifying potential AChE inhibitors from plant sources, including those for 
memory disorders. A variety of plants has been reported to show AChE inhibitory 
activity and so may be relevant to the treatment of neurodegenerative disorders such 
as AD [144].  
 
Majority of studies have focused on the anticholinesterase alkaloids, such as physostigmine 
and galantamine. So far, more than 35 alkaloids have been reported to have AChE inhibitory 
activity [144]. The other major classes of compound reported to have such activity are the 
terpenoids, glycosides and coumarins. Plants belonging to families Acanthaceae, 
Apocynaceae, Amaryllidaceae, Angelicae, Araceae, Asclepiadaceae, Berberidaceae, 
Buxaceae, Combretaceae, Compositae, Coniferae, Cyperaceae, Ebenaceae, Ericaceae, 
Euphorbiaceae, Fumariaceae, Gentianaceae, Guttiferae, Lamiaceae, Leguminosae, Lilliaceae, 
Lycopodiaceae, Malvaceae, Magnoliaceae, Menispermaceae, Molluginaceae, Moraceae, 
Musaceae, Nelumbonaceae, Papaveraceae, Piperaceae, Rubiaceae, Rutaceae, Sapotaceae, 
Solanaceae and Tamaricaceae have been reported to have AChE inhibitory potential [149]. 
 
The present study was undertaken to screen the anti-acetylcholinesterase potential of 
Canarium patentinervium Miq. from family of Burseraceae. No anti-
acetylcholinesterase studies have been reported on this species to date. 
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6.2 Materials and methods 
 
6.2.1 Anti-acetylcholinesterase determination assays 
 
6.2.1.1   Principle of the assay 
 
Acetylcholinesterase (AChE) inhibitory activity was measured by slightly modifying the 
spectrophotometric method developed by Ellman et al. [150]. Acethylcholine iodide which 
is the substrate is hydrolysed by acethylcholinesterase enzyme resulting in the 
formation thiocholine that reacts with dithiobisnitrobenzoate ion (DTNB) resulting in 
yellow 5-thio-2-nitrobenzoate anion observed at a wavelength of 412 nm. 
acethylcholine   thiocholine + acetate 
Thiocholine + dithiobisnitrobenzoate   yellow color 
This is accomplished by the continuous reaction of the thiol ykvj" 7." 7Ó" dithiobis-2-
nitrobenzoate ion (I) to produce the yellow anion of 5-thio-2-nitro-benzoic acid (II). 
H2O + (CH3)3N+CH2CH2SCOCH3 (enzyme) (CH3)3N+CH2CH2S- 
        + CH3+COO-   +   2H+ 
(CH3)3N+CH2CH2S- + RSSR (I)  (CH3)3N+CH2CH2SSR  
        + RS- (II) 
    R =  
The reaction with the thiol has been shown to be sufficiently rapid so as not to be rate limiting 
in the measurement of the enzyme, and in the concentrations used does not inhibit the 
enzymic hydrolysis. 
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6.2.1.2 Protocol 
 
5,5´-Dithio-bis(2-nitrobenzoic) acid (DTNB), galanthamine, nordihydroguairetic acid 
(NDGA) and electric eel acetylcholinesterase (AChE) (Type-VI-S, EC 3.1.1.7)  purchased 
from Sigma AldrichR was used. Samples were dissolved in dimethyl sulfoxide (DMSO, 
R&M) prior to assay and serial dilutions were done. In brief, 130 µL of 0.1 mM sodium 
phosphate buffer (pH 8.0), 20 µN" qh" FVPD." 42" たN" qh" vgut solution and 20 µL of AChE 
solution were added by multichannel automatic pipette (Eppendorf, Germany) in a 96-well 
microplate and incubated for 15 min at 25 °C. The reaction was then initiated with the 
addition of 10 µL of acetylthiocholine iodide. The hydrolysis of acetylthiocholine iodide was 
monitored by the formation of the yellow 5-thio-2-nitrobenzoate anion as a result of the 
reaction of DTNB with thiocholines, catalyzed by enzymes at a wavelength of 412 nm 
utilizing a 96-well microplate Thermo Scientific Varioskan Flash microtiter plate 
reader, linked to a computer equipped with (SkanIt Software 2.4.3).  
 
Percentage inhibition of AChE was determined by comparison of rates of reaction of 
samples relative to blank sample (ethanol in phosphate buffer pH=8) using the 
formula (E-S)/E x 100, where E is the activity of enzyme without test sample and S is 
the activity of enzyme with test sample. The experiments were done in triplicate. 
Galanthamine was purchased from Sigma (St. Louis, MO, USA) and used as 
reference. 
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6.2.2 Statistical analysis 
 
ConcentrationÎresponse curves were calculated using the Prism software package 
5.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com (GraphPad, San Diego, USA) and data were reported as mean 
and SD values obtained from a minimum of three determinations. Non-linear best fit 
was plotted with SD and 95% confidence interval. All data were expressed as mean ± 
standard deviation. SD was computed but values were not shown in the graphs via 
this software. Data were analyzed using one way Anova followed by Tukey test using 
GraphPad Prism5 software. A significant difference was considered at the level of P < 
0.01. 
 
 
6.3 Results 
 
In the anti-acethylcholinesterase assay, chloroform extract of the barks displayed the 
best activity (IC50 = 88.59±0.14 たi1on+ as opposed to galanthamine (IC50 = 0.74±0.06 
たi1on+"*Hkiwtg"803+0""Vjg"gvjcpqn"gzvtcev"qh"dctmu"cpf"ngcxgu"hqnnqy"vjtqwij"ykvj"IC50 
= 186.00±0.15 たi1on"cpf"IC50 = 201.24±0.15 たi1on"tgurgevkxgn{. Hexane extracts of 
bark and leaves and the chloroform extract of leaves had the lowest enzyme inhibition 
activity (IC50 = 570.00±0.08 たi1on." IC50 = 842.00±0.25 たi1on" cpf" IC50 = 
1780.00±0.24 たi1on"tgurgevkxgn{+. Thus the potency of activity against AChE was BC 
> BE > LE > BH >LH > LC (Table 6.1). 
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Extracts Anti-acetylcholinesterase assay, IC50"*たi1on+
LH 842.00±0.25
LC 1780.00±0.24
LE 201.34±0.15
BH 570.00±0.08
BC 88.59±0.14
BE 186.00±0.15
Galantamine 0.74±0.06
LH: leaf hexane extract, LC: leaf chloroform extract, LE: leaf ethanol extract, BH: bark hexane extract, BC: bark 
chloroform extract, BE: bark ethanol extract. Data were obtained from three independent experiments, each 
performed in triplicates (n=9) and represented as mean ± SD.Values with the same capital letter are not 
significantly different (P<0.01) according to Tukey multiple comparison test.
Table 6.1. Anti-acetylcholinesterase values of Canarium patentinervium  Miq.
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Figure 6.2: AChE inhibition by BC. 
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                                         Figure 6.3: AChE inhibition by galanthamine. 
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6.4. Discussion 
 
This assay measures the inhibition properties against AChE, which is the key enzyme 
in the hydrolysis of acetylcholine that is responsible for muscle and organ relaxations. 
Acetylcholinesterase inhibitors are used medicinally to treat myasthenia gravis to 
kpetgcug"pgwtqowuewnct" vtcpuokuukqp"cpf" vq" vtgcv"Cn¦jgkogtÓu"fkugcug" *fghkekgpe{" kp"
the production of acetylcholine). Furthermore, oxidative and inflammatory processes 
are among the pathological features associated with the central nervous system in 
AlzheiogtÓu"fkugcug [151]. The brain of patients suffering from AD is said to be under 
oxidative stress as a result of perturbed ionic calcium balances within their neurons 
and mitochondria [152][153]. Accumulating evidence suggests that oxidative damage 
to neurons plays an important role in the AD pathogenesis [154].  
 
Thus, efforts to reduce oxidative injury may prove beneficial in retarding or 
preventing the onset and progression of AD in patients. In this study (Chapter 4), BC 
had displayed good antioxidant potential via enzymatic and non-enzymatic assays. 
This in addition to its anti-acetylcholinesterase activity exhibited in this chapter 
suggest that chloroform extract of the barks hold lead compounds that inhibit 
acetylcholinesterase activity as well as reduce the oxidative stress with possible 
neuroprotective effects. Moreover, there is evidence that AChE inhibitors have an 
anti-inflammatory role through action against free radicals and amyloid toxicity, as 
well as through decreasing release of cytokines from activated microglia in the brain 
and blood [153].  
There is an established link between the cholinergic system and inflammation as 
acetylcholine, the principle neurotransmitter, is reported to attenuate the release of 
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cytokines in the parasympathetic anti-inflammatory pathway by which the brain 
modulates systemic inflammatory responses to endotoxin [155]. Destruction of 
neurons due to inflammation around Abeta plaques is thought to be a major factor in 
the pathogenesis of AD [2]. In Chapter 5 it has been found that BC had an anti-
inflammatory action against 5-LOX (IC50 = 29.53±0.03 µg/ml) against the positive 
control NDGA ((IC50 = 29.19±0.02 µg/ml). This in relation to the anti-
acetylcholinesterase activity exhibited herein suggest that BC may also acts as an anti-
inflammatory agent related to AD pathogenesis. 
 
Because of the unclear pathogenesis of AD, there have been several hypothesis 
associated with the disease such as amyloid-く peptide-containing plaque formation, 
excess metal ions, oxidative stress, and reduced acetylcholine levels. As proposed by 
Zhang et al. [156], finding more than one approach with multifunction for AD 
treatment draws attention to researchers. Thus, BC that exhibits good antioxidant 
potential, anti-inflammatory and anti-acetylcholinesterase action warrants further 
study for isolation of its bioactive principle. 
 
 
6.5 Conclusion 
 
The creation of effective therapeutic agents for AD would be a major medical 
milestone. Different causation targets are being targeted and medicinal, 
pharmacological, clinical and pathological research is on-going around the world. The 
anti-acetylcholinesterase activity of Canarium patentinervium Miq. in agreement with 
its potent antioxidant and anti-inflammatory activity demonstrated in Chapter 4 and 5 
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respectively represents an exciting scaffold from which to develop leads for treatment 
of neurodegenerative disease. 
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CHAPTER 7 
ANTIMICROBIAL ACTIVITY 
 
7.1 Introduction 
 
7.1.1 Infectious disease 
 
Since their introduction, antimicrobials (antibiotics) have played an essential role in 
decreasing morbidity due to infectious diseases. Antimicrobials are used for treatment 
of infections and for prophylaxis against infections in humans and animals, for growth 
promotion in food animal rearing and in agriculture. However infectious diseases 
remain the leading cause of death worldwide and bacteria have become more resistant 
to conventional antibiotic in recent years. The widespread use of these compounds is 
thought to further encourage the emergence of antimicrobial resistance [157]. The 
number of resistant pathogenic bacteria grows at an alarming rate worldwide and the 
search for novel antimicrobial agents from medicinal plants to combat such pathogens 
has become crucial for avoiding the emergence of untreatable bacterial infections  
[158][159]. 
 
7.1.2 Chemotherapeutic agents: Factors affecting their effectiveness 
 
The ideal chemotherapeutic agent has a high therapeutic index with selective toxicity, 
thereby resulting in lethal damage to pathogens through the inhibition of cell wall 
synthesis, protein synthesis or nucleic acid synthesis, as well as through the disruption 
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of the cell membrane and the inhibition of certain essential enzymes. This results in 
selective disruption of the specific structure and/or function essential to bacterial 
growth and survival, without causing similar effects to its eukaryotic host [160]. 
 
The efficacy of antimicrobial agents is influenced by a number of factors. Firstly, it is 
of obvious importance that the antimicrobial agent reaches the site of the infection. 
This greatly depends on the stability of the drug, its lipophilic or hydrophilic nature, 
its absorption from a specific site and the presence of blood clots or necrotic tissue, 
the latter of which may protect the pathogen against the antibiotic. Secondly, the 
susceptibility of the pathogen to the particular chemotherapeutic agent is of utmost 
importance, as well as the specific growth phase in which the pathogen is in at that 
particular stage [160]. 
 
7.1.3 Drug resistance 
 
Bacteria have evolved many different mechanisms of resistance. These can be 
classified as: a) alteration in, or addition of, the target site of antimicrobial binding; b) 
alteration in access to the target site for instance the decreased permeability of cell 
wall or efflux mechanisms; and c) inactivation of the antimicrobial binding. 
Furthermore resistance may arise through mutation or by acquisition of resistance 
genes by horizontal transmission from another bacterial species [157]. 
 
On the other hand, drug resistance may be brought about by the limited drug diffusion 
into the biofilm matrix, enzyme-mediated resistance, genetic adaptation, efflux 
pumps, as well as through the adaptation of the outer microbial membrane, the latter 
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occurring either through the lack of or through the overexpression of certain 
membrane proteins [161]. 
 
This phenomenon of increased drug resistance, combined with the multiplicity of side 
effects by existing agents and the emergence of diseases for which no treatment yet 
exists, makes the search for the new antimicrobial agents a highly relevant and 
important subject for research. For centuries, plants have been used in the traditional 
treatment of microbial infections. This assembly of knowledge by indigenous peoples 
about plants and their products continue to play an essential role in health care of a 
great proportion of the population [162]. 
 
7.1.4 Natural products and their role in drug discovery 
 
Natural products have played a pivotal role in the discovery of antimicrobial drugs, 
with the drug either being completely derived from the natural product, or serving as a 
lead for novel drug discovery. Most antimicrobials discovered during the past 6-7 
decades have been discovered through screening of soil samples, of which the 
antimicrobial efficacies were determined first in vivo and later in vitro [162]. 
 
Plants synthesize a diverse array of secondary metabolites, which play a key role in 
the natural defence mechanisms employed by the plant against predation by 
microorganisms and insects. It is thus no surprise that these aromatic compounds 
have,  in numerous instances, been found to be useful antimicrobial phytochemicals 
and, as a result, these compounds are now divided into different chemical categories: 
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phenolics, terpenoids and essential oils, alkaloids, lectins and polypeptides, as well as 
polyacetylenes [163]. An increase in the isolation and identification of such 
compounds may thus contribute greatly to the success in antibiotic discovery. 
 
7.1.5 Canarium species and their known antimicrobial activity 
 
Studies conducted on Canarium species have suggested that these species may well 
be active against micro-organisms. Antibacterial activities was previously reported in 
Canarium schweinfurthii Engl. Dichloromethane extract of Canarium schweinfurthii 
Engl. had bactericidal activity against Gram-negative Vibrio cholerae with minimum 
inhibitory concentration (MIC) of 0.62 mg/ml while the ethylacetate extract was 
active against Gram-positive and Gram-negative bacteria namely Staphylococcus 
aureus and Proteus vulgaris with MIC values of 10 mg/ml and 5 mg/ml respectively. 
Ethanol extract was active against Gram-negative Vibrio cholerae and Proteus 
vulgaris with MIC values of 0.62 mg/ml and 10 mg/ml respectively. The oil was also 
fungicidal against Candida albicans with an inhibition zone of 23 mm [28]. In a 
separate disc diffusion assay, the essential oil of Canarium schweinfurthii Engl. 
abrogated the survival of Gram-negative Salmonella enterica, Gram positive 
Streptococcus pyogenes and Staphylococcus aureus with an inhibition zone of 27 mm, 
25 mm and 18 mm respectively [25]. Canarium patentinervium Miq. have been used 
traditionally in healing wounds [164], as such this study will attempt to validate these 
ethnopharmacological claims. 
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7.2 Materials and Methods 
 
The in vitro antimicrobial properties of Canarium patentinervium Miq. was evaluated 
using the disc diffusion assay, minimum inhibitory concentration (MIC) assay, 
minimum bactericidal assay (MBC) and death kinetic assay. The hexane, chloroform 
and ethanol extracts of Canarium patentinervium Miq. were prepared (see Chapter 2 
for the extraction process). The following bacterial strains were employed in the 
screening:   
i. Gram-positive bacteria such as Staphylococcus aureus (ATCC 11632), 
Bacillus cereus (ATCC 10876), methicillin-resistant Staphylococcus 
aureus (ATCC 43300) and Gram-negative bacteria such as Escherichia 
coli (ATCC 10536) and Pseudomonas aeruginosa (ATCC 10145). 
ii. Ten clinical bacterial strains and 3 clinical strain of yeasts obtained from 
the Bacteriology Unit, Department of Microbiology and Immunology of 
UKM Medical Centre. The assays involving these clinical strains were 
also perfomed at HUKM. 
 
7.2.1 Disc diffusion assay 
 
7.2.1.1 Principle of method 
 
The principles of determining the effectivity of a noxious agent to a bacterium were 
well enumerated by Rideal, Walker and others at the turn of the century. The 
discovery of antibiotics made these tests (or their modification) too cumbersome to be 
put up as a routine due to the large number of tests it requires [165]. The ditch plate 
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method of agar diffusion used by Alexander Fleming was the forerunner of a variety 
of agar diffusion methods devised by workers in this field. The Oxford group used 
these methods initially to assay the antibiotic contained in blood by allowing the 
antibiotics to diffuse out of reservoirs in the medium in containers placed on the 
surface [165]. With the introduction of a variety of antimicrobials it became necessary 
to perform the antimicrobial susceptibility test as a routine.  
 
In this assay, the antimicrobial contained in a reservoir was allowed to diffuse out into 
the medium and interact in a plate freshly seeded with the test organisms.  Even now a 
variety of antimicrobial containing reservoirs are used but the antimicrobial 
impregnated absorbent paper disc is by far the commonest type used.  The disc 
diffusion method of antimicrobial susceptibility testing (AST) is the most practical 
method and is still the method of choice for the average laboratory.  Automation may 
force the method out of the diagnostic laboratory but in this country as well as in the 
smaller laboratories of many countries, it will certainly be the most commonly carried 
out microbiological test for many years to come [165]. 
 
The Kirby-Bauer and Stokes' methods are usually used for antimicrobial susceptibility 
testing, with the Kirby-Bauer method being recommended by the National Committee 
for Clinical Laboratory Standards (NCCLS). The accuracy and reproducibility of this 
test are dependent on maintaining a standard set of procedures. NCCLS is an 
international, interdisciplinary, non-profit, non-governmental organization composed 
of medical professionals, government, industry, healthcare providers, educators etc. It 
promotes accurate antimicrobial susceptibility testing (AST) and appropriate reporting 
by developing standard reference methods, interpretative criteria for the results of 
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standard AST methods, establishing quality control parameters for standard test 
methods, provides testing and reporting strategies that are clinically relevant and cost-
effective [165]. Interpretative criteria of NCCLS are developed based on international 
eqnncdqtcvkxg"uvwfkgu"cpf"ygnn"eqttgncvgf"ykvj"OKEÓu"cpf"vjg"tguwnvu"jcxg"eqttqdqtcvgf"
with clinical data. Based on study results NCCLS interpretative criteria are revised 
frequently. NCCLS is approved by FDA-USA and recommended by WHO 
[165][166]. 
 
7.2.1.2 Protocol [166][167][168] 
 
i. Preparation of Mueller Hilton Agar 
Mueller Hilton Agar was prepared from a commercially available dehydrated base 
ceeqtfkpi"vq"vjg"ocpwhcevwtgtÓu"kpuvtwevkqpu0 The agar solution was then autoclaved. 
It was then allowed to cool in a 45-50 oC water bath. The agar was then poured into 
plastic flat bottomed petri dishes on a level, horizontal surface to give a uniform depth 
of approximately 4 mm. This corresponds to 25 ml for plates with a diameter of 100 
mm. The agar medium was then allowed to cool to room temperature and unless plate 
is used the same day, stored in a refrigerator (2 to 8 oC). A representative sample of 
each batch of plates was examined for sterility by incubation at 30-35 oC for 24 hrs or 
longer. 
 
ii. Preparation of dried filter paper discs/ cotton swabs/ tryptic soy broth/ 
normal saline solution 
Whatman filter paper no.1 was used to prepare discs approximately 6 mm in diameter. 
They are then placed in a bijou bottle and autoclaved for sterility. Same was done for 
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cotton swabs. Tryptic soy broth (TSB) (20 ml) ycu"rtgrctgf" cu" vjg"ocpwhcevwtgtÓu"
instructions. About 5 ml was poured into a Bijou bottle and autoclaved.  About 150 
ml of sodium chloride solution of 0.9 % was prepared and autoclaved 
 
iii. Preparation of sample extracts, negative control and standard antibiotic 
solution. 
Sample extracts were dissolved in DMSO at a concentration of 100 mg/ml and 
filtered. Negative control was DMSO. Standards used were ampicillin and 
streptomycin which were prepared at the concentration of 100 µg/ml. 
 
iv. Preparation of fresh/ pure colonies of bacteria 
Tryptic soy agar was prepared according to the manufacturers intructions. Agar was 
autoclaved and poured on petri dishes to 4 mm, approximately 25 ml to a 100 mm 
petri dish. Bacterias are streaked on the tryptic soya agar (TSA) plates in 4 density 
level around the plates. Plates are then sealed with a parafilm and incubated for 18 hrs 
to obtain single colonies. 
 
v. Preparation of disc with extracts, control and standards 
About 10 µl of sample extracts was pipetted onto the disc in triplicates. Same was 
done for controls and standards. Impregnated discs are left to air dry overnight for 12 
hrs. 
 
vi. Inoculum Preparation 
At least 3-5 well isolated colonies of the same morphological type are selected from 
an agar plate culture. The top of each colony was touched with a sterilized loop and 
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the growth was transferred into the Bijou bottle containing TSB. This was repeated 
for each bacteria into each Bijou bottle. The broth culture was incubated at 35 oC for 
about 2 hrs till it achieved the turbidity of 0.5 Mcfarland standard/625 nm to yield 1 X 
108 cfu/ml. Using optical density at 625 nm, the reading below must be obtained for 
different bacteria, turbidity was adjusted with sterile normal saline. 
 
vii. Inoculation of test plates 
The bacterial broth was used within 15 mins after the turbidity of the inoculum 
suspension was adjusted.  Sterile cotton swab was dipped into the suspension and 
rotated several times and pressed firmly on the inside wall of the tube above the fluid 
level. This was to remove any excess inoculum from the swab. The dried surface of a 
Mueller Hilton agar plate was inoculated by streaking the swab over the entire agar at 
every 60 oC. As a final step, the rim of the agar was swabbed. 
 
viii. Application of discs to inoculated agar plates 
Each disc was pressed down on the agar to ensure complete contact according to 
prepared template. Plates were placed in 35 oC incubator within 15 mins after discs 
are applied. 
 
viiii. Reading plates and interpretation of results 
After 18 hrs of incubation, each plate was examined. Zone of inhibition was measure 
using sliding calipers to the nearest millimeters. The inhibition zones would thus 
include disc size of 6 mm. The experiment was done three times and the mean values 
are presented.  
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7.2.2 Minimum inhibitory concentration assay 
 
7.2.2.1 Principle of method 
 
The MIC is the lowest concentration being beyond the concentration where no growth 
inhibition of test organisms was observed. Minimum inhibitory concentration (MIC) 
assays investigate the in vitro susceptibility of organisms to antimicrobial agents. This 
method employs different dilutions of the antimicrobial agent and quantitatively 
investigates the lowest concentration at which visible microbial growth inhibition is 
achieved. Microbial growth is visualised through the addition of the tetrazolium salts, 
specifically p-iodonitrotetrazolium (INT, Sigma-Aldrich). The assay is based on the 
detection of dehydrogenase activity in living cells by being converted from a 
colourless solution to an intensely coloured formazan (red) product [169]. This 
method yields reproducible results within one doubling dilution of the end point of the 
activity. 
 
 
7.2.2.2 Protocol 
 
The MIC of the plant extracts was determined by serial dilution, as described by Eloff 
[169]. These dilution experiments were performed in sterile 96-well microtiter plates. 
 
i. Preparation of sample 
Stock solutions of the respective plant extracts were prepared in 1.5 ml 
microcentrifuge tubes (Eppendorff) by dissolving dry plant extract in 
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dimethylsulphoxide (DMSO, Saarchem) to a final concentration of 64 mg/ml. 
Cnkswqvu"qh"322"たn"qh"vjg"uvqem"uqlution were transferred aseptically into the top row 
qh"oketqvkvgt"rncvg"*tqy"C+."yjkej"cntgcf{"eqpvckpgf"322"たn"cnkswqvu"qh"uvgtkng"ycvgt."
thereby resulting in a 50 % dilution of the stock solution to 32 mg/ml. After adequate 
mixing of the contents of eacj"ygnn."322"たn"cnkswqvu"qh"tqy"C"ygtg"vtcpuhgttgf"htqo"
tqy"C"vq"vjg"eqttgurqpfkpi"ygnnu"kp"tqy"D"*cnuq"eqpvckpkpi"322"たn"cnkswqvu"qh"uvgtkng"
water), followed by mixing and resulting in yet another 50% dilution of the plant 
extract (to 16 mg/ml). This process was repeated hqt" gxgt{" tqy." tguwnvkpi" kp"322"たn"
aliquots ranging in concentration from 32 mg/ml (row A) to 0.25 mg/ml (row H).  
 
ii. Preparation of inocolums 
In order to determine the range of antimicrobial activity of Canarium patentinervium 
Miq., four different microbial (reference) cultures and 10 clinical strains were used 
and are listed below.  
i. Gram-positive bacteria  
‚ Staphylococcus aureus (ATCC 11632) 
‚ Bacillus cereus (ATCC 10876) 
‚ Methicillin-resistant Staphylococcus aureus (ATCC 43300) 
‚ Staphylococcus aureus MSSA 
‚ Staphylococcus aureus MRSA 
‚ Coagulase negative Staph: Oxacillin (S) 
‚ Coagulase negative Staph: Oxacillin (R) 
‚ Enterococcus faecalis 
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ii.  Gram-negative bacteria 
‚ Pseudomonas aeruginosa (ATCC 10145) 
‚ Escherichia coli 
‚ Klebsiella sp 
‚ Escherichia coli ESBL 
‚ Klebsiella pneumoniae ESBL 
iii. Yeast 
‚ Candida parapsilosis 
 
Bacterias are streaked on TSA plates in 4 density level around the plate. Plates are 
then sealed with a parafilm and incubated for 18 hrs to obtain fresh single colonies. At 
least 3-5 well isolated colonies of the same morphological type are selected from the 
agar plate culture. The top of each colony was touched with a sterilized loop and the 
growth was transferred into Bijou bottle containing TSB/MHB. This was repeated for 
each bacteria placed into each Bijou bottle. Broth was incubated at 35 oC for about 2 
hrs till it achieved 0.5 Mcfarland Standard/ 600 nm (OD-0.1 nm) to yield 1 x 108 
cfu/ml [170]. Turbidity was adjusted with sterile normal saline. To obtain 10 x 105 
cfu/ml, add 100 µl of adjusted broth to 9900 µl of TSB/MHB (1:100 dilution). 
 
 
iii. MIC assay 
Vjku"ycu"hqnnqygf"d{"cffkvkqp"qh"322"たn"cv"concentration of 10 x 105 colony forming 
units (cfu)/ml, of liquid microbial culture grown in Mueller Hilton Broth (MHB) to 
gcej" ygnn0" Vjku" {kgnfgf" c" hkpcn" xqnwog" qh" 422" たn" kp" gcej" ygnn" cpf" hkpcn" gzvtcev"
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concentrations ranging from 16 mg/ml in row A to 0.125 mg/ml in row H (Figure 4.1) 
with bacteria 5 x 105 cfu/ml. The microtiter plates were incubated at 37 °C, overnight 
for bacteria and 48 hours for yeasts (as yeasts require a greater time period for 
growth). After incubation at 37 ̇E."62"たn"qh"c"206"oi1on"uqnwvkqp"qh"KPV"ycu"cffgf"vq"
each well as an indicator of microbial growth. The plates were incubated at 37 oC for 
30 min (bacteria) and 24 hr (yeast) and the MIC values visually determined. The 
lowest concentration of each extract displaying no visible growth was recorded as the 
minimum inhibitory concentration. The concentration that inhibited bacterial/yeast 
growth completely (the first clear well) was taken as the MIC value. MIC values were 
determined at least in duplicate and repeated to confirm activity 
 
In order to determine the sensitivity of the microorganisms, positive control 
experiments were conducted: (1) for bacterial strains, ampicillin (Sigma-Aldrich) at a 
starting concentration of 0.10 mg/ml in sterile water, and (2) for yeast strains, 
Amphotericin B (Sigma-Aldrich), at a starting concentration of 0.10 mg/ml in DMSO 
and water (where 1.00 mg/ml was prepared in DMSO, and diluted to 0.10 mg/ml in 
sterile water thereafter). The final concentrations for these experiments ranged from 
25.00 µg/ml (row A) to 0.19 µg/ml (row H). A negative control experiment was 
conducted using only DMSO. 
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7.2.3 Minimum bactericidal concentration (MBC) 
 
7.2.3.1 Principle of method 
 
Minimum bactericidal concentration (MBC) was recorded as a lowest extract 
concentration killing 99.9 % of the bacterial inocula after 24 hr incubation at 37 °C. 
Each experiment was repeated at least three times. 
 
7.2.3.2 Protocol 
 
The determination of MBC was performed using the method of Ozturk & Ercisli 
[171] only for the susceptible bacterias/ fungi from the MIC assay (Section 7.2.2). 
Ten microliters were taken from the well obtained from the MIC experiment (MIC 
value) and two wells above the MIC value well and spread on MHA plates. The 
number of colony was counted after 18-24 hrs of incubation at 37 °C. The 
concentration of sample that produces < 10 colonies was considered as MBC value. 
 
7.2.4 Time-kill assay 
 
7.2.4.1 Principle of method 
 
Death kinetic studies are often referred to as time-kill studies, and are used to 
determine the rate at which the antimicrobial agent kills pathogens over time, as well 
as the extent at which the activity occurs. Upon introduction of a micro-organism into 
a new environment, its growth displays a lag phase during which no cell growth 
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occurs, after which its growth enters the exponential phase, where microbial cell 
multiplication occurs at an exponential rate (doubling in number at regular intervals). 
This exponential phase is followed by the stationary phase, the latter of which usually 
results from the depletion of nutrients (carbon, nitrogen and/or oxygen sources) [160]. 
However, upon exposure to a constant concentration of an antimicrobial agent, the 
organism will remain within the lag phase for a certain amount of time. This is 
followed by a log-linear killing phase, during which the number of microbial colonies 
are decreased until it enters into a second lag phase. Re-growth may occur after this 
second lag phase, but documentation of this phenomenon rarely occurs as time-kill 
studies are usually performed over a 24 hour period only [172][173]. 
 
7.2.4.2 Protocol 
 
Only samples that have MIC values of  lower or equivalent to 0.5 mg/ml (strong 
inhibitors) are tested for the time-kill [174]. Concentration of samples to be tested is 
determined base on the MIC values (up to 4 times the MIC value) [175].  Samples and 
incolums are prepared as in section 7.2.2.2 (i-ii). This was followed by addition of 
322"たn"qh"oketqdkcn"dtqvj"cv"concentration of 10 x 105 colony forming units (cfu)/ml, 
of liquid microbial culture grown in Mueller Hilton Broth (MHB) to each well. This 
{kgnfgf" c" hkpcn" xqnwog" qh" 422" たn" kp" gcej" ygnn" of the extract. The plates are then 
incubated at 37 °C and optical density was recorded at 1 hr intervals up to 18 hrs at 
wavelength of 600 nm. Graphs were plotted on the basis of the turbidity varying over 
a period of time. The growth rate thus obtained was studied for any signs of 
bactericidal effects of the plant extract. Ampicillin was used as positive control. A 
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solution of the solvent in which dried extract was dissolved served as negative 
control. 
 
7.2.5 Statistical analysis 
 
Growth curve of bacteria were analysed using MS-Excel and data were reported as 
mean and SD values obtained from a minimum of three determinations. Bacterial 
growth curve was plotted with SD and 95% confidence interval. All data were 
expressed as mean ± standard deviation. Data were analyzed using one way Anova 
followed by Tukey test. A significant difference was considered at the level of P < 
0.01. 
 
 
7.3 Results  
 
7.3.1 Disc diffusion assay 
 
The six extracts of Canarium patentinervium Miq. that were screened for 
antimicrobial activity using the disc diffusion assay displayed good activity (Table 
7.1). The extracts were screened for activity against Gram-positive bacteria 
(Staphylococcus aureus ATCC 11632, MRSA ATCC 43300, Bacillus cereus ATCC 
10876, clinical strains consisting of MSSA, MRSA, Coagulase-negative 
Staphyloccocus: oxacillin sensitive/resistant, Enterococcus faecalis and Streptococcus 
pneumoniae), Gram-negative bacteria (Escherichia coli ATCC 10536, Pseudomonas 
aeruginosa ATCC 10145, clinical strains consisting of Esherichia coli, Klebsiella sp, 
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Esherichia coli ESBL and Klebsiella pneumoniae ESBL and yeasts (Candida 
albicans, Candida glabrata and Candida parapsilosis). All the bacterias and yeast 
were sensitive to the extracts except Streptococcus pneumoniae, Eschericia coli 
ATCC 10536, Candida glabrata and Candida albicans. The ethanol extract of leaves 
and the hexane extract of bark displayed good antibacterial activity against both 
Gram-positive bacteria and Gram-negative bacteria. The ethanol extracts and hexane 
extract of the bark had the best sensitivity to Candida parapsilopsis (inhibition zone 
14 mm).  
 
Both ATCC and clinical strains of MSSA and MRSA were sensitive to the ethanol 
extracts (9-12 mm) (Figure 7.1) and hexane extract of barks (8-14 mm). Coagulase-
negative Staphylococcus aureus: oxacillin sensitive and resistant and Enterococcus 
faecalis were most sensitive to the ethanol extracts (inhibition zone 8-12 mm). Gram-
negative bacteria Klebsiella pneumoniae ESBL (inhibition zone 9-14 mm) had 
sensitivity to all the bark extracts while Klebsiella sp showed sensitivity only towards 
the ethanol extracts (inhibition zone 11-13 mm). Pseudomonas aeruginosa ATCC 
10145 was inhibited by the ethanol extract of leaves (inhibition zone 11 mm) (Figure 
7.2)  and hexane extract of barks (inhibition zone 12 mm) while poor activity was 
seen with Esherichia coli with all extracts. 
 
7.3.2 MIC assay 
 
All extracts displayed some activity against Gram-positive and Gram-negative 
bacteria and yeast (Table 7.2). The activity against MSSA reference and clinical 
strains ranged from 0.50 mg/ml to 2.00 mg/ml with the strongest activity seen with 
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the ethanol extract of leaves. The activity against MRSA reference and clinical strains 
ranged from 0.25 mg/ml to 2.00 mg/ml with the lowest MIC seen in the ethanol 
extract of leaves. All the extracts had activity against coagulase-negative 
Staphylococcus aureus: oxacillin resistant and sensitive with MIC ranging from as 
low as 0.50 mg/ml (ethanol extract of leaves) to 16.00 mg/ml (hexane extract of 
leaves). Enterococcus faecalis had activity only against the ethanol extracts with an 
MIC of 0.50 mg/ml. Bacillus cereus ATCC 10876 showed sensitivity only against the 
ethanol extracts (MIC 0.5 mg/ml) and hexane extract of barks (MIC 1.00 mg/ml).  
 
All the bark extracts showed activity against Gram-negative Klebsiella sp. with an 
MIC range of 0.50 mg/ml to 4.00 mg/ml while only the ethanol extracts of leaves and 
barks showed activity against Klebsiella pneumoniae ESBL with MIC of 0.5 mg/ml. 
Pseudomonas aeruginosa ATCC 10145 was sensitive towards ethanol extract of 
leaves and hexane extract of barks with an MIC of 1.00 mg/ml and 4.00 mg/ml 
respectively. Esherichia coli clinical strain was sensitive only towards ethanol extract 
of barks with an MIC of 0.50 mg/ml while Escherichia coli ESBL was inhibited by 
the chloroform extracts and hexane extract of barks with MIC of 8.00 mg/ml. The 
ethanol extracts and hexane extract of bark both had activity against yeast Candida 
parapsilopsis with the MIC of 2.00 mg/ml and 8.00 mg/ml respectively. 
 
7.3.3 MBC assay and MBC/MIC ratio 
 
The action of an antibacterial on the bacterial strains can be characterized with two 
parameters such as minimum inhibitory concentration (MIC) and minimum 
bactericidal concentration (MBC). According to the ratio MBC/MIC, we appreciated 
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antibacterial activity. If the ratio ODE1OKE" ø" 6, the effect was considered as 
bactericidal but if the ratio MBC/MIC > 4 , the effect was defined as bacteriostatic 
[176][177]. The MBC and MBC/MIC ratio are displayed in Table 7.3 and 7.4 
respectively. 
 
Both the ethanol extract of leaf and bark were bactericidal against Bacillus cereus 
ATCC 10876 (MBC of 1.00 mg/ml), MSSA ATCC 11632 (MBC range of 1.00 to 
2.00 mg/ml), Klebsiella sp and Klebsiella pneumonia ESBL (MBC of 2.00 mg/ml) 
and yeast Candida parapsilopsis (MBC 8.00 mg/ml). The hexane extract of barks was 
bactericidal against MSSA, MRSA (both strains) and Pseudomonas aeruginosa 
ATCC 10145 with MBC range of 2.00 mg/ml to 8.00 mg/ml. Chloroform extract of 
barks showed bactericidal activity against MSSA (ATCC 11632 and clinical strains) 
with MBC of 1.00 mg/ml and 4.00 mg/ml respectively. Both hexane and chloroform 
extract of barks were bactericidal against Klebsiella sp with MBC/MIC ratio of 4. 
Rest of the MBC as displayed in Table 7.3 were all having bacteriostatic action with 
an MBC/MIC ratio > 4. 
 
7.3.4 Time-kill assay 
 
Only samples that have MIC values of  lower or equivalent to 0.5 mg/ml (strong 
inhibitors) are tested for the time-kill [174]. The results obtained for the time-kill 
study of Canarium patentinervium Miq. are shown in Figure 7.3-7.22. The MBC 
values (Table 7.3) was consistent with the cidal concentration as displayed in the 
growth curve of this time-kill study. Blank control (broth alone) was the curve marked 
as 0 mg/ml of extract. The antibacterial activity was observed at different times upon 
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exposure of bacterias to the different concentration of extracts. This observation was 
made by varying turbidity over time for a period of 18 hrs. 
 
7.4 Discussion 
 
7.4.1 Disc diffusion assay 
 
According to Gislene et al. [178], chemicals that have antibacterial activity with zones 
of inhibition of 7 mm and above can be considered as potential antimicrobial 
candidates. In the present study, antibacterial screening of six extracts of Canarium 
patentinervium Miq. showed varying degrees of antibacterial activity against human 
pathogenic bacteria such as Staphyloccocus aureus, MRSA, Bacillus cereus (ATCC 
strain respectively), coagulase-negative Staphylococcus aureus, Enterococcus 
faecalis, Klebsiella pneumoniae ESBL and yeast Candida parapsilopsis (clinical 
strain respectively) cultured in vitro. Out of six extracts, the ethanol extract of leaves 
and hexane extract of barks exhibited significant antibacterial activity against both 
Gram-positive and Gram-negative bacteria. The best sensitivity to the ethanol extract 
of the leaves at 1 mg/disc was obtained against Staphyloccocus aureus (12 mm), 
MRSA (10 mm), Bacillus cereus (12 mm) and Enterococcus faecalis (12 mm), 
Klebsiella pneumoniae ESBL (13 mm) and yeast Candida parasilopsis (14 mm). The 
hexane extract of the barks showed best activity against MSSA (14 mm), Klebsiella 
sp (14 mm) and yeast Candida parapsilopsis (14 mm).  
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This is of special interest since most Gram-negative bacteria are more resistant to 
plant extracts [179].  Results from our phytochemical analysis revealed that the 
ethanol extract of leaves and barks of Canarium patentinervium Miq. accumulate 
substantial amounts of flavonoids and tannins which could be well correlated with the 
activities measured.  
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Figure 7.1: Zone of inhibition against Staphylococcus aureus (left plate) and methicillin resistant Staphylococcus aureus (right plate) for leaf ethanol extract 
at 1 mg/disc. 
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Figure 7.2: Zone of inhibition against Bacillus cereus (left plate) and Pseudomonas aeruginosa (right plate) for leaf ethanol extract at 1 mg/disc. 
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Table 7.1: Antibacterial activity of Canarium patentinervium Miq. (1 mg/disc ) vs. ampicillin against 5 ATCC bacterias and 10 clinical bacterial strains and 3 clinical yeast strains tested by disc 
diffusion assay 
Bacteria/ yeast 
Plant extract (Zone of inhibition) (mm) a 
LH LC LE  BH  BC BE Ampicilinc Amphotericinc 
MSSA Staphylococcus aureus ATCC 11632 
- - 12.00±0.21 11.00±0.25 7.00±0.29 9.00±0.58 10.00±0.66 NA 
MRSA Staphylococcus aureus ATCC 43300 
- - 10.00±0.42 9.00±0.25A - 9.00±0.00A - NA 
Bacillus cereus ATCC 10876 
- - 12.00±0.25B 12.00±0.45B - 9.00±0.00 8.00±0.00 NA 
Eschericia coli ATCC 10536  
- - - - - - 7.00±0.00 NA 
Pseudomonas aeruginosa ATCC 10145 
- - 11.00±0.34 12.00±0.47 - - - NA 
MSSA Staphylococcus aureus 
- - 11.00±0.23 14.00±0.43 13.00±0.17 10.00±0.45 7.00±0.26 NA 
MRSA Staphylococcus aureus 
- - 10.00±0.37C 8.00±0.29 - 10.00±0.47C - NA 
Eschericia coli 
- - - - - 8.00±0.57 - NA 
Eschericia coli ESBL 
- 7.00±0.18 - 8.00±0.38D 8.00±0.26D - - NA 
Coagulase-negative Staphylococcus aureus: O (R) 
- 7.00±0.59 10.00±0.00 8.00±0.34E 8.00±0.36E 9.00±0.34 - NA 
Coagulase-negative Staphylococcus aureus: O (S) 7.00±0.37F 7.00±0.16F 12.00±0.29G - - 12.00±0.23G 10.00±0.27 NA 
Enterococcus faecalis 
- - 12.00±0.46 - - 8.00±0.15H 8.00±0.28H NA 
Streptococcus pneumoniae 
- - - - - - - NA 
Klebsiella sp 
- - 11.00±0.38I 14.00±0.00 11.00±0.34I 9.00±0.42 10.00±0.14 NA 
Klebsiella pneumoniae ESBL 
- - 13.00±0.25 - - 11.00±0.27 - NA 
Candida parapsilosis 
- - 14.00±0.12K 14.00±0.24K - 14.00±0.10K NA 11.00±0.23 
Candida glabrata 
- - - - - - NA 9.00±0.15 
Candida albicans 
- - - - - - NA - 
LH-leaf hexane extract, LC- leaf chloroform extract, LE-leaf ethanol extract, BH- bark hexane extract, BC- bark chloroform extract, BE- bark ethanol extract, NA-not applicable 
a: inhibition zones are the mean including disc (6 mm) b: sample extract at the concentration of 100 mg/ml (1mg/disc), c: ampicillin/amphotericin at 100 µg/ml = 1 µg/disc, -: no activity noted 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
 Values with the same capital letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
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Table 7.2: MIC values for Canarium patentinervium Miq.  extracts against 4 ATCC bacterias and 9 clinical bacterial strains and 1 clinical yeast strain 
 Bacteria/ yeast Plant extract minimum inhibitory concentration MIC (mg/ml) and positive controla MIC (µg/ml) 
LH LC LE  BH  BC BE Ampicilina Amphotericina 
MSSA Staphylococcus aureus ATCC 11632 
- - 0.50±0.10 2.00±0.10 1.00±0.00A 1.00±0.00A 1.56±0.00 NA 
MRSA Staphylococcus aureus ATCC 43300 
- - 0.50±0.00 1.00±0.00B - 1.00±0.00B - NA 
Bacillus cereus ATCC 10876 
- - 0.50±0.15C 1.00±0.00 - 0.50±0.00C 6.25±0.00 NA 
Pseudomonas aeruginosa ATCC 10145# 
- - 1.00±0.00 4.00±0.05 - - - NA 
MSSA Staphylococcus aureus 
- - 0.50±0.10 2.00±0.00D 2.00±0.00D 0.50±0.00 >25.00±0.00 NA 
MRSA Staphylococcus aureus 
- - 0.25±0.00E 2.00±0.10 - 0.25±0.00E - NA 
Eschericia coli 
- - - - - 0.50±0.00 - NA 
Eschericia coli ESBL 
-  8.00±0.00F - 8.00±0.00F 8.00±0.00F - - NA 
Coagulase-negative Staphylococcus aureus: O (R) 
 - 8.00±0.00 1.00±0.00 0.50±0.00 2.00±0.00 0.50±0.00 - NA 
Coagulase-negative Staphylococcus aureus: O (S) 16.00±0.00 8.00±0.00 0.50±0.00G - - 0.50±0.10G 8.00±0.00 NA 
Enterococcus faecalis 
- - 0.50±0.00I - - 0.50±0.00I 3.13±0.00 NA 
Klebsiella sp 
- - 0.50±0.00J 4.00±0.00K 4.00±0.00K 0.50±0.00J >25.00±0.00 NA 
Klebsiella pneumoniae ESBL# 
- - 0.50±0.00 - - 0.50±0.00 - NA 
Candida parasilopsis 
- - 2.00±0.00K 8.00±0.00 - 2.00±0.00K NA 0.78±0.00 
LH-leaf hexane extract, LC- leaf chloroform extract, LE-leaf ethanol extract, BH- bark hexane extract, BC- bark chloroform extract, BE- bark ethanol extract 
 Data were obtained from three independent experiments, each performed in duplicates (n=6) and represented as mean ± SD, -: no activity, NA-not applicable 
 Values with the same capital letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
#: statistical analysis not performed due to insufficient data 
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Table 7.3: MBC values for Canarium patentinervium Miq.  extracts against 4 ATCC bacterias and 9 clinical bacterial strains and 1 clinical yeast strain 
 Bacteria/ yeast Plant extract minimum inhibitory concentration,MBC (mg/ml) and positive controla MBC (µg/ml) 
LH LC LE  BH  BC BE Ampicilina Amphotericina 
MSSA Staphylococcus aureus ATCC 11632 
- - 2.00±0.00A 2.00±0.00A 1.00±0.00B 1.00±0.00B 6.25±0.00 NA 
MRSA Staphylococcus aureus ATCC 43300 
- - 2.00±0.00 4.00±0.00C - 4.00±0.00C - NA 
Bacillus cereus ATCC 10876 
- - 1.00±0.10D 8.00±0.00 - 1.00±0.00D >25.00±0.00 NA 
Pseudomonas aeruginosa ATCC 10145 
- - 4.00±0.00 8.00±0.05 - - - NA 
MSSA Staphylococcus aureus 
- - 4.00±0.10E 4.00±0.00E 4.00±0.00E 2.00±0.00 >25.00±0.00 NA 
MRSA Staphylococcus aureus 
- - 2.00±0.00 8.00±0.10 - 1.00±0.00 - NA 
Eschericia coli# 
- - - - - 2.00±0.00 - NA 
Eschericia coli ESBL# 
  >16.00±0.00 - >16.00±0.00 >16.00±0.00 - - NA 
Coagulase-negative Staphylococcus aureus: O (R) 
  >16.00±0.00 4.00±0.00F 2.00±0.00 8.00±0.00 4.00±0.00F - NA 
Coagulase-negative Staphylococcus aureus: O (S)# >16.00±0.00 >16.00±0.00 2.00±0.00 - - 2.00±0.10 12.50±0.00 NA 
Enterococcus faecalis# 
- - 4.00±0.00 - - 4.00±0.00 6.25±0.00 NA 
Klebsiella sp 
- - 2.00±0.00I 16.00±0.00J 16.00±0.00J 2.00±0.00I >25.00±0.00 NA 
Klebsiella pneumoniae ESBL# 
- - 2.00±0.00 - - 2.00±0.00 - NA 
Candida parapsilopsis# 
- - 8.00±0.00 >16.00±0.00 - 8.00±0.00 NA 3.13±0.00 
LH-leaf hexane extract, LC- leaf chloroform extract, LE-leaf ethanol extract, BH- bark hexane extract, BC- bark chloroform extract, BE- bark ethanol extract 
 Data were obtained from three independent experiments, each performed in duplicates (n=6) and represented as mean ± SD, -: no activity, NA-not applicable 
 Values with the same capital letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
#: statistical analysis not performed due to insufficient data 
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Table 7.4: Bacteriostatic (-) and Bactericidal (+) effects of Canarium patentinervium Miq. extracts 
Bacteria/ yeast MBC/MIC ratio (+/-) 
LE  BH  BC BE 
MSSA Staphylococcus aureus ATCC 11632 4 (+) 1 (+) 1 (+) 1 (+) 
MRSA Staphylococcus aureus ATCC 43300 4 (+) 4 (+) - 4 (+) 
Bacillus cereus ATCC 10876 2 (+) 8 (-) - 2 (+) 
Pseudomonas aeruginosa ATCC 10145 4 (+) 2 (+) - - 
MSSA Staphylococcus aureus 8 (-) 2 (+) 2 (+) 4 (+) 
MRSA Staphylococcus aureus 8 (-) 4 (+) - 4 (+) 
Eschericia coli - - - 4 (+) 
Coagulase-negative Staphylococcus aureus: O (R) 4 (+) 4 (+) 4 (+) 8 (-) 
Coagulase-negative Staphylococcus aureus: O (S) 4 (+) - - 4 (+) 
Enterococcus faecalis 8 (-) - - 8 (-) 
Klebsiella sp 4 (+) 4 (+) 4 (+) 4 (+) 
Klebsiella pneumoniae ESBL 4 (+) - - 4 (+) 
Candida parapsilopsis 4 (+) ND - 4 (+) 
LE-leaf ethanol extract, BH- bark hexane extract, BC- bark chloroform extract, BE- bark ethanol extract 
 -: no activity, ND: not determined 
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Figure 7.3: Time-kill plot for MSSA ATCC 11632 in presence of LE 
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Figure 7.4: Time-kill plot for MRSA ATCC 43300 in presence of LE 
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Figure 7.5: Time-kill plot for MSSA (clinical strain) in presence of LE 
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Figure 7.6: Time-kill plot for MRSA (clinical strain) in presence of LE 
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Figure 7.7: Time-kill plot for MSSA (clinical strain) in presence of BE 
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Figure 7.8: Time-kill plot for MRSA (clinical strain) in presence of BE 
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Figure 7.9: Time-kill plot for Bacillus cereus ATCC 10876 in presence of LE 
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Figure 7.10: Time-kill plot for Bacillus cereus ATCC 10876 in presence of BE 
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Figure 7.11: Time-kill plot for for Escherichia coli (clinical strain) in presence of BE 
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Figure 7.12: Time-kill plot for coagulase-negative Staphylococcus aureus: O (R) (clinical strain) in presence of LE 
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Figure 7.13: Time-kill plot for coagulase-negative Staphylococcus aureus: O (R) (clinical strain) in presence of BH 
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Figure 7.14: Time-kill plot for coagulase-negative Staphylococcus aureus: O (R) (clinical strain) in presence of BE 
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Figure 7.15: Time-kill plot for coagulase-negative Staphylococcus.aureus: O (S) (clinical strain) in presence of LE 
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Figure 7.16: Time-kill plot for coagulase-negative Staphylococcus aureus: O (S) (clinical strain) in presence of BE 
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Figure 7.17: Time-kill plot for Enterococcus faecalis (clinical strain) in presence of LE 
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Figure 7.18: Time-kill plot for Enterococcus faecalis (clinical strain) in presence of BE 
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Figure 7.19: Time-kill plot for Klebsiella sp. (clinical strain) in presence of LE 
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Figure 7.20: Time-kill plot for Klebsiella sp. (clinical strain) in presence of BE 
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Figure 7.21: Time-kill plot for Klebsiella pneumonia ESBL (clinical strain) in presence of LE 
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Figure 7.22: Time-kill plot for Klebsiella pneumonia ESBL (clinical strain) in presence of BE 
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7.4.2 MIC, MBC and MIC/MBC ratio 
 
Upon identifying possible antimicrobial action with the disc diffusion assay, a more 
comprehensive investigation was done to evaluate the total bactericidal/ bacteriostatic 
activity of an extract against a microb using the MIC/ MBC and time-kill assay. All 
plant species with MIC values of up to 8 mg/ml are considered to possess at least 
some degree of inhibitory effect, and any concentration exceeding this should not be 
considered effective, according to Fabry et al. [180]. The majority of the crude bark 
and leaf extracts of the six Canarium patentinervium Miq. exhibited moderate to 
relatively good activity against Gram-positive and Gram-negative pathogens with the 
MIC values ranging from 0.25 mg/ml to 8.00 mg/ml.  Only the hexane extract of 
leaves exhibiting weak antimicrobial activity. All active extracts displayed 
concentration-dependent antimicrobial activity. Aligiannis et al. [181] proposed a 
classification system based on MIC results obtained for plant materials, which was 
consequently described and implemented by Duarte et al. [182].  
 
Strong microbial inhibitors possessed MIC values of equal or lower than 0.50 mg/ml; 
a clear indication that the MIC value of 0.25 mg/ml obtained for ethanol extracts (leaf 
and bark) against MRSA Staphylococcus aureus (clinical strain) indicates exceptional 
antimicrobial activity. The ethanol extract of leaves also resulted with the MIC of 
0.50 mg/ml against MSSA (both strains) and MRSA (ATCC 43300). Coagulase-
negative Staphylococcus aureus: oxacillin resistant and sensitive strains were both 
sensitive against both ethanol extracts with an MIC of 0.5 mg/ml for the bark extracts 
and MIC range of 0.5 mg/ml to 1.00 mg/ml for the leaves. Staphylococcus aureus is a 
Gram-positive bacteria that can cause a range of illnesses, from minor skin infections, 
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such as pimples, impetigo, boils, celluliti, folliculitis, carbuncles, scalded skin 
syndrome and abscesses to life threatening diseases such as pneumonia, meningitis, 
osteomyelitis, endocarditis, toxic shock syndrome, bacteremia and sepsis. Its 
incidence ranges from skin, soft tissue, respiratory, bone, joint, endovascular to 
wound infections [183]. MRSA is one of the greatly feared strains of Staphylococcus 
aureus yjkej"jcxg"dgeqog"tgukuvcpv"vq"oquv"く-lactam antibiotics and mostly hospital-
accquired. Coagulase-negative Staphylococcus aureus are differentiated by their 
inability to produce free coagulase resulting in their inability to clot blood plasma 
[184].  
 
The ethanol extracts (bark and leaves) were bactericidal against Bacillus cereus with a  
MIC of 0.50 mg/ml and MBC of 1.00 mg/ml. Bacillus cereus is a causative agent of 
both gastrointestinal infections (diarrheal and emetic type of food poisoning) and non-
gastrointestinal infections (post traumatic wound and burn infections. ophthalmic 
infections, endocarditis, postoperative meningitis and urinary tract infections) [185]. 
The ethanol extracts were also bactericidal against Gram-negative Klebsiella sp and 
Klebsiella pneumoniae ESBL with MIC of 0.50 mg/ml and MBC of 2.00 mg/ml. 
Klebsiella is well known to most clinicians as a cause of community-acquired 
bacterial pneumonia, occurring particularly in chronic alcoholics which have a high 
fatality rate if untreated. Nosocomial Klebsiella infections are caused mainly by 
Klebsiella pneumoniae, the medically most important species of the genus. Due to the 
extensive spread of antibiotic-resistant strains, especially of extended-spectrum b-
lactamase (ESBL)-producing strains, there has been renewed interest in Klebsiella 
infections. Since ESBL production frequently is accompanied by multiresistance to 
antibiotics, therapeutic options become limited [186]. 
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The points above will make the discovery of an antimicrobial agent as effective as 
Canarium patentinervium Miq. against these pathogens highly significant. The 
ethanol extract of leaves displayed good microbial inhibition action against all 
microbs tested except for Pseudomonas aeruginosa and Candida parapsilopsis with 
moderate inhibition but bactericidal action with the MIC of 1.00 mg/ml and 2.00 
mg/ml respectively. Pseudomonas aeruginosa is a Gram-negative bacterium and an 
opportunistic, nosocomial pathogen in immunocompromised individuals. It typically 
infects the pulmonary tract, urinary tract, burns, wounds and blood infections [187]. 
 
Moderate microbial inhibitors are described by Aligiannis et al. [181] as those plant 
extracts with MIC values ranging between 0.60 mg/ml and 1.50 mg/ml. Amongst the 
extracts investigated in the present study, hexane extracts of the barks seemed to have 
most of the moderate inhibitors with an interesting bactericidal action against MRSA 
ATCC 43300 strain (MIC of 1.00 mg/ml and MBC of 4.00 mg/ml). Weak microbial 
inhibitors are classified as those agents with MIC values of between 1.60 mg/ml and 
8.00 mg/ml [181]. None of the extracts in the present study yielded MIC values in 
excess of 8.00 mg/ml against Gram-positive bacteria except with hexane extract of 
leaves. The results obtained against the Gram-positive and Gram-negative bacteria 
thus support the traditional use of Canarium patentinervium Miq. in wound 
healing[164] and hold potential in the treatment of colds, wound healing and as an 
antiseptic.  
 
In general, the Gram-negative bacteria displayed the least sensitivity towards the 
extracts, and most of the plant extracts (except ethanol extract of barks) exhibited 
poor and unvaried activity against Esherichia coli, indicating the resistance of this 
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bacterium to the plant extracts. This was to be expected, as Gram-negative bacteria 
offer a much more complex barrier system against permeation of foreign substances 
(in this case, the antimicrobial agent). This is attributed to the specialised cell wall 
structure and especially the presence of the outer envelope resulting in the 
impermeability of these micro-organisms to biocides and antibiotics, and at times, 
resulting in regulation and prevention of their passage to the target region [188]. 
Resistance to the plant extracts is, thus, exhibited to a far greater extent by the Gram-
negative bacteria than by Gram-positive bacteria [188]. The lipophilic or hydrophilic 
nature of compounds also plays a role in the activity, or lack thereof, against the 
micro-organisms. Compounds considered to be more effective against Gram-negative 
bacteria are considerably less lipophilic. This is as a result of the structure of the 
Gram-negative cell wall which also has a higher lipid content [189]. This could 
explain why in this study the ethanol extracts which contain more hydrophilic 
compounds showed more inhibition against Gram-negative bacteria such as 
Esherichia coli and Klebsiella species. 
 
The ethanol extracts and hexane extract of barks also showed inhibition against 
Candida parapsilopsis with a cidal and static action respectively. Both ethanol 
extracts had MIC of 2.00 mg/ml (MBC of 8.00 mg/ml) and hexane extract of barks 
had an MIC of 8.00 mg/ml (MBC >16.00 mg/ml). More than 80% of all fungal 
bloodstream infections are a direct result from the Candida species and since the 
eighties there has been an explosive rise in the rate of Candidal infections. Over the 
past decade, the incidence of Candida parapsilosis has dramatically increased. In fact, 
reports indicate that Candida parapsilosis is often the second most commonly isolated 
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Candida species from blood cultures and Candida parapsilosis even outranks 
Candida albicans in some European, Asian, and South American  hospitals [190]. 
 
The ethanol extracts have shown to have polyphenols such as tannins and flavonoids 
from the phytochemical analysis (chapter 2). Polyphenols, such as tannins and 
flavonoids, have important antibacterial activity [191]. The antimicrobial activity of 
flavonoids is due to their ability to complex with extracellular and soluble protein and 
to complex with bacterial cell wall while that of tannins may be related to their ability 
to inactivate microbial adhesions, enzymes and cell envelop proteins [163]. Flavones 
are phenolic structures containing one carbonyl group (as opposed to the two 
carbonyls in quinones). The addition of a 3-hydroxyl group yields a flavonol. 
Flavonoids are also hydroxylated phenolic substances but occur as a C6-C3 unit 
linked to an aromatic ring. Their activity is probably due to their ability to complex 
with extracellular and soluble proteins and to complex with bacterial cell walls. More 
lipophilic flavonoids may also disrupt microbial membranes [192].  
 
Tannin is a general descriptive name for a group of polymeric phenolic substances 
capable of tanning leather or precipitating gelatin from solution, a property known as 
astringency. They are found in almost every plant part: bark, wood, leaves, fruits and 
roots. Tannins may be formed by condensations of flavan derivatives or by the 
polymerization of quinine units [191]. Many human physiological activities, such as 
stimulation of phagocytic cell, host mediated tumour activity and a wide range of anti-
infective actions, have been assigned to tannins. Their mode of antimicrobial action as 
described for quinone, may be related to their ability to inactivate microbial 
adhesions, enzymes, cell envelope, transport-proteins etc [191]. They also form a 
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complex with polysaccharide. According to a number of studies, tannins can also be 
toxic to filamentous fungi, yeasts and bacteria [192]. However, it is important to note 
that, if tannins were solely responsible for the activity presented by these results, this 
activity would be observed against all organisms and would not be limited to Gram-
positive bacteria or yeasts. The current hypothesis is thus that tannins are at least 
partially responsible for the antibiotic activity. Coumarins have also demonstrated 
antimicrobial activity [163]. 
 
7.4.3 Time-kill assay 
 
Cnn"gzvtcevu"ykvj"iqqf"kpjkdkvqtu"*OKE"xcnwg"ø"207"oi1on+"was tested for the time-kill 
efficacy. All extracts displayed killing (bactericidal) action except the ethanol extracts 
(leaves and barks) against Enterococcus faecalis which was only bacteriostatic 
(Figure 7.17 & 7.18) and ethanol extract of barks that was bacteriostatic against 
coagulase-negative Staphylococcus aureus: oxacillin resistant (Figure 7.14). The other 
extracts bactericidal effect was achieved in the concentration of 2.00 to 4.00 mg/ml. 
Killing rate was observed at varying times from range of 1 hr to 10 hrs all resulting in 
complete kill. 
 
 
7.5 Conclusion 
 
All crude extracts of Canarium patentinervium Miq. under investigation exhibited 
exceptional concentration-dependent antimicrobial activity against both Gram-
positive and Gram-negative bacteria as well as against yeasts. The most promising 
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activity was displayed against Gram-positive bacteria Staphylococcus aureus, MRSA, 
Bacillus cereus and Gram-negative bacteria and Pseudomonas aeruginosa, Klebsiella 
sp, Klebsiella pneumoniae ESBL and yeast Candida parapsilopsis. This serves as a 
clear indication of the potential of these extracts for further chemical studies as 
antimicrobial agents. The antimicrobial activity exhibited by the bark extracts and 
ethanol extract of leaves against MSSA and MRSA indicates exceptional 
antimicrobial activity. All the tested bacterias and yeast were susceptible to either 
bark or leaf extracts.  
 
In general, the Gram-negative bacteria Escherichia coli displayed the least sensitivity 
towards the extracts, being inhibited only by the ethanol extract of the bark indicating 
the resistance of this bacterium to the rest of the plant extracts. The activity against 
Klebsiella pneumonia ESBL and Klebsiella sp. was, however, far more promising 
with variability amongst the plant extracts. It is at this stage important to note that the 
failure of a plant extract to demonstrate in vitro activity during the general screening 
process does not necessarily imply a total absence of inherent medicinal value. The 
possible presence of synergistic interactions between the different plant constituents 
in crude preparations may result in activities that are not exhibited by isolated 
compounds, and should not be excluded. 
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CHAPTER 8 
ANTIPARASITIC ACTIVITY 
 
8.1 Introduction 
 
8.1.1 Parasitic infection: causative factor and treatment 
 
Parasitic infection is one of a major health problem in the developing world.  Twenty-
five percent of the world's population could be suffering from parasitic infection 
Highest prevalence is in underdeveloped agricultural and rural areas in the tropical 
and subtropical regions.  In some areas incidence may reach 90 % of the population.  
During the evolution of humans a broad set of parasites have evolved, that use us as a 
host organism [193]. Usually a parasite will not kill its host (at least not immediately), 
as this would be an evolutionary dead end for a parasite. However, most parasites are 
either unpleasant for us (think of lice and fleas) or weaken our health (most internal 
parasites). However, some parasitic infections, such as malaria, trypanosomiasis or 
Chagas can be deadly if the patients are not treated with adequate therapeutics. 
Because humans usually live in close proximity and often without good hygienic 
conditions the transmission of parasites within a human population is often facilitated 
[194]. 
 
Many parasitic infections are the cause of tropical diseases, such as malaria, 
trypanosomiasis, leishmaniasis, Chagas disease, schistosomiasis, onchocerciasis, 
lymphatic filariasis, and helminthiases. Parasites are responsible for probably more 
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than 1Î2 billion infections, which lead to several million deaths every year [195]. An 
overview on important endoparasites under this study, their vectors, distribution, and 
disease symptoms is given in Table 8.1. 
 
Table 8.1: Human endoparasites in study 
Parasite Disease 
(estimated 
number of 
infections) 
Vector (hosts); 
route of 
transmission 
Distribution Symptoms 
Trypanosomatida 
Leishmania 
donovani 
Visceral 
leishmaniasis           
(kala-azar)                
(15 million) 
Flies 
(Phlebotomus, 
Lutzomyia); 
bites                                
N.Africa, 
Eurasia, S 
America 
Enlargement of 
liver and 
spleen, fever, 
dermal lesions, 
dermal nodules 
Amoebida 
Entamoeba 
histolytica and other 
species 
Amoebiasis               
(70000 
death/year) 
Infection from 
contaminated 
water or food 
Worldwide Dysentery, 
destruction of 
intestinal 
tissues, fever, 
liver and lung 
abscess 
Diplomonadida 
Giardia lamblia Giardiasis              
(2 million 
infections/ year 
in USA) 
Infection from 
contaminated 
water 
Worldwide Infection of 
duodenal and 
jejunal mucosa; 
diarrhoea, fever 
 
 
Leishmaniasis is a group of disease, caused by Leishmania species. The disease is 
considered as a major public health problem in 82 countries in the world causing 
morbidity and mortality [196]. Different modes of treatment are used in the treatment 
of cutaneous leishmaniasis. Pentavalent antimonial compounds are the first line 
treatment but generally are toxic so several significant advances in the chemotherapy 
of the leishmaniasis have occurred in the last 10 years [193]. Leishmaniasis is caused 
by protozoan parasites of the genus Leishmania which invade macrophages of host 
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organisms. A distinction is made between cutaneous, mucocutaneous, visceral and 
diffuse leishmaniasis, of which visceral leishmaniasis is a fatal disease causing 
approximately 60,000 death per year [197]. Leishmaniasis and HIV infections often 
co-occur and these patients usually have a poor prognosis. Patients are treated with 
the synthetic drugs stibogluconate, meglumine and pentamidine (developed 70 years 
ago), which have severe side effects and fail to work in North Bihar (India) 
[198][199]. Also the macrolide antibiotic amphotericin B has been employed, which 
can also be toxic for patients. New developments include the anticancer drug 
miltefosine, the aminoglycoside antibiotic paronomycin, and the 8-aminoquinoline 
sitamaquine [197]. Among natural products, berberine (which occurs in many TCM 
plants) had promising anti-leishmanial activities [198][199]. 
 
Entamoeba histolytica and Giardia intestinalis are parasite of large and small 
intestine of human, respectively.  Although infection with E. histolytica is 
asymptomatic in 90% of cases, about 50 million people are estimated to suffer from 
the symptoms of amoebiasis such as haemorrhagic colitis and amoebic liver abscess. 
These infections result in 50,000 to 100,000 deaths annually [200].  Giardia 
intestinalis (Synonyms: Giardia duodenalis, Giardia lamblia) is one of the most 
common universal pathogenic intestinal protozoan parasites of humans [201]. It is 
also widely spread in various animals such as dogs [202], cats [203] and cattle [204]. 
It is frequently reported to be a significant cause of diarrhea in people traveling to 
vtqrkecn"eqwpvtkgu"*vtcxgngtÓu"fkcttjgc+0"Cnvjqwij"vjg"oclqtkv{"qh"kphgevgf"jwocpu"ujgf"
Giardia cysts without any symptoms, the major clinical signs of giardiasis in humans 
include acute or chronic diarrhea, nutritional disorders and weight loss. Recent studies 
have shown that Giardia genotypes may be shared between human and numerous 
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other species of animal [205][206]  indicating transmission between humans and 
animal vectors may occur, possibly through exposure to contaminated water.  
 
Metronidazole, the current drug of choice, can cause mutagenicity in bacteria [207] 
and is carcinogenic in rodents [208][209]. It also possesses undesirable side effects 
and failures in treatment have been reported [210][211]. We therefore plan to evaluate 
the in vitro activity of Canarium patentinervium Miq., against Giardia intestinalis in 
the search for an alternative drug suitable for use in preventing and treating cases of 
diarrhoea. 
 
8.1.2 Natural products and parasitic defence 
 
We know that humans have used medicinal plants for several thousands of years to 
treat illness and health disorders [212]. Medicinal chemists have synthesized a 
number of drugs which can be used against many but by far not all endoparasites. A 
major problem is that many of these drugs were developed many years ago and some 
parasitic strains have become resistant to them. The development of new antiparasitic 
drugs has not been much of a priority for the pharmaceutical industry because many 
of the parasitic diseases occur in poor countries where the populations cannot afford 
to pay a high price for the drugs. Thus an investment in drug development against 
parasitic diseases is a risky affair. An alternative to synthetic drugs is the search for 
anti-parasitic plant extracts or secondary metabolites derived from them. Natural 
products still play an important role in therapy: between 1981 and 2006, 1,184 new 
drugs were registered of which 28% were natural products or their derivatives. 
Another 24% of the new drugs had pharmacophores (i.e., functional groups with 
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pharmacological activity) derived from natural products  [213]. A good starting point 
to find antiparasitic natural products would be traditional medicinal plants, such as 
those known from Asia, Africa or America [212] that have been employed to treat 
infections. 
 
 
8.2 Materials and Methods 
 
8.2.1 Principle of method 
 
The antiprotozoal activity of the compounds was perform according to the standard 
methods as described by Sawangjaroen et al. [214][200]. The antileishmanial activity 
of the compounds was perform according to the standard methods as described by 
Mosmann [215]. 
 
8.2.2 Protocol 
 
8.2.2.1 Antiparasitic assay against Giardia intestinalis and Entamoeba histolytica 
 
8.2.2.1.1 Test organisms 
Giardia intestinalis  
A local Thai strain of Giardia intestinalis, originally described by Siripanth et al. 
[216] was used throughout this experiment.  
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Entamoeba histolytica 
Entamoeba histolytica strain HM1: IMSS, purchase from ATCC was used throughout 
this experiment.   
 
8.2.2.1.2 Cultivation of organisms 
 
Both Giardia intestinalis and Entamoeba histolytica were cultured axenically in screw 
capped tubes at 37 oC, under anaerobic condition, on YI medium [217] supplemented 
with 10% heat-inactivated horse serum. Subculture was performed every 48 hr. For 
assays, trophozoites were harvested by chilling the tube on ice for 15 min to detach 
the monolayer and centrifuged at 300 g for 5 min. The supernatant was decanted and 
cells were re-suspended in fresh medium. The numbers of viable cells were calculated 
using a haemocytometer and 0.4 % (w/v) trypan blue. The criteria used for viability 
were motility and dye exclusion. 
 
8.2.2.1.3 Antiprotozoal assay 
 
Briefly, trophozoites, 2x105 cells/ml, was incubated, in triplicate, in the presence of 
serial two fold dilutions of plant extracts that ranged from 31.25 to 500 og/ml for 
crude extract in 96 well tissue culture plates (200 ol/well).  Metronidazole and 
complete medium with added DMSO will be used as negative and positive control, 
respectively.  After 24 hr of incubation at 37 oC under anaerobic conditions, the 
trophozoites from each well will examine with an inverted microscope.  The 
appearance of trophozoites will score and presented as score values from 1 to 4 with 1 
showing the most inhibition of growth and 4 showing no inhibition, according to 
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Upcroft and Upcroft [218]. The minimum inhibitory concentration (MIC) will be 
recorded (the lowest concentration at which >90% of the trophozoites rounded up). 
Each concentration was tested in triplicates and at least three experiments were 
performed on separate occasions. 
 
8.2.2.2 Antiparasitic activity against Leishmania donovani promastigotes 
 
Antileishmanial activity of tested plant extract, against Leishmania donovani (strain 
MHOM/IN/1983/AG83) promastigotes, was evaluated by a quantitative colorimetric 
assay using MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide; 
Sisco Research Laboratory, Mumbai, India]. Amphotericin B (Sigma-Aldrich Co., 
MO, USA; IC50 =0.4±0.1µM) was used as the positive control in all the experiments. 
Promastigotes (5×105 cells/ml; 300 µl), were treated with and without tested samples 
at concentrations of 100 and 500 µg/mL, and incubated at 22 ± 2 oC. After 72 hr, cells 
were harvested, and re-suspended in PBS (500 µl) containing MTT (0.3 mg/ml).  
Purple formazan crystals were dissolved in DMSO and the optical density (O.D.) was 
measured at 570 nm in an ELISA reader (BIO-RAD; model 680, USA). The number 
of viable cells was directly proportional to the amount of formazan produced through 
the reduction of yellow MTT by the dehydrogenase enzymes present in the inner 
mitochondrial membrane of the living cells.   
The percentage of growth inhibition was calculated as follows:  
% inhibition = [(O.D. of untreated control - O.D. of treated set)/ O.D. of untreated 
control] x 100. 
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8.2.3 Statistical analysis 
 
The IC50 values (concentration of drug which inhibited at least 50% cell growth) for 
each compounds were determined from respective dose-responsive percentage 
inhibition curves with the help of Microsoft Excel and data were reported as mean and 
SD values obtained from a minimum of three determinations. Graph was plotted with 
SD and 95% confidence interval. 
 
 
8.3 Results 
 
The result of the in vitro effect of extracts on Giardia intestinalis and Entamoeba 
histolytica was summarized in Table 8.2. It was found that the ethanol extracts were 
both active against growth of Giardia intestinalis in vitro with MIC 500 µg/ml (Table 
8.2). The MIC of metronidazole was 2.5 µg/ml and the remaining extracts showed no 
activity (MIC >500"µg/ml for crude extract). The appearance of trophozoites in 
negative, positive and with exposure to LE under microscope is shown in Figure 8.1.  
 
The result of the in vitro effect of extracts on Leishmania donovani was  summarized 
in Table 8.3. The potency of extracts against Leishmania donovani was LH > BH > 
BC > LC. Both ethanol extracts of leaves and barks had IC50 values of above 500 
µg/ml. Hexane extract displayed lowest IC50 value of 257.40±0.30 µg/ml. Figure 8.2 
shows the inhibition of the hexane and chloroform extracts.  
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8.4 Discussion 
Parasites are eukaryotes and therefore share most molecular and biochemical 
properties with their eukaryotic hosts, making it often difficult to find antiparasitic 
drugs which are both effective and non-toxic for humans. This limitation always has 
to be kept in mind when discussing the numerous findings that some drug or extract 
from a medicinal plant is active against parasites in vitro. In order to be medicinally 
useful, such a drug must have bioavailability and should not intoxicate the patient. A 
first guidance is the determination of a selectivity index (SI) which compares the 
cytotoxicity of a drug against a parasite and a library of human cells [194]. 
Most of the antiparasitic properties of extracts and isolated natural products have been 
tested in vitro only. Translation of the in vitro research results into in vivo trials is 
urgently required. Furthermore, even if animal experiments were successful, we 
would need clinical trials of the new compounds alone or in combination with 
established parasiticidal drugs to prove their efficacy and safety. These developments 
are costly and it is presently difficult to attract the pharmaceutical industries into these 
fields for various reasons. TCM and other traditional medicine systems employ 
several thousand of medicinal plants; some of which have known antiparasitic 
properties.  
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Table 8.2:  MIC values of Canarium patentinervium Miq. incubated for 24 hr with Giardia 
intestinalis and Entamoeba histolytica growing in vitro. 
Sample MIC (µg/ml) 
Giardia intestinalis Entamoeba histolytica 
LH >500 >500 
LC >500 >500 
LE 500 >500 
BH >500 >500 
BC >500 >500 
BE 500 >500 
Metronidazole 2.5 2.5 
LH: leaf hexane extract, LC: leaf chloroform extract, LE: leaf ethanol extract, BH: bark hexane extract, BC: bark 
chloroform extract, BE: bark ethanol extract. Data were obtained from three independent experiments, each performed in 
triplicates (n=9) and represented as mean ± SD. Values with the same capital letter are not significantly different (P<0.01) 
according to Tukey multiple comparison test. 
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Figure 8.1: Appearance of trophozoites under microscope in negative control, positive control and with LE 
 
 
 
Negative control of G. intestinalis 
Negative control of E. histolytica 
Positive control: 10 og/ml of 
metronidazole ふcell deathぶ  
Positive control: 10 og/ml of 
metronidazole"ふcell deathぶ  
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Table 8.3:  Antiparasitic values of Canarium patentinervium Miq.  against Leishmania donovani (AG 83) 
promastigotes 
 
Sample IC50 (µg/ml) 
LH 257.40±0.30 
LC 457.70±0.25 
LE >500 
BH 284.20±0.40 
BC 359.90±0.20 
BE >500 
LH: leaf hexane extract, LC: leaf chloroform extract, LE: leaf ethanol extract, BH: bark hexane extract, BC: bark 
chloroform extract, BE: bark ethanol extract.  
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± 
SD. Values with the same capital letter are not significantly different (P<0.01) according to Tukey multiple comparison 
test. 
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Figure 8.2: MTT assay of Canarium  patentinervium Miq. against Leishmania donovani. 
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They offer a unique opportunity to identify natural products which could be 
potentially used to treat parasitic infections. The success story of artemisinin from 
Artemisia annua [213][219] can probably be repeated. A number of medicinal plants 
and secondary metabolites isolated from them have been screened for anti-
trypanosomal activity [220]. Active natural products include several groups of 
alkaloids, phenolics, saponins, cardiac glycosides, other terpenoids, and 
polyacetylenes (common in Apiaceae, Asteraceae and Araliaceae). Although some 
natural products are active in the submicromolar range and show good selectivity, 
only few have been studied in vivo in an animal model.  
 
In the present study, six different extracts of Canarium patentinervium Miq. 
(Burseraceae) leaves and barks were screened for their in vitro antiparasitic activities, 
among the different extracts tested, the hexane extract of leaves showed moderate 
antileshmanial activity with IC50 values of 257.40±0.30 µg/ml. This could be due to 
essential oils present in the hexane extracts as shown previously in the family of 
Burseraceae [221]. Only ethanol extracts showed activity against Giardia intestinalis 
and Entamoeba histolytica at concentration of 500 µg/ml. Other extracts were inactive 
against these two intestinal parasites.  
 
Small lipophilic secondary metabolites, such as terpenoids or phenylpropanoids as 
found in the essential oil of many plants (especially in Lamiaceae, Myrtaceae, 
Rubiaceae, Apiaceae, Asteraceae, Lauraceae, Rutaceae, Burseraceae, Verbenaceae, 
Pinaceae, Cupressaceae), can dissolve in biomembranes and disturb their fluidity and 
the function of membrane proteins [221]. Therefore, many of the lipophilic mono- and 
sesquiterpenes, phenylpropanoids and isothiocyanates (as present in Brassicaceae, 
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Tropaeoleaceae) have a certain degree of antimicrobial and antiparasitic properties 
[222]. 
 
  
8.5 Conclusion 
 
Plant substances continue to serve as a wellspring of drugs for the world population 
and several   plant-based drugs are in extensive clinical use. Preliminary antiparasitic 
screening of six extracts of Canarium patentinervium Miq. showed that the ethanol 
extract had promising growth inhibition on Giardia intestinalis and Entamoeba 
histolytica. The hexane extract of leaves was active against Leshmanial donovani. The 
results obtained suggest that further isolation studies can be performed on Canarium 
patentinervium Miq to identify the active constituents responsible for the antiparasitic 
activities. 
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CHAPTER 9 
ANTICANCER ACTIVITY 
 
9.1 Introduction 
 
9.1.1 Carcinogenesis 
 
Cancer, a cellular malignancy that results in the loss of normal cell-cycle control, such 
as unregulated growth and the lack of differentiation, can develop in any tissue of any 
organ, and at any time [223] . 
 
Carcinogenesis is the transformation of a normal cell to a cancerous cell through 
many stages, which occur over a number of years or even decades. The first stage of 
carcinogenesis is the initiation stage, which involves the reaction between the 
carcinogens and the DNA of the cells. Inhibiting this early stage of cancer is an 
important strategy in cancer prevention or treatment. Promotion is the second stage 
and may occur slowly over an extended period of time, ranging from several months 
to years. Beneficial effects may arise from a change in lifestyle and diet, which may 
result in the individual not developing cancer during his or her lifetime. The third 
stage is the progressive stage, involving the spread of the cancer. It is evident that, 
upon entering into this stage, preventative factors such as diet have less of an impact. 
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Despite the therapeutic advances made in understanding the processes involved in 
carcinogenesis, cancer has become one of the most serious medical problems today. 
The worldwide mortality rate increases annually, with more than seven million deaths 
occurring per year. For this reason, cancer chemotherapy has become a major focus 
area of research. Different lifestyles, risk factors (such as age, gender, race, genetic 
disposition) and the exposure to different environmental carcinogens, lead to the 
varying patterns of cancer incidence [223]. At least 35% of all cancers worldwide 
result from an incorrect diet, and in the case of colon cancer, diet may account for 
80% of these cases [224]. One of the most important contributions to the development 
of cancer is the oxidative damage to DNA [225]. Permanent genetic alterations may 
occur in those cells where DNA is damaged and where division of this DNA occurs 
before it can be repaired. These cells may begin to divide more rapidly and result in 
carcinogenesis [224]. 
  
9.1.2 Natural products and carcinogenesis defence 
 
ÐEjgoqrtgxgpvkqpÑ" ku" fghkpgf as a process to delay or prevent carcinogenesis in 
humans through the ingestion of dietary or pharmaceutical agents. This also implies 
the identification of chemical entities (specifically cytotoxic entities) that are effective 
against a range of cancer cell lines, although less active or non-toxic against the 
normal (healthy) cell population. The search for such anticancer agents from plant 
uqwtegu" uvctvgf" kp" vjg" 3;72Óu." cpf" rlant products have proven to be an important 
source of anticancer drugs [226]. This directly results from the biological and 
chemical diversity of nature, which allows for the discovery of completely new 
chemical classes of compounds. 
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The discovery and development of plant-derived compounds led to the first treatment 
of cancer, specifically upon administration of these compounds in combination with 
synthetic agents. At present more than 450 different compounds have been isolated 
from active plants that have shown in vitro and/or in vivo antitumor activity. Virtually 
every major class of natural chemical compound is represented in the list of active 
constituents [227].  Of the 121 medications being prescribed for use in cancer 
theraphy, 90 are sourced from plants. It was also determined that approximately 74% 
of these discoveries were as a result of an investigation into the claims made by 
folkloric tradition [228]. A number of natural products are used as chemoprotective 
agents against commonly occurring cancers. Examples of these compounds used as 
cytotoxic drugs are shown in Table 9.1. 
 
A number of mechanisms exist by which phytochemicals aid in the prevention of 
cancer. This preventative action most probably results from the additive or synergistic 
effects of a number of phytochemicals, since cancer is a multi-step process  [227]. 
Proposed mechanisms by which phytochemicals may prevent cancer include: (i) anti-
oxidant and free radical scavenging activity; (ii) antiproliferative activity; (iii) cell-
cycle arresting activity; (iv) induction of apoptosis; (v) activity as enzyme cofactors; 
(vi) enzyme inhibition; (vii) gene regulation; (viii) activity as hepatic phase I enzyme 
inducers, and (ix) activity as hepatic phase II enzyme inducers. Oxidative damage to 
DNA, proteins and lipids, resulting from an increase in oxidative stress, is considered 
to be one of the most important mechanisms contributing to the development of 
cancer  [227] . 
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The phytochemicals that most often appear to be protective against cancer are 
curcumin, genistein, resveratrol, diallyl sulfide, (S)-allyl cystein, allicin, lycopene, 
ellagic acid, ursolic acid, catechins, eugenol, isoeugenol, isoflavones, protease 
inhibitors, saponins, phytosterols, vitamin C, lutein, folic acid, beta carotene, vitamin 
E and flavonoids, to name but a few [224]. These phytochemicals suppress the 
inflammatory processes that lead to transformation, hyperproliferation, and initiation 
of carcinogenesis. The inhibitory influences of these phytochemicals may ultimately 
suppress the final steps of carcinogenesis via angiogenesis and metastasis.  
  
The present study was undertaken to screen the anticancer potential Canarium 
patentinervium Miq. No anticancer studies have previously been reported on this 
species to date. 
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Table 9.1: Cytotoxic drugs developed from plant sources. 
Therapeutic agent Plant source Mechanism of 
action 
Treatment of 
cancer type 
Reference 
Vincristine, 
vinblastine 
Catharanthus 
roseus 
Inhibition of 
tubulin 
polymerisation 
JqfimkpÓu"fkugcug [229] 
Etoposide, teniposide Podophyllum 
peltatum 
Inhibition of 
topoisomerase 
II 
Testicular cancer, 
and small 
cell lung carcinoma, 
leukaemias, 
lymphomas 
[229] 
[230] 
[231] 
Paclitaxel, docetaxel Taxus 
brevifolia 
Promotion of 
tubulin 
stabilization 
Ovarian and breast 
carcinoma 
[229] 
Irinotecan, topotecan, 
9-aminocampothecin, 
9-nitrocamptothecin 
Camptotheca 
acuminata 
Inhibition of 
topoisomerase 
I 
Advanced colorectal 
cancer, 
also active in lung, 
cervix 
and ovarian cancer 
[230] 
 
Homoharingtonine Harringtonia 
cephalotaxus 
Inhibition of 
DNA 
polymerase   
Various leukaemias [229] 
4-Ipomeanol Ipomoea 
batatas 
Cytochrome P-
450- 
mediated 
conversion 
into DNA-
binding 
metabolites 
Lung cancer [229] 
Elliptinium Bleekeria 
vitensis 
Inhibition of 
topoisomerase 
II 
Advanced breast 
cancer 
[229] 
Flavopiridol Amoora 
rohituka, 
Dysoxylum 
binectariferum 
Inhibition of 
cyclin- 
dependent 
kinases 
Encouraging results 
noted 
in a variety of solid 
and 
haematological 
malignancies, in 
patients 
with colorectal, 
prostate, 
lung, renal 
carcinoma, 
non-JqfimkpÓu"
lymphoma 
and chronic 
lymphocytic 
leukaemia 
[229] 
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9.2 Materials and Methods 
 
9.2.1 Principle of the MTT assay 
 
MTT assay is dependent on the reduction of the tetrazolium salt MTT (3-(4,5-
dimethylthazol-2-yl)-2,5-diphenyl tetrazolium bromide) by the mitochondrial 
dehydrogenase of viable cells to form a blue formazan product. The assay measures 
cell respiration and the amount of formazan produced is proportional to the number of 
living cells present in culture which will result in lower optical density (OD) [232]. 
Biological in vitro assay was determined as follows [233]. 
 
9.2.2 Protocol 
 
9.2.2.1 Cell lines and cell culture 
 
Human derived cell lines [HCT 116,colon cancer cell line and MCF-7 (ER+), MDA 
468 (ER-) breast carcinoma] were routinely cultivated at 37 °C in an atmosphere of 5 
% CO2 in RPMI 1640 medium supplemented with 2 mM L-glutamine and 10 % fetal 
calf serum and subcultured twice weekly to maintain continuous logarithmic growth. 
Cells were seeded into 96-well microtiter plates at a density of 3-5 × 103 per well and 
allowed 24 hr to adhere before extracts were introduced (final concentration 200 
µg/ml to 1 µg/ml). 
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9.2.2.2 Preparation of plant samples 
 
Extracts were prepared as 400 µg/ml top stock solutions, dissolved in DMSO, and 
stored at 4 oC, protected from light for a maximum period of 4 weeks. Serial sample 
dilutions were prepared in medium immediately prior to each assay. 
 
9.2.2.3 The MTT assay 
 
At the time of extract addition and following 72 hr exposure, MTT (3-(4,5-
dimethylthazol-2-yl)-2,5-diphenyl tetrazolium bromide) was added to each well. 
Incubation at 37 °C for 4 hr allowed reduction of MTT by viable cells to an insoluble 
formazan product. Well contents were aspirated and formazan solubilized by addition 
of DMSO:glycine buffer (pH 10.5) (4:1). Absorbance was read on an Anthos Labtec 
System plate reader at 550 nm as a measure of cell viability, thus cell growth or 
extract toxicity was determined. Doxorubicin was used as positive control. 
  
9.2.3 Statistical analysis 
 
ConcentrationÎresponse curves were calculated using Microsoft Excel and data were 
reported as mean and SD values obtained from a minimum of three determinations. 
Graph was plotted with SD and 95% confidence interval. 
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9.3 Results 
 
A range of extracts were evaluated in MTT assays following a 3-day exposure against 
a panel of two human breast cancer cell lines, MCF-7 (ER+) and MDA 468 (ER-), 
and a colon cancer cell line, HCT 116. In general, the breast cancer cell lines were 
more sensitive to the extracts, and the MDA 468 line was the most sensitive of the 
three lines (Table 9.2) The best growth inhibition was observed with the chloroform 
and ethanol extract of barks, GI50 values of 23.44 µg/ml and 34.40 µg/ml respectively 
(Figure 9.1-9.3). 
 
 
9.4 Discussion 
 
In the present study, six different extracts of Canarium patentinervium Miq. 
(Burseraceae) leaves and barks were screened for their in vitro antitumor activities. 
Among the different extracts tested, the chloroform and ethanol extract of barks 
showed good antitumor activities with GI50 values of 23.44±0.05 µg/ml and 
34.40±0.21 µg/ml respectively. The most susceptible cell lines were found to be the 
breast cancer cell line, MDA 468.  
 
It is known that nature is able to produce a wide variety of chemical entities of novel 
structure. Many of the new and novel compounds isolated from natural sources might 
otherwise have never been discovered, especially those of considerable complexity 
requiring the development of methods for the creation of new ring systems. 
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Table 9.2: Growth inhibition of human cancer cell lines by crude plant extracts of Canarium patentinervium Miq. 
Extracts Cell line/ GI50 (µg/ml) 
MDA 468 HCT 116 MCF-7 
LH >100 >100 >100 
BH >100 >100 >100 
LC >100 >100 >100 
BC 23.44±0.05 62.46±0.23 64.50±0.27 
LE 61.48±0.23 97.18±0.08 85.40±0.18 
BE 34.4±0.21 46.53±0.12 39.06±0.16 
Doxorubicin 0.06±0.12 0.70±0.18 0.34±0.26 
LH: leaf hexane extract, LC: leaf chloroform extract, LE: leaf ethanol extract, BH: bark hexane extract, BC: bark chloroform extract, BE: bark ethanol xtract 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same  letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
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Figure 9.1a: Effects of extract of leaves against MDA 468 growth 
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Figure 9.1b: Effects of extract of barks against MDA 468 growth 
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Figure 9.2a: Effects of extract of leaves against MCF-7 growth 
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Figure 9.2b: Effects of extract of barks against MCF-7 growth 
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Figure 9.3a: Effects of extract of leaves against HCT 116 growth 
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Figure 9.3b: Effects of extract of barks against HCT 116 growth 
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Natural products appeared to be a promising source for new types of  compounds with 
antitumor activity [234].  
 
 
9.5 Conclusion 
 
Plant substances continue to serve as a wellspring of drugs for the world population 
and several plant-based drugs are in extensive clinical use [3]. Preliminary anticancer 
screening of six extracts of Canarium patentinervium Miq. showed that the 
chloroform and ethanol extract of the barks had promising effect on the cell viability 
of breast cancer cell line MDA 468. The results obtained suggest that further isolation 
studies can be performed on Canarium patentinervium Miq to identify the active 
constituents responsible for the anticancer activities. 
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CHAPTER 10 
ISOLATION AND IDENTIFICATION OF COMPOUNDS 
 
10.1 Introduction 
 
10.1.1 Secondary metabolites 
 
Medicinal plants have formed the basis of health care since earliest times of humanity 
and are still being widely used. The clinical, pharmaceutical and economic value 
continues to grow, varying between countries. Chemodiversity in plants has proven to 
be important in pharmacological research and drug development, not only for the 
isolation of bio-active compounds used directly as therapeutic agents, but also as 
leads to the synthesis of drugs or as models for pharmacologically active compounds 
[235]. The rapid identification of these bio-active compounds, however, is critical if 
this tool of drug discovery is to compete with developments in technology. Plant 
preparations are distinguished from chemical drugs due by their complexity of 
mixtures containing large numbers of bio-active compounds or secondary metabolites. 
This brings about the challenge of drug discovery from natural sources [236].  
 
Plants produce primary and secondary metabolites which encompass a wide array of 
functions. Primary metabolites, which include amino acids, simple sugars, nucleic 
acids, and lipids, are compounds that are necessary for cellular processes [237]. 
Secondary metabolites include compounds produced in response to stress, such as the 
case when acting as a deterrent against herbivores. Plants can manufacture many 
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different types of secondary metabolites, which have been subsequently exploited by 
humans for their beneficial role in a diverse array of applications [237]. Although 
secondary metabolites from natural products have formed the basis of medicines, the 
presence of these compounds in the biochemistry of the plant is very often difficult to 
justify. It has been suggested that these compounds may have been synthesized by the 
plant as part of the defense system of the plant, e.g. plants are known to produce 
phytoalexins as a response to attack by bacteria and fungi [236]. The presence of 
highly toxic natural products has also been highlighted in some animals namely the 
Amazonian frogs so as to deter predation by other animals [236].  
 
Secondary metabolites are organic molecules that are not involved in the normal 
growth and development of an organism. While primary metabolites have a key role 
in survival of the species, playing an active function in the photosynthesis and 
respiration, the absence of secondary metabolites does not result in immediate death 
but rather in long-term korcktogpv"qh" vjg"qticpkuoÓu"uwtxkxcdknkv{."qhvgp"rnc{kpi"cp"
important role in plant defense [238]. Secondary metabolites are frequently produced 
at highest levels during a transition from active growth to stationary phase [238]. The 
producer organism can grow in the absence of their synthesis, suggesting that 
secondary metabolism is not essential, at least for short term survival. A second view 
proposes that the genes involved in secondary metabolism provide c"ÒÒigpgvke"rnc{kpi"
hkgnfÑ" vjcv" cnnqyu" owvcvkqp" cpf" pcvwtcn" ugngevkqp" vq" hkz" pgy" dgpghkekcn traits via 
evolution. A third view characterizes secondary metabolism as an integral part of 
cellular metabolism and biology; it relies on primary metabolism to supply the 
required enzymes, energy, substrates and cellular machinery and contributes to the 
long term survival of the producer [238].  
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Different classes of these compounds are often associated to a narrow set of species 
within a phylogenetic group and constitute the bioactive compound in several 
medicinal, aromatic, colorant, and spice plants and/or functional foods. These 
compounds are an extremely diverse group of natural products synthesized by plants, 
fungi, bacteria, algae, and animals [239]. A simple classification of secondary 
metabolites includes three main groups: terpenes (such as plant volatiles, cardiac 
glycosides, carotenoids and sterols) constituting about 25,000 types, phenolics (such 
as phenolic acids, coumarins, lignans, stilbenes, flavonoids, tannins and lignin) 
constituting about 8,000 types and nitrogen containing compounds (such as alkaloids 
and glucosinolates) constituting about 12,000 types [240]. Whatever the reasons for 
the presence of these compounds in nature, they provide an invaluable resource that 
have been used to find new drug molecules [241]. A number of traditional separation 
techniques with various solvent systems and spray reagents, have been described as 
having the ability to separate and identify secondary metabolites [48][238]. 
 
When an active extract has been identified, the first task is the identification of the 
bio-active phytocompounds. The coupling of preliminary bioassay screening on crude 
extracts and chromatographic methods such as column chromatography, preparative 
thin layer chromatography (PTLC), high performance liquid chromatography 
(HPLC), mass spectrometry (MS) and nuclear magnetic resonance (NMR) 
spectroscopy, eventually leading to final bioassay screening, are important for the 
acquisition of biologically active compounds.. The successful isolation of compounds 
from plant materials largely depends on the type of solvent used for extraction [242]. 
The extract is separated into individual components and the biological activity of each 
fraction is determined until a pure active compound is obtained. The pure compound 
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is then identified using methods such as mass spectrometry and nuclear magnetic 
resonance spectroscopy. 
 
Research has demonstrated that natural products represent an unparalleled reservoir of 
molecular diversity. The isolation and identification of bio-active phytocompounds in 
medicinal plant extracts generally used by local population to treat diseases would 
prove an immeasurable contribution to drug discovery and development [235]. This 
would not only validate the traditional use of herbal remedies but also provide leads in 
the search for new active principles. Investigations surrounding the constituents of the 
indigenous Canarium patentinervium Miq. in general, have not been the focus of any 
phytochemical study. 
 
10.1.2 Isolation methods  
 
Once the extract has been obtained, the activity within can be demonstrated by 
bioassay methods using both the crude extract or by using the fractionated extracts. 
Fractionation has the added advantage of getting to the biologically active material 
faster. One of the simplest separation methods is partitioning which is a widely used 
method as an initial extract purification step. A combination of solventsÏmiscible 
and immiscible ones are used to separate the phytochemicals making up the extract. 
This method relies on the ability or the components to be either soluble in water or in 
the organic phase [241]. This was then followed by various methods of 
chromatography to isolate the bioactive molecules. 
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10.1.3 Crude Fractionation 
 
The objectives at this stage are to simplify the extract composition by dividing it into 
groups of compounds sharing similar physicochemical characteristics and/or to 
remove the bulk of unwanted materials and thus enrich the extract with respect to the 
target compounds. Procedures commonly employed involve solvent partitioning, 
defatting, and desalting. The procedure used in this study is a modification of the 
method developed by Kupchan [48]. It can be used for defatting and desalting as well. 
Most of fats will go with the n-hexane fraction, while inorganic salts will go with the 
aqueous one. The advantage of the method is total recovery of target compounds. 
Drawbacks are the problems of emulsion formation, time ineffectiveness, and use of 
large volumes of solvents. 
 
10.1.4 Chromatography 
 
ÒEjtqocvqitcrj{Ó" ku" vjg" igpgtcn" vgto" hqt" c" xctkgv{" qh" physico-chemical separation 
techniques, all of which have in common the distribution of a component between a 
mobile phase and a stationary phase. The stationary phase is fixed in the system and 
the mobile phase which is a fluid, streams through the chromatographic system. The 
various chromatographic techniques are sub-divided according to the physical state of 
these two phases. The molecules of the analytes are distributed between the mobile 
and the stationary phases. When present in the stationary phase, they are retained and 
do not move through the system but when present in the mobile phase, they migrate 
with a velocity equivalent to that of the mobile phase. Due to the different 
distributions of the analytes, their mean residence time in the stationary phase differs, 
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resulting in a different 40 net migration velocity. This is the principle of the 
chromatographic system [243]. Chromatograhic techniques have been instrumental in 
the separation of natural products.  
 
10.1.4.1 Thin Layer Chromatography (TLC) 
 
One of the fastest and most widely used chromatographic techniques is Thin Layer 
Chromatography. TLC is an analytical technique that can be used to monitor reactions 
and for the qualitative analysis of complex mixtures and for the identification of 
unknown compounds. It is also important for determining the correct solvent system 
with which to run a column chromatography. TLC is composed of two phases, a 
mobile and a solid phase. The solid phase is a thin solid support that usually consists 
of alumina or silica [48].. The mobile phase is a solvent that moves through capillary 
action right through the solid phase. In general, the solid phase is usually polar while 
the mobile solvent is non polar relative to the solid phase. The choice of the solvent 
depends on the properties of compounds that you want to separate and the nature of 
the solid support you are using (ie, is it silica or alumina). If some compounds cannot 
be visualized with eyes UV light can be used and a variety of visualisation reagents 
can be used [48]. 
 
The behaviour of a compound on a TLC is usually described in terms of its relative 
mobility or retention factor (Rf) value. Rf is a unique value for each compound under 
the same conditions. The Rf for a compound is a constant from one experiment to the 
next only if the chromatography conditions (solvent system, adsorbent, thickness of 
adsorbent, amount of material spotted and temperature) are also constant [244]. Since 
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these factors are difficult to keep constant from experiment to experiment, relative Rf 
xcnwgu" ctg" igpgtcnn{" eqpukfgtgf0" ÐTgncvkxg" ThÑ" ogcpu" vjcv" vjg" xcnwgu" ctg" tgrqtvgf"
relative to a standard. Based on the Rf values, the identity and characteristics of the 
different compounds can be determined. More polar compounds will have smaller Rf 
values since they will have a stronger affinity for the polar solid phase. This would 
result in the compound not being carried very far along the TLC plate. Compounds 
with larger Rf values interact strongly with the less polar mobile phase and thus, tend 
to be non polar themselves [238].  
 
PTLC is used for analytical separations of larger quantities of materials. Because 
sample mass loading capacity is proportional to the square root of the sorbent layer 
thickness, thicker layers are used (>250 たo"wr"vq"3"oo+0"Yjgp"c"dkpfgt"ku"tgswktgf."
the softer inorganic binders (like calcium sulphate) are used so the sample bands can 
be easily removed. The compounds to be separated are often applied as long streaks, 
developed and then recovered by scraping the adsorbent from the plate and eluting 
with a strong solvent [244]. 
 
TLC has the advantage of being a highly cost-effective qualitative technique in as 
much as a large number or samples can be analysed or separated simultaneously. 
Although it is a very simple and convenient technique, one of its limitations is that it 
cannot tell the difference between enantiomers and some isomers. Another 
disadvantage of TLC is that in order to identify specific compounds, the Rf values for 
the compounds of interest must be known beforehand [245]. 
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10.1.4.2 Liquid chromatography (column) 
 
Column chromatography is the most common form of chromatography. Column 
chromatography is suitable for the physical separation of microgram to kilogram 
quantities of material. A solvent acts as the mobile phase while a finely divided solid 
surface acts as the stationary phase. The stationary phase will adsorb the components 
of the mixture to varying degrees. As the solution containing the mixture passes over 
the adsorbent, the components are distributed between the solvent and adsorbent 
surface. This process may be described by a three-way equilibrium between the 
sample, the solvent and the adsorbent [48]. The solvent and sample compete for 
positions on the solid adsorbent, the solvent displacing the sample reversibly and 
continuously in the direction of the solvent flow. Consequently, a weakly adsorbed 
compound will spend more time in the solvent, and will therefore be eluted first. The 
stationary phase is solid and packed in a column made of glass, stainless steel, or 
other inert material. The common solid adsorbents are alumina (aluminum oxide) and 
silica gel (silicon dioxide).  The sample mixture is applied to the top of the column 
and the mobile phase passes through the column either by gravity, vacuum, or 
pressure [238]. 
 
Liquid-solid column chromatography is an effective separation technique when all 
appropriate parameters and equipment are used. This method is especially effective 
when the compounds within the mixture are colored, as this gives the scientist the 
ability to see the separation of the bands for the components in the sample solution. 
Even if the bands are not visible, certain components can be observed by other 
visualization methods. One method that may work for some compounds is irradiation 
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with ultraviolet light.  This makes it relatively easy to collect samples one after 
another.  However, if the components within the solution are not visible by any of 
these methods, it can be difficult to determine the efficacy of the separation that was 
performed.  In this case, separate collections from the column are taken at specified 
time intervals. Since the human eye is the primary detector for this procedure, it is 
most effective when the bands of the distinct compounds are visible [246]. 
 
10.1.4.3 Size Exclusion Chromatography 
 
Size exclusion chromatography separates molecules by their size. This is done by 
having the stationary phase be packed with small particles of silica or polymer to form 
uniform pores. The smaller molecules will get trapped in the silica particles and will 
elude from the column at a rate that is greater than that of larger molecules. Thus, the 
retention time depends on the size of the molecules. Larger molecules will be swept 
away in the mobile phase, therefore having a smaller retention time [245]. In this type 
qh" ejtqocvqitcrj{" vjgtg" kupÓv" cp{" kpvgtcevkqp." dgkpi" rj{ukecn" qt" ejgokecn." dgvyggp"
the analyte and the stationary phase. The most commonly used size inclusion sorbents 
are the dextran gels, particularly the lipophilic versions such as Sephadex LH-20, 
which are mostly used for the separation of small hydrophobic natural products from 
vjgkt"nctigt"ÒÒeqpvcokpcpvu.ÓÓ"wuwcnn{ chlorophylls, fatty acids, and glycerides [48]. In 
organic solvents such as chloroform and methanol, these gels swell to form a matrix. 
As compounds migrate with the solvent through the gel, small molecules become 
included into the gel matrix, whereas larger ones are excluded and migrate at a greater 
rate [238].  
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One of the most extensively used gels in natural product separation, especially 
nonpolar or intermediate polarity compounds, is Sephadex LH-20, a 
hydroxypropylated form of Sephadex G-25. The derivatization offers lipophilicity to 
the gel, at the same time preserving its hydrophilicity. As a result of the added 
lipophilicity, LH-20 gel swells sufficiently in organic solvents and allows handling of 
natural products that are soluble in organic solvents [245]. The useful fractionation 
range of LH-20 is approx. 100Î4000 amu, and is particularly ideal for removal of 
chlorophyll from plant extracts. It should be noted that separations on gels such as 
Sephadex LH-20 also involve the mechanisms of adsorption, partition, possibly ion 
exchange, and occasionally the trend of larger molecules eluting first and smaller ones 
eluting last may be reversed [245]. The gel filtration mode is operational when a 
single eluent is used. The partition mechanism comes into play when the eluent is a 
mixture of solvents (usually a mixture of polar and nonpolar solvents); the more polar 
of the solvents is taken up by the gel, resulting in a two-phase system with stationary 
and mobile phases of different compositions [238] .  
 
This form of chromatography has found considerable use in the removal of 
ÒkpvgthgtkpiÓ"rncpv"rkiogpvu"uwej"cu"vjg"ejnqtqrj{nnu that tend to be larger and more 
lipophilic than many plant natural products. Sephadex LH-20 has also been used for 
the separation of various avermectins and is the most common method for the 
preparative isolation of condensed and hydrolysable tannins [247]. This is a non-
destructive method for the recovery of a high quantity or extract [48]. 
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10.1.4.4 High performance liquid chromatography system 
 
HPLC instrumentation includes a pump, injector, column, detector and recorder or 
data system. The heart of the system is the column where separation occurs. Since the 
stationary phase is composed of micrometer size porous particles, a high pressure 
pump is required to move the mobile phase through the column. The components (or 
analytes) are first dissolved in a solvent, and then forced to flow through a 
chromatographic column under a high pressure. The chromatographic process begins 
by injecting the solute onto the top of the column where the mixture is resolved into 
its components [243]. The amount of resolution is important and is dependant upon 
the extent of the interaction between the solute components and the stationary phase. 
The stationary phase is defined as the immobile packing material in the column. 
Separation of components occurs as the analytes and mobile phase are pumped 
through the column. Eventually each component elutes from the column as a narrow 
band (or peak) on the recorder [245]. The interaction of the solute with the mobile and 
stationary phases can be manipulated through different choices of both solvents and 
stationary phases. As a result, HPLC acquires a high degree of versatility not found in 
other chromatographic systems and it has the ability to easily separate a wide variety 
of chemical mixtures [243]. 
 
Modern HPLC uses a non-polar solid phase, like C-18, and a polar liquid phase, 
generally a mixture of water and another solvent. High pressures up to 400 bars are 
required to elute the analytes through the column before they pass through a diode-
array detector. The detector measures the absorption spectra of the analytes to aid in 
their identification. HPLC is useful for compounds that cannot be vaporized or that 
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decompose under high temperature [243]. Initially, pressure was selected as the 
principle criterion of modern liquid ejtqocvqitcrj{" cpf" vjwu" vjg" pcog" ycu" Òjkij"
rtguuwtg"nkswkf"ejtqocvqitcrj{Ó0"Vjku"ycu. however, an unfortunate term because it 
seems to indicate that the improved performance is primarily due to the high pressure. 
This is not true. In fact, high performance is the result of many factors: very small 
particles of narrow distribution range and uniform pore size and distribution, high 
pressure column slurry packing techniques, accurate low volume sample injectors, 
sensitive low volume detectors and good pumping systems [243]. 
 
There is a growing interest in the chemical composition of plants and the use of 
HPLC has several advantages over other methods. The technique is sensitive, rapid 
and does not require the preparation of derivatives before separation. A further 
advantage is that ultraviolet absorption detectors set in the aromatic region of the 
spectrum (e.g. 275 nm) may also be used. Several reports have also been published of 
the application of HPLC to various phenolic acids and aldehydes that occur in plants 
[248]. 
 
10.1.5 Structure elucidation 
 
In most cases of extraction and isolation of natural products, the end point is the 
identification of the compound or the conclusive structure elucidation of the isolated 
compound. However, structure elucidation of compounds isolated from plants, fungi, 
bacteria, or other organisms is generally time consuming, and sometimes can be the 
ÒÒdqvvngpgemÓÓ" kp"pcvwtcn" rtqfwev" tgugctej [48]. There are many useful spectroscopic 
methods of getting information about chemical structures, but the interpretation of 
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these spectra normally requires specialists with detailed spectroscopic knowledge and 
wide experience in natural product chemistry. With the remarkable advances made in 
the area of artificial intelligence and computing, there are a number of excellent 
automated structure elucidation programs available that could be extremely useful 
[238]. 
 
If the target compound is known, it is often easy to compare preliminary 
spectroscopic data with literature data or to make direct comparison with the standard 
sample. However, if the target compound is an unknown and complex natural 
product, a comprehensive and systematic approach involving a variety of physical, 
chemical, and spectroscopic techniques is required [48]. Information on the chemistry 
of the genus or the family of plant or microbe under investigation could sometimes 
provide additional hints regarding the possible chemical class of the unknown 
compound [249]. Some of the spectroscopic methods used for structure elucidation 
include ultraviolet-visible spectroscopy (UV-vis), infrared spectroscopy (IR), mass 
spectrometry (MS) and nuclear magnetic resonance (NMR). In this study we have 
used NMR. 
 
10.1.5.1 Nuclear magnetic resonance (NMR) 
 
Nuclear magnetic resonance (NMR) is a spectroscopic technique involving a 
magnetic field in which a sample is placed. The sample is then subjected to 
radiofrequency radiation at the appropriate frequency, allowing for the absorption of 
energy depending on the type of nucleus, whether, for example, it is a 1H or 13C. The 
frequency also depends on chemical environment of the nucleus, whether methyl or 
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hydroxyl protons are present, molecular conformations, and dynamic processes. Both 
1H NMR and 13C NMR are used, with the latter providing information on the carbon 
skeleton, and the former relating to the specifics of the hydrogen atoms, thus 
complementing each other [245]. 
 
 
10.2 Materials and methods 
 
10.2.1 Isolation of compound 1-5 (crude fractionation) 
 
The isolation scheme for compound 1-5 is shown in Figure 10.1. The ethanol extract 
of the leaves (LE-40 g) was dissolved in water. It is then partitioned with petroleum 
ether, chloroform, and water to yield the respective solvent extracts (LE-PE, LE-CL 
and LE-WA). Phytochemical analysis was repeated as in 3.2 (iv) to confirm the 
absence of tannins in LE-PE and LE-CL and the presence of tannins in LE-WA. The 
solvent partitioning thus concentrates all tannins in the water fraction. 
 
10.2.2 Isolation of compound 1 & 2  
 
10.2.2.1 Silica gel column chromatography 
 
A glass column was clamped upright and packed with silica gel (size 0.063-0.200 
mesh) mixed with the appropriate mobile phase and poured into the column (4 cm x 
90 cm)  as a compact even suspension. This constituted the stationary phase. The 
extract (LE-CL weighing 6 g) was then mixed with a small amount of  chloroform 
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and introduced as a thin band to the silica gel. Once the extract was loaded onto the 
silica gel, the mobile phase was added at a constant flow rate. Gradient elution of 
increasing polarity was initiated with chloroform/methanol gradient elution (the ratio 
from 100:0 to 92:8).  Thirteen column fractions were collected and analyzed by TLC 
(chloroform/methanol). Fractions with similar TLC pattern were combined to total of 
four fractions. 
 
10.2.2.2 Preparative thin layer chromatography (PTLC) 
 
Fraction 2 that was yielded from chloroform/ methanol ratio 96:4 was 
rechromatographed on a preparative TLC (silica gel plate with 2 mm thickness) with 
solvent system chloroform/ methanol (ratio of 1000:15) yielding total 7 bands. Band 
five was collected and rechromatographed on preparative TLC (0.5 mm thickness) 
with solvent system chloroform/ methanol (ratio of 89:11) to yield four bands, with 
band two and band three sent for NMR characterisation. 
 
10.2.3 Isolation of compound 3, 4 & 5 
 
10.2.3.1 Size-exclusion column chromatography 
 
The principle governing this method is based on the molecular size differences of the 
compounds, which result in the separation of these compounds. The stationary phase 
comprised of a porous three-dimensional polymeric matrix, namely SephadexTM LH-
20 (GE Healthcare). This matrix was initially saturated with ethanol in order to 
facilitate swelling before use. SephadexTM LH-20 in ethanol adsorbs tannins while it 
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desorbs tannins in acetone [247]. This is then useful for the separation of tannin and 
non-tannin containing fractions. Once swelling was achieved the matrix was then 
introduced into a glass column and the fraction (LE-WA) which was dissolved in 
ethanol was introduced as a thin band was then applied to the column. The mobile 
phase consisted ethanol. Sixteen fractions were collected analyzed by TLC. Fractions 
with similar TLC pattern were combined to total of four fractions. The adsorbed 
tannins were then flushed with a change of mobile phase to acetone:water (70:30) 
resulting in fraction WT. The phytochemical tannin test (section 3.2-iv) was again 
performed to confirm the presence of tannins in WT and absence in the other 
fractions. The matrix had irreversibly sorbed material that could be tannin [247].  
 
Fraction WB was reintroduced to another column with SephadexTM LH-20 that was 
swelled in methanol. Total 3 fractions were collected and fraction WB2 was sent for 
nuclear magnetic resonance (NMR) characterisation. Fraction WD was also 
introduced to SephadexTM LH-20 that was swelled in methanol. Total five fractions 
were collected and fraction WD3 and WD4 were sent for nuclear magnetic resonance 
(NMR) characterisation. 
 
10.2.4 Isolation of compound 6-8 
 
10.2.4.1 Isolation of compound 6-8 (PTLC and solvent partioning) 
 
The isolation scheme for compound 6-8 is shown in Figure 10.2.  The chloroform 
extract of the barks were dissolved in dicloromethane:methanol (2:1). Mixture was 
chromatographed on a PTLC (silica gel plate with 2 mm thickness) with solvent 
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system ethyl acetate: methanol (10:1) yielding total three bands (Figure 10.3). First 
band (B1) was rechromatographed on PTLC (2 mm thickness) with solvent system 
ethyl acetate: methanol (6:1) yielding four bands. The third band upon reconstitution 
resulting in fraction B1-BA was subjected to HPLC (section 10.4.5). The second band 
(B2) from Figure 10.3 was rechromatographed on PTLC (2 mm thickness) with 
solvent system ethyl acetate: methanol (6:1) yielding three bands. The second band of 
this PTLC plate upon reconstitution (B2-BA) was subjected to HPLC (section 10.4.5).  
The third band (B3) from Fig 10.3 and all the other areas including origin was 
combined and partitioned between water and ethyl acetate resulting in aqueous (B3-
AL) and organic layer (B3-OL). The B3-AL fraction was subjected to HPLC (section 
10.4.5).  
 
10.2.4.2 Isolation of compound 6-8 (HPLC) 
 
Fraction B1-BA, B2-BA and B3-AL was concentrated in vacuum and then dissolved 
in methanol. The solution was then subjected to HPLC individually. The samples 
were then qualitatively analyzed by using Agilent 2690 semi-prep HPLC system 
(Luna C-18 column, 100 mm x 30 mm) equipped with a 996 photodiode-array 
detector (PDA). The injection of the sample was 5 µl and the flow rate was 2 ml/min. 
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 Liquid- liquid partitioning 
 
                   With petroleum ether   with chloroform    with water 
 
       
 
       Silica gel 60            SephadexTM LH-20   Final flushing 
       Chloroform:methanol           column            with  
       (100:0       92:8)            Ethanol    acetone:water 
                                     13 fractions recombined          16 fractions recombined   (70:30)     
               to 4 fractions            to 4 fractions   
 
 
 
 
 
        PTLC                               SephadexTM-LH 20 
        Chloroform:methanol               Methanol 
       (1000:15) 
        7 fractions 
 
 
 
     PTLC              
     Chloroform:methanol     
     (89:11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1: Schematic representation of the isolation and purification of compound 1 
(scopoletin), compound 2 (scoparone), compound 3 (+-catechin), compound 4 (hyperin) and 
compound 5 (cynaroside) isolated from Canarium patentinervium Miq. 
Ethanol extract of leaves, LE 
Dissolved in water Î 40 g 
 
Extraction of Canarium patentinervium Miq. bark and leaves (500 g) 
Crude hexane extract Crude chloroform extract Crude ethanol extract 
LE-PE Î 11 g LE-CL Î 6 g LE-WA Î 24 g 
2% met 
CA 
4% met 
CB 
6% met 
CC 
8% met 
CD 
CB1 CB2 CB3 CB4 CB5 CB6 CB7 
CB4-1 CB4-2 CB4-3 CB4-4 
Compound 1 
(scopoletin) 
49 mg 
Compound 2 
(scoparone) 
11 mg 
WA WB WC WD 
Final  
fraction
WT 
WB1 WB2 WB3 
Compound 3 
(+-catechin) 
14 mg 
WD1 WD2 WD3 WD4 WD5 
Compound 4 
(hyperin) 
5.2 mg 
Compound 5 
(cynaroside) 
4.8 mg 
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      PTLC 
      Ethyl acetate:methanol 
      (10:1) 
      
 
 
 
 
 
          PTLC                  PTLC            Combined and partitioned 
        Ethyl acetate: methanol     Ethyl acetate:methanol    between water and 
         (6:1)       (6:1)             ethyl acetate 
          
 
 
 
 Concentrated in vacuum             Concentrated in vacuum          Concentrated in vacuum 
 Dissolved in methanol             Dissolved in methanol          Dissolved in methanol 
 5 ml of solution             5 ml of solution           5 ml of solution 
 Semi-Prep HPLC             Semi-Prep HPLC           Semi-Prep HPLC 
 Mobile phase             Mobile phase           Mobile phase 
 (A: water, B: acetonitrile)            (A:water, B:acetonitrile)          (A:ammonium bicarbonate, 
                 B: acetonitrile) 
  
 
 
 
Acetonitrile removed by            Acetonitrile removed by          Acetonitrile removed by 
Evaporation and                       evaporation and           evaporation and 
freeze dried             freeze dried            freeze dried 
 
 
  
Dissolved in methanol                    Dissolved in methanol 
Dried under nitrogen            Dried under nitrogen 
 
 
 
 
Figure 10.2: Schematic representation of the isolation and purification of compound 6 
(vomifoliol), compound 7 (lioxin) and compound 8 syringic acid isolated from Canarium 
patentinervium Miq. 
 
Chloroform extract of barks (BC) 
 Dissolved in dicloromethane:methanol 
(2:1) -7.2g 
 
Extraction of Canarium patentinervium Miq. bark and leaves (500 g) 
Crude hexane extract Crude chloroform extract Crude ethanol extract 
Band 1, B1 Band 2, B2 Band 3, B3 Others, BO 
B1-BA Others 
Fraction 
(Rt= 14.1 
min) 
B1-14 (Solid) 
Compound 6 
(vomifoliol) -15 mg 
B2-BA 
Fraction 
(Rt= 15.8 
min) 
B2-15 (Solid) 
Compound 7 
(lioxin) Î 3.4 mg 
Others 
Aqueous layer 
(B3-AL) 
Organic 
layer 
Fraction (Rt= 
3.3 min) 
B3-3 (Solid) 
Compound 8 (syringic 
acid) Î 3.6 mg 
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Figure 10.3: The PTLC of chloroform extract of barks 
 
Solution B1-BA: The mobile phase started off with 15 % acetonitrile and 85 % water. 
The solvent ratio was changed through a linear gradient to 20 % acetonitrile and 80 % 
water in 14 min. This ratio was maintained for 2 min and thereafter the solvent ratio 
was changed back to the initial starting conditions. At Rt (retention time) = 14.1 min 
the fraction eluted (B1-14) was collected and the acetonitrile was removed by 
evaporation and freeze-drying. The solid in the vial was then redissolved in methanol 
and dried under nitrogen. B1-14 was then sent for nuclear magnetic resonance (NMR) 
characterisation. 
 
Solution B2-BA: The mobile phase started off with 15 % acetonitrile and 85 % water. 
The solvent ratio was changed through a linear gradient to 20 % acetonitrile and 80 % 
water in 14 min. This ratio was maintained for 4 min and thereafter the solvent ratio 
was changed back to the initial starting conditions. At Rt (retention time) = 15.8 min 
the fraction eluted (B2-15) was collected and the acetonitrile was removed by 
evaporation and freeze-drying. The solid in the vial was then redissolved in methanol 
Diagram of TLC 
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and dried under nitrogen. B2-15 was then sent for nuclear magnetic resonance (NMR) 
characterisation. 
 
Solution B3-AL: The mobile phase started off with 5 % acetonitrile and 95 % water 
(containing 10 mM ammonium bicarbonate). The solvent ratio was changed through a 
linear gradient to 16% acetonitrile and 84 % water (containing 10 mM ammonium 
bicarbonate) at 1 min. This ratio was maintained for 5 min and thereafter the solvent 
ratio was changed back to the initial starting conditions. At Rt (retention time) = 3.3 
min the fraction eluted (B3-3) was collected and the acetonitrile was removed by 
evaporation and freeze-drying. The solid in the vial was then redissolved in methanol 
and dried under nitrogen. B3-3 was then sent for nuclear magnetic resonance (NMR) 
characterisation. 
 
10.2.5 Nuclear magnetic resonance (NMR) 
 
Final chemical characterisation of the 8 isolated compounds was achieved by NMR, 
which was performed in collaboration with Assistant Professor Dr. Achyut Adhikari 
(HEJ Research Institute of Chemistry, University of Karachi, Pakistan). Nuclear 
magnetic resonance spectroscopy was performed on a Varian 500 MHz NMR 
spectrometer. Samples CB4-2 and CB4-3 were recorded at room temperature in 
deuterated chloroform (CDCL3), samples B1-14,B2-15, WB-2, WD-3 and WD-4 
were recorded at room temperature in deuteromethanol (CD3OD) while sample B3-3 
were recorded at room temperature in deuterated water (D2O). 
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10.3 Results  
 
Compound 1 was isolated as a pale yellow powder. On the basis of the spectral data 
obtained for 1H NMR and 13C NMR [Table 10.1 and Figure A1 & A2 (Appendix A )], 
and compared to that of relative references [250][251][252], compound 1 was 
identified as scopoletin (Figure 10.4). It has an empirical formula of C10H8O4 with 
molecular weight of 192.16. 
 
Table 10.1: 1H and 13C NMR spectral data (CDCL3, 500 MHz) of scopoletin  
Position hC hH H's Type J (Hz) 
2 161.6  -  - -   - 
3 111.6 6.3 1H d 9.5 
4 143.3 7.63 1H d 9.5 
5 103.2 6.87 1H s -  
6 144  -  -  - - 
7 150.2 -   - -   - 
8 107.4 6.95 1H s  - 
9 149.7  - -   - -  
10 113.5  -  -  - -  
6- OCH3 56.4 3.98 3H s  - 
 
 
 
Figure 10.4: The chemical structure of compound 1 (scopoletin) 
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Compound 2 was isolated as a pale yellow powder. On the basis of the spectral data 
obtained for 1H NMR and 13C NMR [Table 10.2 and Figure A3 & A4 (Appendix A)], 
and compared to that of relative references [253][254], compound 2 was identified as 
scoparone (Figure 10.5). It has an empirical formula of C11H10O4 with molecular 
weight of 206.19.  
 
Table 10.2: 1H and 13C NMR spectral data (CDCL3, 500 MHz) of scoparone 
Position hC hH H's Type J (Hz) 
2 161.41  - -  -   - 
3 111.45 6.32 1H d 9.6  
4 150.06 7.64 1H d 9.6 
5 100.05 6.87 1H s   
6 152.87  - -  -   - 
7 146.37  - -  -   - 
8 143.28 6.88 1H s   
9 113.59  - -  -   - 
10 107.98  - -  -   - 
6-OCH3 56.38 3.95 3H s - 
7-OCH3 56.4 3.98 3H s -  
 
 
 
Figure 10.5: The chemical structure of compound 2 (scoparone) 
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Compound 3 was isolated as light yellow needles. On the basis of the spectral data 
obtained for 1H NMR and 13C NMR [Table 10.3 and Figure A5 & A6 (Appendix A)], 
and compared to that of relative references [255][256], compound 3 was identified as 
catechin. Catechin exists in nature as (+) and (-) enantiomers. The optical rotation of 
the compound in methanol was tested using Schmidt + Haensch Polartronic H532 
Polarimeter. The experimental rotation was an average of +69.25 (n=4) concluding 
that this compound is (+)-catechin (Figure 10.6). Previous published data on (+)-
catechin reports an optical rotation of +56.60 [257]. It has an empirical formula of 
C15H14O6 with molecular weight of 290.26. 
 
Table 10.3: 1H and 13C NMR spectral data (CD3OD, 500 MHz) of (+)-catechin 
Position hC hH H's Type J (Hz) 
2 81.46 4.01 1H d 7.5 
3 67.41 3.98 1H m 5.5, 8.5 
4 27.12     
4a - 2.52 1H dd 8.2, 16.1 
4b - 2.87 1H dd 5.5, 16.1 
5 156.19 -  - -  - 
6 94.86 5.94 1H d 2.3 
7 156.45 - -  -  - 
8 94.08 5.87 1H d 2.3 
9 155.52 -  -  - - 
10 99.40 2.52 1H dd - 
OH - 4.58 1H d - 
1' 130.82 - -  -  - 
2' 113.84 6.85 1H d 1.8 
3' 144.83  - -  -  - 
4' 144.85  - -  -  - 
5' 114.66 6.78 1H d 8.1 
6' 118.62 6.74 1H dd 1.8, 8.1 
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Figure 10.6: The chemical structure of compound 3 [(+)-catechin] 
 
Compound 4 was isolated as a pale yellow powder. On the basis of the spectral data 
obtained for 1H NMR and 13C NMR [Table 10.4 and Figure A7 & A8 (Appendix A)], 
and compared to that of relative references [258][259],  compound 4 was identified as 
hyperin (Figure 10.7).  It has an empirical formula of C21H20O12 with molecular 
weight of 460.37. 
 
Figure 10.7: The chemical structure of compound 4 (hyperin) 
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Table 10.4: 1H and 13C NMR spectral data (CD3OD, 500 MHz) of hyperin 
Position hC hH H's Type J (Hz) 
2 157.37  - -  -   - 
3 134.36  - -  -   - 
4 178.13  - -  -   - 
5 161.63  - -  -   - 
6 98.55 6.23 1H d 2.10 
7 164.90  - -  -   - 
8 93.34 6.43 1H d 2.10 
9 157.08  - -  -   - 
10 104.17  - -  -   - 
1' 121.51  - -  -   - 
2' 114.67 7.86 1H d 2.60 
3' 144.43  - -  -   - 
4' 148.56  - -  -   - 
5' 116.36 6.88 1H d 8.60 
6' 121.51 7.60 1H dd 2.6, 8.6 
1'' 103.99 5.19 1H d 8.20 
2'' 71.77 3.84 1H dd 8.2, 8.0 
3'' 75.80 3.60 1H dd 8.0, 2.1 
4'' 68.62 3.87 1H dd 3.2, 2.1 
5'' 77.88 3.45 1H m -  
6'' 60.53  - -  -   - 
6a''  - 3.67 1H dd 11.0, 3.0 
6b''  - 3.56 1H dd 11.0, 5.8 
 
 
Compound 5 was isolated as a light yellow powder. On the basis of the spectral data 
obtained for 1H NMR and 13C NMR [Table 10.5 and Figure A9 & A10 (Appendix 
A)], and compared to that of relative references [260][261], compound 5 was 
identified as cynaroside (Figure 10.8).  It has an empirical formula of C21H20O11 with 
molecular weight of 448.38. 
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Table 10.5: 1H and 13C NMR spectral data (CD3OD, 500 MHz) of cynaroside 
Position hC hH H's Type J (Hz) 
2 165.52  - -  -   - 
3 102.72 6.60 1H s   
4 182.66  - -  -   - 
5 161.51  - -  -   - 
6 100.27 6.53 1H d 2.00 
7 163.43  - -  -   - 
8 94.65 6.83 1H d 2.00 
9 157.58  - -  -   - 
10 105.69  - -  -   - 
1' 121.98  - -  -   - 
2' 112.81 7.43 1H d 2.20 
3' 145.77  - -  -   - 
4' 149.80  - -  -   - 
5' 115.40 6.93 1H d 8.40 
6' 119.12 7.45 1H dd 8.40, 2.20 
1'' 99.75 5.09 1H d 7.30 
2'' 73.33 3.48 1H t 9.20 
3'' 76.46 3.56 1H t 9.20 
4'' 69.86 3.45 1H t 9.20 
5'' 77.00 3.60 1H m  - 
6'' 61.06  - -  -   - 
6a''  - 3.75 1H dd 12.40, 5.80 
6b''  - 3.95 1H dd 12.40, 1.90 
 
 
Figure 10.8: The chemical structure of compound 5 (cynaroside) 
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Compound 6 was isolated as white solid (HPLC chromatogram in Figure B1-
Appendix B). On the basis of the spectral data obtained for 1H NMR and 13C NMR 
[Table 10.6 and Figure A11 & A12 (Appendix A)], and compared to that of relative 
references [262][263],  compound 5 was identified as vomifoliol (Figure 10.9).  It has 
an empirical formula of C13H20O3 with molecular weight of 224.30. 
 
Table 10.6: 1H and 13C NMR spectral data (CD3OD, 500 MHz) of vomifoliol 
Position hC hH H's Type J (Hz) 
1 78.54  - -  -   - 
2 41.03  - -  -   - 
3a  - 2.18 1H d 15.00 
3b  - 2.54 1H d 15.00 
4 199.85  - -  -   - 
5 125.69 5.90 1H m  -  
6 166.10  - -  -   - 
7 128.71 5.81 1H m  - 
8 135.49 5.82 1H m  - 
9 67.34 4.34 1H m  - 
10 22.41 1.26 3H d 7.50 
11 23.06 1.03 3H s  - 
12 22.05 1.06 3H s - 
13 18.15 1.94 3H s  -  
 
 
Figure 10.9: The chemical structure of compound 6 (vomifoliol) 
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Compound 7 was isolated as white powder (HPLC chromatogram in Figure B2-
Appendix B). On the basis of the spectral data obtained for 1H NMR and 13C NMR 
[Table 10.7 and Figure A13 & A14 (Appendix A)], and compared to that of relative 
references [264][265], compound 7 was identified as lioxin (Figure 10.10).  It has an 
empirical formula of C8H8O3 with molecular weight of 152.15. 
 
Table 10.7: 1H and 13C NMR spectral data (CD3OD, 500 MHz) of lioxin 
Position hC hH H's Type 
1 127.72  - -  -  
2 110.07 7.30 1H m 
3 149.09  - -  -  
4 147.08  - -  -  
5 115.51 7.30 1H d 
6 125.64 7.31 1H m 
7 191.60 9.57 1H s 
OH  - 6.77 1H s 
10 54.80 3.80 3H s 
 
 
 
 
Figure 10.10: The chemical structure of compound 7 (lioxin) 
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Compound 8 was isolated as pale yellow powder (HPLC chromatogram in Figure B3-
Appendix B). On the basis of the spectral data obtained for 1H NMR and 13C NMR 
[Table 10.8 and Figure A15 & A16 (Appendix A)], and compared to that of relative 
references [266][267], compound 8 was identified as syringic acid (Figure 10.11).  It 
has an empirical formula of C9H10O5 with molecular weight of 198.17. 
 
Table 10.8: 1H and 13C NMR spectral data (D2O, 500 MHz) of syringic acid 
Position hC hH H's Type 
1 121.08  - -  -  
2 106.92 7.11 1H s 
3 147.08  - -  -  
4 148.41  - -  -  
5 147.08  - -  -  
6 106.92 7.11 1H s 
2-OCH3, 
6-OCH3 56.26 3.57 3H s 
COOH 174.29  - -  -  
 
 
 
 
Figure 10.11: The chemical structure of compound 8 (syringic acid) 
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10.4 Discussion 
 
All the compounds were isolated for the first time from Canarium patentinervium 
Miq. Seven phenolic compounds (compounds 1-6 and 8) and one norsesquiterpene 
with cyclohexenone ring (compound 7) was isolated. 
 
The 1H-NMR spectrum of compound 1 (Table 10.1) revealed the presence of two 
doublets at hH 7.63 (H-4, J = 9.5 Hz) and 6.30 (H-3, J = 9.5 Hz). The two singlet 
signals appeared at hH 6.87 and 6.95 were assigned for the two protons H-5 and H-8, 
respectively. The 1H NMR spectra of compound 2 identified as scoparone (Table 
10.2) showed two doublets with coupling constant of 9.82"J¦"cv"h"8054"cpf"h 7.64, 
which were assigned as H-3 and H-4, respectively, characteristic for coumarins [253]. 
The 1H NMR spectrum of scoparone was similar to that of scopoletin, except for an 
additional sipingv"cv"h"50;:"ppm indicating its identity as scoparone [268]. 
 
Compound 3 were isolated as light yellow crystals. The structural identity of this 
compound was determined through NMR spectral analysis (Table 10.3) that was 
compared to literature [255][256]. Catechin possesses two benzene rings (called the 
A- and B-rings) and a dihydropyran heterocycle (the C-ring) with a hydroxyl group 
on carbon 3. The A ring is similar to a resorcinol moiety while the B ring is similar to 
a catechol moiety. There are two chiral centers on the molecule on carbons 2 and 3 
resulting in 4 optical isomers (+) catechin, (-) catechin, (+) epicatechin and (-) 
epicatechin. Of these, (+) catechin and (-) epicatechin occur in nature [269]. From the 
experimental data of optical rotation, this compound was confirmed to be (+) 
catechin. 
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Compound 4 was isolated as pale yellow powders. In the 1H-NMR spectrum, the 
typical proton signals of quercetin moiety, that is, those of an AMX system due to a 
1',3',4'-vtkuwduvkvwvkqp"qh"tkpi"D"]h 7.86 (d, J = 2.8"J¦+."9082"*ff."L"?"408.":08"J¦+"cpf"h"
6.88 (d, J = 8.6 Hz)], and a typical meta-coupled pattern for H-8 and H-8"rtqvqpu"]h"
6.43 (d, J = 2.1 Hz) and 6.23 (d,J = 2.1 Hz)], were observed. The 13C-NMR of 
compound 4 showed resonances for twenty one carbons and presence of a quercetin 
moiety with the exception of monosaccharide moiety (Table 10.4). An anomeric 
proton signals of compound 4 crrgctgf"cv"h 5.19 (d, J = 8.2 Hz) and other oxygenated 
methines and methylene signals qh"uwict"oqkgv{"cv"h"50:9 (dd, J = 3.2, 2.1 Hz, H-4''), 
3.84 (dd, J = 8.2, 8.0 Hz, H-2''), 3.67 (dd, J = 11.0, 3.0, H-6''a), 3.56 (dd, J = 11.0, 5.8 
Hz, H-6''b), 3.60 (dd, J = 8.0, 2.1 Hz, H-3'') and 3.45 (m, H-5''). Also, the carbon 
ukipcnu"qh"vjg"uwict"oqkgv{"ygtg"qdugtxgf"cv"h 103.99 (C-1''), 77.88 (C-5''), 75.80 (C-
3''), 71.77 (C-2''), 68.62 (C-4'') and 60.53 (C-8))+" uwiiguvkpi" vjg" rtgugpeg" qh" く- 
galactopyranoside units. Thus, the structure of compound 4 was identified as 
quercetin-3-O-く-D-galactopyranoside, hyperin [258]. 
 
 
The 1H NMR spectrum of compound 5, a light yellow powder, showed two metaÎ
coupled doublets (J=2.0 Hz) at h"6.83 and 6.53, each integrating for one proton, and 
were assigned to H-8 and H-6, respectively of ring A of 5,7-dihydroxyflavonoids 
[270]. The presence of ABX system at h"7.45 (dd, J = 8.4, 2.2 Hz, H-6'), 7.43 (d, J = 
2.2 Hz, H-2') and 6.93 (d, J = 8.3 Hz, H-5'), characteristic of 1, 2, 4-trisubstituted 
phenyl unit [270]. The only singlet at h"6.60, integrating for one proton, was attributed 
C-3 to proton of flavonoids (35). These spectral data revealed the presence of luteolin 
skeleton [271]. In addition, the 1H NMR spectrum showed a series of signals between 
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h"50;7"*ff."L"?"34062."70:2"J¦."J-6''b), 3.75 (dd, J = 12.40, 1.90 Hz, H-6''a), 3.60 (t, 
H-5''), 3.56 (t, J = 9.2 Hz, H-3''), 3.48 (dd, J = 9.2, H-2'') and 3.45 (t, J = 9.2 Hz, H-4'') 
attributable to a sugar moiety. The coupling constant (J = 7.3 Hz) of the anomeric 
proton nqecvgf" cv" h" 702; (d, J = 7.3 Hz, H-1'') and the 13C NMR (Figure 10.8) 
chemical shifts of the sugar carbons *h";;097."99022."98068."95055."8;0:8 and 61.06) 
tgxgcngf"vjg"rtgugpeg"qh"く-O-glucoside unit in luteolin- 7-O-glucoside. The 13C NMR 
data showed the presence of a ketone carbonyl at C-6"*h"3:4088), two olefinic carbons 
at C-2 and C-3 *h"387074"cpf"324094), and four hydroxyl carbons at C-7, C-5, C-4' 
and C-5)"*h"385065, 161.51, 149.80 and 145.77). On comparison with the literature on 
flavonoids of luteolin, it was revealed that the physical and spectral data of luteolin-7-
O-glucoside isolated were in good agreement with those recorded for luteolin- 7-O-
glucoside or cynaroside [271][260]. 
 
The comparison of the corresponding NMR data of compound 6, a white solid (Table 
10.6) with those reported in literature [262][263] led to its identification as vomifoliol. 
The cyclohexenone structure was confirmed by the observation in the HMBC (Figure 
A13-Appendix A) spectrum of correlations between the AB system H-3ab (h"403:."h"
2.54, J = 15.00 Hz) and C-4 *h" 3;;0:7), C-1 *h" 9:076) and C-5 *h" 347.69). The 
location of the two high field methyl groups C-11 and C-12 at C-2 was ascertained by 
the detection of the H3ab-C11 and H3ab-C12 correlations. The position of the side 
chain on C-1 of the cyclohexenone ring is confirmed by the observation in the HMBC 
spectrum of the H7-C1 correlation. The COSY (Figure A14-Appendix A) spectrum 
revealing eqttgncvkqpu"dgvyggp"vjg"qnghkpke"ukipcn"J9"*h"70:3+"ykvj"vjg"qvjgt"qnghkpke"
proton H8 *h"70:4) which in turn had a cross peak with H9 *h"6056) permitted us to 
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confirm the structure of this side chain. All these NMR data together suggested the 
structure of vomifoliol. 
 
The 1H NMR spectrum of compound 7 which was isolated as white powder exhibited 
the following signals (Table 10.7).""h";0:4" (CHO), multiplets at h 7.30, 7.31 (2H) and 
h fqwdngv" cv" h 7.04 (1H) (aromatic protons), and 3.80 ppm (CH3O). The 13C NMR 
urgevtwo"ujqygf"ukipcnu"cv"h"3;3082 (CHO), 149.09, 147.08, 127.72, 125.64, 115.51, 
and 110.07 (aromatic carbons) and 54.80 ppm (CH3O). The 1H and 13C spectra were 
identical to those of 4-hydroxy-3-methoxybenzaldehyde (Figure 10.10) (also known 
as vanillin or lioxin) [265]. 
 
Compound 8 eluted first to give a pale yellow powder on drying. The 13C NMR 
showed two methoxyls, two olefinic methines and five quaternary carbons, including 
a carboxy, and three oxygenated olefinic carbons. The only signals appearing in the 
1H NMR were a 6H singlet for the two methoxyls (h"5079) and a 2H singlet for two 
aromatic protons (h 7.11) (Table 10.8). Further analysis of the NMR data indicated a 
symmetric trisubstituted phenolic acid. Two of the substituents were methoxyl groups 
and the third a hydroxyl group. The data was found to fit well with that of 4-hydroxy-
3,5-dimethoxybenzoic acid (syringic acid) [266][267]. Further evidence for the 
structure of 8 was provided by a 3-bond correlation between H-2/6 (h"7.11) and the 
carboxy carbon (h 174.29) (Figure 10.11). The possibility of 4-hydroxy-2,6-
dimethoxybenzoic acid was thus eliminated.  
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10.5 Conclusion 
 
Eight compounds were isolated for the first time from Canarium patentinervium Miq. 
using various isolation techniques such as TLC, CC, HPLC and identified with NMR 
method. Compounds isolated scopoletin, scoparone, (+)-catechin, hyperin, 
cynaroside, lioxin and syringic acid were phenolics while vomifoliol was a 
norsesquiterpene with a cyclohexenone ring. Lioxin, syringic acid and vomifoliol 
were isolated from this genus for the first time. These findings agree with the 
phytochemical analysis which was done in Chapter 2. 
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CHAPTER 11 
BIOACTIVITY OF ISOLATED SECONDARY METABOLITES 
 
11.1 Introduction 
 
11.1.1 Terpenes and phenols 
 
Terpenes are the most numerous and structurally diverse plant natural products. The 
term terpene usually refers to a hydrocarbon molecule while terpenoid refers to a 
terpene that has been modified, such as by the addition of oxygen. Terpenoids 
(sometimes called as isoprenoids) are hydrocarbon natural products based on 5- 
carbon (isoprene) units as their building blocks [237]. Terpenes are an enormous class 
of natural products spanning well over 30,000 members having been discovered to-
date [272]. These compounds are classified as to the number of isoprene units, which 
include the hemiterpenes (1), monoterpenes (2), sesquiterpenes (3), diterpenes (4), 
sesterterpenes (5), tripterpenes (6), and polyterpenes (many units). Sometimes the 
prefix nor- is added to name a structural analog that can be derived from a parent 
compound by the removal of one carbon atom along with the accompanying hydrogen 
atoms (norsesquiterpene) [237].  
 
Of these different major classes of terpenoids, the diterpenes are structurally most 
diversified, possessing at least 6 large structural groups. Biological active compounds 
are found in each class of the terpenoids, particularly among the sesquiterpenes, 
diterpenes and triterpenes [237]. Isopentyl diphosphate (IPP) and dimethyl allyl 
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diphosphate (DMAPP) are found to be the actual building blocks in terpene 
biosynthesis [273]. There are 2 biosynthetic pathways for the production of IPP and 
DMAPP, the mevalonate pathway and the more recently discovered deoxyxylulose 
pathway. All terpenes are formed through the reactions of IPP and DMAPP [237]. 
Rare terpenoids such as norisoprenoids, like the C13-norisoprenoids 3-oxo-g-ionol are 
found to be present in Muscat of Alexandria leaves and 7,8-dihydroionone 
derivatives, and megastigmane-3,9-diol and 3-oxo-7,8-dihydro-g-ionol found in 
Shiraz leaves (both grapes in the species Vitis vinifera) or wine (responsible for some 
of the spice notes in Chardonnay) [274]. 
 
Polyphenols are the third most widespread class of metabolites in nature, and their 
distribution is almost ubiquitous [241]. It is estimated that 100,000 to 200,000 
secondary metabolites exist and some 20% of the carbon fixed by photosynthesis is 
channeled into the phenylpropanoid pathway, thus generating the majority of the 
natural-occurring phenolics, such as flavonoids and stilbenes [275].. Although a large 
variety of plant phenols exists, most of these compounds arise from a common origin: 
the amino acids phenylalanine or tyrosine. These aminoacids are deaminated to 
cinnamic acids, which enter the phenylpropanoid pathway. As a general rule recently 
proposed by Quideau et al. [276]."vjg"vgto"Òrncpv"rjgpqnkeuÓ"ujqwnf"dg"uvtkevn{"wugf"vq"
refer to secondary natural metabolites arising biogenetically from the shikimate/ 
phenylpropanoid pathway, which directly provides phenylpropanoids (Figure 11.1), 
qt"vjg"Òrqn{mgvkfgÓ"acetate/malonate pathway, which can produce simple phenols, or 
both of them [277]. A key step in this biosynthetic route is the introduction of one or 
more hydroxyl groups into the phenyl ring. As result, these compounds are derived 
from a common carbon skeleton building block: the C6-C3 phenylpropanoid unit [53].  
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Biosynthesis, according to this pathway, produces the large variety of plant phenols: 
cinnamic acids (C6-C3), benzoic acids (C6- C1), flavonoids (C6-C3-C6), 
proanthocyanidins [(C6-C3-C6)n], coumarins (C6-C3), stilbenes (C6-C2-C6), lignans 
(C6-C3-C3-C6) and lignins [(C6-C3)n]. Main classes of phenolics include phenolic acid 
(benzoic acid derivatives and cinnamic acid derivatives), flavonoids (flavones, 
flavonols, flavanones, flavan-3-ols, anthocyanidins and isoflavones), coumarins, 
stilbenes and lignans (Figure 11.2) [275]. These pathways produce a bewildering 
array of monomeric and polymeric uvtwevwtgu"*vjg"vgto"Òrqn{rjgpqnuÓ"fghkpkpi"vjqug"
with more than one phenolic ring) that fulfill a very broad range of physiological roles 
in plants [277]. Although the bulk of these compounds play cell wall structural roles, 
plant tissues synthesize a vast array of non-structural constituents that have various 
roles in plant growth cpf"uwtxkxcn0"Vjwu."vjg"gzrtguukqp"Ðrncpv"rjgpqnkeuÑ"godtcegu"c 
highly diverse group with an extremely large structural diversity: tens of thousands of 
diverse structures have been identified, with the number continually increasing  
[276][278]. 
 
11.1.2 General antioxidant mechanisms of phenolics 
 
Phenolics are able to act as antioxidants in a number of ways. Phenolic hydroxyl 
groups are good hydrogen donors: hydrogen-donating antioxidants can react with 
reactive oxygen and reactive nitrogen species in a termination reaction, which breaks 
the cycle of generation of new radicals [279]. Following interaction with the initial 
reactive species, a radical form of the antioxidant is produced, having a much greater 
chemical stability than the initial radical. The interaction of the hydroxyl groups of 
phenolics with the ヾ-electrons of the benzene ring gives the molecules special 
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properties, most notably the ability to generate free radicals where the radical is 
stabilized by delocalization. The formation of these relatively long-lived radicals is 
able to modify radical-mediated oxidation processes [280]. The antioxidant capacity 
of phenolic compounds is also attributed to their ability to chelate metal ions involved 
in the production of free radicals [281]. However, phenolics can act as pro-oxidants 
by chelating metals in a manner that maintains or increases their catalytic activity or 
by reducing metals, thus increasing their ability to form free radicals [282]. Phenolic 
structures often have the potential to strongly interact with proteins, due to their 
hydrophobic benzenoid rings and hydrogen-bonding potential of the phenolic 
hydroxyl groups. This gives phenolics the ability to act as antioxidants also by virtue 
of their capacity to inhibit some enzymes involved in radical generation, such as 
various cytochrome P450 isoforms, lipoxygenases, cyclooxygenase and xanthine 
oxidase [280][283]. 
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Figure 11.1: Schematic of the major branch pathways of (poly) phenol biosynthesis. PAL: phenylalanine ammonia-lyase, C4H: cinnamate-4-hydrolase, 4CL: 4-coumaroyl:CoA-ligase, HCT: 
hydroxycinnamoyl transferase, C3H: p-coumarate-3-hyroxylase, CHS: chalcone synthase, CHI: chalcone isomerase, ANS: anthocyanidinstnthase, DFR: dihydroflavonol reductase, FS: flavone 
synthase, F3H: Flavanone 3-hydroxylase, IFS: isoflavone synthase, ANR: anthocyanidin reductase, LAR: leucoanthocyanidin reductase [277]. 
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 Figure 11.2: Main classes of phenolics [275]
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11.1.3 Flavonoids 
 
Approximately 9000 different flavonoids have been reported from plant sources, and 
with almost certainty many more are still to be discovered, as they continue to capture 
the interests of scientists from numerous disciplines. Based on the 10-carbon skeleton 
of flavonoids, they can be substituted by a range of different groups, viz. hydroxyl, 
methoxyl, methyl, isoprenyl and benzyl substituents [284]. Flavonoids are 
characterized by a phenylbenzopyran chemical structure. The general structure 
includes a C15 (C6-C3-C6) skeleton joined to a chroman ring (benzopyran moiety). The 
heterocyclic benzopyran ring is known as the C ring, the fused aromatic ring as the A 
ring, and the phenyl constituent as the B ring (Figure 11.2). Commonly flavonoids are 
further modified by the addition of substituent groups such as methyl groups, 
aromatic acyl groups, and/or sugar moieties [284]. Increasingly, flavonoids are 
becoming the subject of medical research. Flavonoids play a role in disease 
prevention in humans. They have been reported to possess many useful properties, 
including anti-inflammatory, oestrogenic, enzyme inhibition, antimicrobial, 
antiallergic, vascular and cytotoxic antitumour activity [285], but the antioxidant 
activity is, without a doubt, the most studied one attributed to flavonoids. This well 
established antioxidant activity of flavonoids is also responsible for other biological 
activities in which the prevention of oxidative stress is beneficial [286]. 
 
The anti-oxidants activity of the flavonoids which neutralize damaging chemicals in 
the body such as free radicals results in reduction of oxidative stress, which are 
thought to contribute to a number of diseases, including atherosclerosis, degenerative 
brain fkugcugu"nkmg"Cn¦jgkogtÓu"fkugcug"cu"ygnn"cu"rtgocvwtg"cigkpi [52]. Flavonoids 
  
271 
 
 
have also been found to help the body fight viruses and decrease allergic reactions. 
There is abundant evidence to support the role of flavonoids in disease prevention a 
high dietary intake of quercetin is related to a reduced risk of heart disease [287]. 
Rutin has been found to help prevent stomach ulcers by protecting the stomach lining 
and it also protects blood vessels. Flavonoids have also been found to reduce the 
ÒuvkemkpguuÓ" qh" dnqqf" rncvgngvu" cpf thus reduce the formation of blood clots, which 
reduce the risks of certain cardiovascular diseases [288]. Flavan-3-ols are thought to 
interfere in the pathogenesis of cardiovascular disease via several mechanisms: 
antioxidative, antithrombogenic, and antiinflammatory. In particular, 
proanthocyanidins and flavan-3-ol monomers aid in lowering plasma cholesterol 
levels, inhibit LDL oxidation, and activate endothelial nitric oxide synthase to prevent 
platelet adhesion and aggregation that contribute to blood clot formation [289][290]. 
 
The anticancer activity of some flavonoid compounds is due to their ability to 
scavenge free radicals, thus avoiding the early stages of cancer promotion. Besides 
this mechanism, flavonoids have also been reported to act as anticancer agents via 
regulation of signal transduction pathways of cell growth and proliferation, 
suppression of oncogenes and tumor formation, induction of apoptosis, modulation of 
enzyme activity related to detoxification, oxidation and reduction, stimulation of the 
immune system and DNA repair, and regulation of hormone metabolism [289]. In the 
past few years we have witnessed the establishment of other flavonoid classes as 
potent molecules for the treatment of other pathologies that do not involve these 
eqorqwpfuÓ" cpvkqzkfcpv properties. This is the case of some isoflavones, whose 
estrogen-like capacity is now well established. The activity of these compounds is 
related with their similarity to estradiol estrogen. Genistein and daidzein have 
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demonstrated to be promising molecules for the treatment of conditions in which the 
agonist effect in estrogen receptors is beneficial, such as menopause conditions. In 
fact, several preparations containing these compounds, mainly soya-derived, are now 
used in therapeutics [291]. 
 
11.1.4 Phenolic acids 
 
Phenolic acids have a carboxyl group attached or linked to benzene ring (Figure 11.2). 
Two classes of phenolic acids can be distinguished depending on their structure: 
benzoic acid derivatives (i.e. hydroxybenzoic acids, C6-C1) and cinnamic acid 
derivatives (i.e. hydroxycinnamic acids, C6-C3) (Figure 11.2) [292]. Hydroxycinnamic 
acid compounds (p-coumaric, caffeic acid, ferulic acid) occur most frequently as 
simple esters with hydroxy carboxylic acids or glucose, while the hydroxybenzoic 
acid compounds (p-hydroxybenzoic, gallic acid, ellagic acid) are present mainly in the 
form of glucosides. Furthermore, phenolic acids may occur in food plants as esters or 
glycosides conjugated with other natural compounds such as flavonoids, alcohols, 
hydroxyfatty acids, sterols, and glucosides [293].  
 
They have been the subject of a great number of chemical, biological, agricultural, 
and medical studies. Among the wide diversity of naturally occurring phenolic acids, 
at least 30 hydroxy- and polyhydroxybenzoic acids have been reported in the last 10 
years to have biological activities [294]. They have antioxidant, antimutagenic and 
even leaf movement regulating agents that protect the organism that produces them 
from the oxidative stress created by metabolism and their physical environment [294]. 
They also have antiviral, antibacterial (bactericidal, bacteriostatic), algicidal, plant 
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growth regulating, phytotoxic, antifungal, antiprotozoal, nematicidal, insecticidal, 
antifeedant, and mammalian estrogenic, keratolytic, platelet aggregation inhibiting, 
hypoglycemic, cytotoxic, and neurotoxic activities that may serve to protect the 
organism that biosynthesizes them from competing, pathogenic, and herbivorous 
organisms in their biological environment [295][296]. The diverse biological 
functions of these phenolic acids suggest potential pharmacological activities. 
 
11.1.5 Coumarins 
 
Eqwoctkpu" qyg" vjgkt" encuu" pcog" vq" ÒeqwoctqwÓ." vjg" xgtpcewnct" pcog" qh" vjg" vqpmc"
bean (Dipteryx odorata Willd., Fabaceae), from which coumarin itself was isolated in 
1820 [297]. The primary site of synthesis of coumarins is suggested to be the young, 
actively growing leaves, with stems and roots playing a comparatively minor role. 
Coumarins belong to a group of compounds known as the benzopyrones, all of which 
consist of a benzene ring joined to a pyrone (Figure 11.2). To this days, around 1,300 
coumarins are known, with all of them being derivatives of 5,6-benzo-2- pirone (g-
chromone) (with OH, OCH3 or CH3 substituents on the benzoic ring.). Coumarins 
may also be found in nature in combination with sugars, as glycosides. As derivatives 
of simple coumarins, other compounds are known, such as furanocoumarins, which 
include a furanic ring, linear pyranocoumarins, angular pyranocoumarins, dimeric 
coumarins, of which dicoumarol is an example and also furanochromones [298]. 
 
Historically, the ability of dicoumarol to inhibit blood clotting, that later led to the 
development of the anticoagulant drug warfarin, was the first call to this class of 
eqorqwpfuÓ" dkqnqikecn" rtqrgtvkgu0
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which acts as a vitamin K antagonist. Warfarin is a clinically useful anticoagulant and 
widely employed rodenticide. Several biological activities have been reported in 
natural-occurring coumarins, from photo sensitizers to vasodilatation. Recently, the 
interest has been given to synthetic derivatives of coumarins, such as fluorinated and 
1-azo coumarins, which displayed moderate analgesia properties, and excellent anti-
inflammatory and anti-microbial activities [299].  
 
Coumarins have a variety of bioactivities including anticoagulant, estrogenic, dermal, 
photosensitizing, antimicrobial, vasodilator, molluscidal, antihelmintic, sedative, 
hypnotic, analgesic and hypothermic activity [300]. Various coumarins have been 
reported to possess anti-inflammatory activity as shown in carrageenan-induced 
inflammation and cotton pellet granuloma tests [301][302]. There have been reports 
on efficacies of pure coumarins as well as extracts containing them against Gram-
positive and Gram-negative bacteria as well as fungi [303]. The free OH group at C-6 
in the coumarins nucleus has been found to be important for antifungal activity, while 
the free hydroxyl group at C-7 is important for antibacterial activity [304]. The 
bioactivities of phototoxic psoralens and dicoumaroul derivatives are well known and 
several of these compounds are used in antipsoriatic and anticoagulant therapy [305]. 
Other than psoriasis, skin disease like cutaneous T-cell lymphoma, atopic dermatitis, 
urticaria pigmentosa and lichen planus [306] are treated with the photochemotherapy 
of linear furanocoumarins (psoralens). The most widely used compound is 
xanthotoxin [307]. Bergapten is considered a valuable alternative for chemotherapy of 
psoriasis, since its clinical efficacy is comparable to that of xanthotoxin, although 
bergapten requires higher cumulative UVA doses. 
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The inherent fluorescent properties of many coumarins are a key factor in many 
applications. Areas where coumarins are widely used include estimation of enzymatic 
activity [308], labeling of proteins, antibodies, DNA and lipids, derivatising agents in 
chromatography, etc. Coumarins have a wide variety of uses in industry, mainly due 
to their strong fragrant odour [308]. Uses include that of a sweetener and fixative of 
perfumes (e.g. 3,4-dihydrocoumarin), an enhancer of natural oils such as lavender, a 
food additive in combination with vanillin, a flavour/odour stabilizer in tobaccos and 
an odour masker in paints and rubbers. 6-Methylcoumarin is mainly used as a flavour 
enhancer, and 7- hydroxycoumarin is mainly used in sunscreens. 
 
 
11.2 Material and methods 
 
Eight compounds that have been isolated in Chapter 11 were subjected to various 
biological assays. 
 
11.2.1 Antioxidant capacity assays 
 
Samples were dissolved in dimethyl sulfoxide (DMSO, R&M) prior to assay at a 
stock concentration of 1 mg/ml, and serial dilution was done accordingly to obtain a 
good EC50 curve. Trolox (6-hydroxy-2,5,7, 8-tetramethylchromon-2-carboxylic acid, 
Sigma-Aldrich), vitamin C (l-ascorbic acid), and quercetin were used as positive 
control at a stock concentration of 1 mg/ml. Assay was performed using Thermo 
Scientific Varioskan Flash microtiter plate reader, linked to a computer equipped with 
(SkanIt Software 2.4.3). EC50 values were determined using Prism 5.00 software. At 
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least three independent tests were performed for each sample. Method is as explained 
in Chapter 4, DPPH assay (section 4.2.1.2), ABTS assay (section 4.2.2.2), FRAP 
cuuc{" *ugevkqp" 6040504+." く-carotene bleaching assay (section 4.2.4.2) and SOD assay 
(section 4.2.5.2) 
 
11.2.2 Anti-inflammatory determination assays 
 
Test samples and positive controls were dissolved in dimethyl sulfoxide (DMSO, 
R&M) prior to assay at a stock concentration of 1 mg/ml, and serial dilution was done 
according to the assay to obtain a good EC50 curve. Absorbance was recorded using 
Thermo Scientific Varioskan Flash microtiter plate reader, linked to a computer 
equipped with (SkanIt Software 2.4.3). Percentage inhibition of enzyme was 
determined by comparison of rates of reaction of samples relative to blank sample 
using the formula (E Î S)/ E × 100, where E is the activity of enzyme without test 
sample and S is the activity of enzyme with test sample. The experiments were done 
in triplicate. Method has been explained in Chapter 5, 5-LOX inhibition assay (section 
5.4.2.2) and the peroxidase endpoint assay for COX-1 and COX-2 (section 5.5.3.2) 
 
11.2.3 Anti-acetylcholinesterase determination assays 
 
Test samples and galanthamine which was used as positive control was dissolved in 
dimethyl sulfoxide (DMSO, R&M) prior to assay at a stock concentration of 1 mg/ml, 
and serial dilution was done accordingly to obtain a good EC50 curve. The reaction 
was monitored utilizing a 96-well microplate Thermo Scientific Varioskan Flash 
microtiter plate reader, linked to a computer equipped with (SkanIt Software 2.4.3). 
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Percentage inhibition of AChE was determined by comparison of rates of reaction of 
samples relative to blank sample (ethanol in phosphate buffer pH = 8) using the 
formula (E Î S)/ E × 100, where E is the activity of enzyme without test sample and S 
is the activity of enzyme with test sample. The experiments were done in triplicate. 
Method is explained in Chapter 6 (section 6.4.6.2). 
 
11.2.4 Anticancer assay 
 
All samples except syringic acid (insufficient yield) were tested for this activity 
against human derived cell lines MDA 468 (ER-) breast carcinoma]. Samples were 
prepared as 1 mg/ml stock solutions, dissolved in DMSO, and stored at 4 0C, 
protected from light for a maximum period of 4 weeks. Serial drug dilutions were 
prepared in medium immediately prior to each assay. Due to good activity exhibited, 
scopoletin was also tested against HT-29, MCF-7 and HCT 116 cell lines. Method is 
as explained in Chapter 9 section 9.3.2. 
 
11.2.5 Antibacterial assay 
 
Due to insufficient yield of compounds isolated, all samples were tested for the 
antimicrobial effect only against S. aureus ATCC 11632. Samples was dissolved in 
dimethyl sulfoxide (DMSO, R&M) prior to assay at a stock concentration of 1 mg/ml. 
Method used is as explained previously, MIC assay (section 7.2.2.2), MBC assay 
(section 7.2.3.2) and time-kill assay (section 7.2.4.2). 
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11.2.6 Antiparasitic assay  
 
Due to insufficient yield of compounds isolated, scopoletin was tested for both assays 
and only scoparone, (+)-catechin, lioxin and vomifoliol was tested for the 
antileshmanial assay. Method is as explained in chapter 8, for antiparasitic assay 
against Giardia intestinalis and Entamoeba histolytica (section 8.3.2.2.1) and 
antileishmanial activity against Leishmania donovani promastigotes (section 
8.3.2.2.2). 
 
11.2.7 Formulation of scopoletin  
 
Due to potent antioxidant, antibacterial and anti-inflammatory activity (to be 
discussed in 11.8), scopoletin was formulated as a gel. Scopoletin (25 mg) was 
prepared as a 0.5 % w/w preparation. Scopoletin was dissolved in few drops of carrier 
solvent DMSO. Then orange oil is added to increase the penetration via skin. Pure 
aloe vera gel was then added in sufficent amount to make up a total of 5 g of gel. 
 
11.2.8 Statistical analysis  
 
For section 11.2.1-11.2.3, concentrationÎresponse curves were calculated using the 
Prism software package 5.00 for Windows, GraphPad Software, San Diego California 
USA, www.graphpad.com (GraphPad, San Diego, USA) and data were reported as 
mean and SD values obtained from a minimum of three determinations. Non linear 
best fit was plotted with SD and 95% confidence interval. All data were expressed as 
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mean ± standard deviation. SD was computed but values were not shown in the 
graphs via this software. For section 11.2.4-6 growth curve of bacteria/parasite/cell 
were analysed using MS-Excel and data were reported as mean and SD values 
obtained from a minimum of three determinations. All data were expressed as mean ± 
standard deviation. Data were analyzed using one way Anova followed by Tukey test. 
A significant difference was considered at the level of P < 0.01. 
 
 
11.3 Results 
 
11.3.1 Antioxidant capacity assays 
 
The antioxidant capacity of the isolated compounds is shown in Table 11.1. In the 
DPPH assay, the highest antioxidative action was exhibited by (+)-catechin (EC50 
4.77±0.01 µg/ml) similar with positive control trolox (EC50 4.77±0.01 µg/ml), 
followed by hyperin (EC50 4.89±0.02 µg/ml), cynaroside (EC50 7.89±0.03 µg/ml), 
syringic acid (EC50 15.43±0.02 µg/ml) and scopoletin (EC50 36.80±0.01 µg/ml). Both 
lioxin and vomifoliol had EC50 >100 µg/ml. 
 
In the ABTS assay, the highest antioxidative action was exhibited by cynaroside 
(EC50 0.26±0.02 µg/ml) followed by scopoletin (EC50 1.08±0.03 µg/ml), (+)-catechin 
(EC50 5.03±0.06 µg/ml), syringic acid (EC50 7.38±0.02 µg/ml) hyperin (EC50 
8.19±0.04 µg/ml), vomifoliol (EC50 34.89±0.04 µg/ml) and lioxin (EC50 83.22±0.03 
µg/ml).  
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In the FRAP assay, antioxidant activity was calculated as Ferrous Equivalents, the 
concentration of samples which produced an absorbance value equal to that of 1mM 
FeSO4. The compounds absorbance equivalent to 1 mM FeSO4 was calculated from 
equation of linearity of scopoletin (y=0.0203x+0.5259, r2=0.9837), scoparone 
(y=0.0009x+0.1708, r2=0.5026), (+)-catechin (y=0.0141x+0.1442, r2=0.7415), 
hyperin (y=0.0140x+0.2189, r2=0.8319), cynaroside (y=0.0156x+0.3277, r2=0.6009), 
vomifoliol (y=0.0062x+0.0549, r2=0.6990), lioxin (y=0.0126x+0.0471, r2=0.8546), 
syringic acid (y=0.0172x+0.2963, r2=0.6901). Total FRAP value was determined 
from the absorbance value above using the standard Fe (II) calibration curve equation 
(y=0.0105x+0.0136, r2=0.9817). Both scopoletin and (+)-catechin displayed 
significantly lower FRAP value (49.00±0.64 µg/ml and 75.59±0.42 µg/ml 
respectively) than positive control ascorbic acid and quercetin (347.00±0.23 µg/ml 
and 86.00±0.24 µg/ml respectively).  
 
In the く-carotene decolourisation assay, the most potent activity was displayed by 
vomifoliol (EC50 6.85±0.37 µg/ml), followed by lioxin (EC50 20.13±0.47 µg/ml), 
hyperin (EC50 32.21±0.35 µg/ml), syringic acid (EC50 53.69±0.36 µg/ml), cynaroside 
(EC50 56.38±0.38 µg/ml), (+)-catechin (EC50 83.22±0.56 µg/ml) and scopoletin (EC50 
124.50±0.07 µg/ml). Only scoparone had EC50 of >100 µg/ml. 
 
In the SOD assay, both hyperin and (+)-catechin has IC50 values significantly lower 
(IC50 0.75±0.03 µg/ml and IC50 0.94±0.27 µg/ml respectively) than positive control 
SOD enzyme (IC50 1.60±0.06 µg/ml). Cynaroside (IC50 1.87±0.03 µg/ml) had activity 
similar to SOD, followed by scoparone (IC50 48.72±0.02 µg/ml) and lioxin (IC50 
53.69±0.38 µg/ml). Scopoletin, vomifoliol and syringic acid had IC50 of >100 µg/ml. 
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11.3.2 Anti-inflammatory determination assays 
 
The results are shown in Table 11.2 and Figure 11.3-11.5. In the 5-LOX inhibition 
assay, all isolated compounds displayed significantly lower IC50 compared to positive 
control NDGA.  Both scoparone and scopoletin (IC50 0.20±0.01 µg/ml and 0.34±0.01 
µg/ml respectively) had the most potent 5-LOX enzyme inhibition (Figure 11.3) 
which was more than eightyfold compared to NDGA (IC50 29.21±0.05 µg/ml). This 
was followed by syringic acid (IC50 1.38±0.03 µg/ml), hyperin (IC50 3.02±0.02 
µg/ml), vomifoliol (IC50 8.72±0.02 µg/ml), (+)-catechin (IC50 16.10±0.03 µg/ml), 
lioxin (IC50 17.79±0.03 µg/ml) and cynaroside (IC50 18.12±0.04 µg/ml) (Figure 11.4). 
 
In the COX enzyme inhibition assay, only (+)-catechin and syringic acid showed 
good enzyme inhibition while no enzyme inhibition was noticed with lioxin and all 
other compounds had IC50 values >100 µg/ml. Compound (+)-catechin displayed 
COX-1 selective activity with COX-1/COX-2 ratio of 0.14 with COX-1 enzyme IC50 
of 12.08±0.02 µg/ml and COX-2 enzyme IC50 83.89±0.03 µg/ml (Figure 11.5). 
Syringic acid had COX-1 enzyme inhibition at IC50 34.89±0.02 µg/ml with COX-2 
inhibition at IC50 >100 µg/ml. 
 
11.3.3 Anti-acetylcholinesterase determination assays 
 
The anti-acetylcholinesterase values for isolated compounds are shown in Table 11.3 
and Figure 11.6. Only 4 compounds showed moderate enzyme inhibition namely 
syringic acid (IC50 29.53±0.19 µg/ml), scopoletin (IC50 51.00±0.02 µg/ml), scoparone 
(IC50 86.58±0.05 µg/ml) and vomifoliol (IC50 96.64±0.09 µg/ml) as shown in Figure 
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Table 11.1: Antioxidant values of isolated compounds from Canarium patentinervium Miq. 
 
Compounds ABTS assay, 
EC50 *たi1on+ 
DPPH assay, 
EC50 *たi1on+ 
FRAP assay, 
FRAP value
 *たi1on+ 
く-carotene 
bleaching assay, 
EC50 *たi1on+ 
Superoxide 
dismutase 
assay, IC50 *たi1on+ 
scopoletin 1.08±0.03 36.80±0.01. 49±0.64 124.5±0.07 >100 
scoparone >100 >100 11492±0.16 >100 48.72±0.02 
(+)-catechin 5.03±0.06 4.77±0.01A 75.59±0.42 83.22±0.56 0.94±0.27C 
hyperin 8.19±0.04 4.89±0.02 791.96±0.52 32.21±0.35 1.87±0.03D 
cynaroside 0.26±0.02 7.79±0.03 694.63±0.32 56.38±0.38 0.75±0.03C 
vomifoliol 34.89±0.04 >100 1686.89±0.28 6.85±0.37 >100 
lioxin 83.22±0.03 >100 830.67±0.53 20.13±0.47 53.69±0.38 
syringic acid 7.38±0.02 15.43±0.02 594.03±0.41 53.69±0.36 >100 
AA 1.57±0.06 1.83±0.01 345.15±0.23 NA NA 
QC 0.98±0.03 2.78±0.02A 88.16±0.24 1.70±0.03B NA 
TRO 0.65±0.02 4.77±0.01A 35.00±0.54 1.69±0.03B NA 
SOD NA NA NA NA 1.60±0.06D 
AA: ascorbic acid, QC:quercetin, TRO:trolox and SOD: superoxide dismutase 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same capital letter are not significantly different (P<0.05) according to Tukey multiple comparison test. 
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Table 11.2: Anti-inflammatory values of the isolated compound from Canarium patentinervium Miq. 
 
Compounds Anti-inflammatory assay 
5-LOX, IC50 *たi1on+ 
COX-1 inhibition assay 
IC50*たi1on+ 
COX-2 inhibition assay 
IC50*たi1on+ 
COX-1/COX-2 
ratio 
scopoletin 0.34±0.01 >100 >100 
 
scoparone 0.20±0.01 >100 >100 
 
(+)-catechin 16.1±0.03 12.08±0.02 83.89±0.03 0.14 
hyperin 3.02±0.02 >100 >100 
 
cynaroside 18.12±0.04 >100 >100 
 
vomifoliol 8.72±0.02 >100 >100 
 
lioxin 17.79±0.03 NO INH NO INH 
 
syringic acid 1.38±0.03 34.89±0.02 >100 
 
NDGA 29.21±0.05 NA NA NA 
INDO NA 0.30±0.04 0.25±0.03 1.20 
NDGA: nordihydroguairetic acid, INDO: indomethacin, NO INH: no inhibition noted 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
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Figure 11.3: 5-LOX inhibition by scopoletin and scoparone isolated from Canarium patentinervium Miq 
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Figure 11.4: 5-LOX inhibition by compounds isolated from Canarium patentinervium Miq 
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Figure 11.5: COX inhibition by (+)-catechin isolated from Canarium patentinervium Miq. 
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11.6. Rest of the compounds showed poor enzyme inhibition with IC50 values >100 
µg/ml. 
 
11.3.4 Anticancer assay 
 
The anticancer activity of the compounds that were tested are shown in Table 11.4 
and Figure 11.7a and 11.7b. Isolated compound with the highest yield scopoletin was 
tested against four cell lines, two human breast cancer cell lines, MCF-7 (ER+) and 
MDA 468 (ER-), and two colon cancer cell line, HCT 116 and HT-29. Scopoletin 
exhibited potent growth inhibition of MDA 468 (GI50 0.09±0.25 µg/ml) (Figure 
11.7a) and HT-29 (GI50 0.17±0.05 µg/ml) (Figure 11.7b) with significantly lower GI50 
compared to positive control doxorubicin (GI50 0.69±0.06 µg/ml) for the HT-29 cell 
line. Cell line MCF-7 and HCT 116 were less sensitive to scopoletin with GI50 values 
>2 µg/ml. Scoparone, (+)-catechin, hyperin, cynaroside, vomifoliol and lioxin were 
tested only against MDA 468 cell line and all having GI50 values  >2 µg/ml. 
 
11.3.5 Antibacterial assay 
 
The antibacterial assay results are shown in Table 11.5 and Figure 11.8. 
Staphylococcus aureus ATCC 11632 was sensitive against all compounds tested. 
Scopoletin had the best activity with MIC 25.00±0.00 µg/ml and MBC of 50.00±0.00 
µg/ml with complete bacterial kill at 50.00±0.00 µg/ml (Figure 11.8). Scoparone, 
Hyperin, cynaroside and syringic acid had bactericidal activity at 100.00±0.00 µg/ml. 
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Table 11.3: Anti- acetylcholinesterase values for isolated compounds from Canarium patentinervium Miq. 
 
Compounds Anti-acetylcholinesterase assay, IC50*たi1on+ 
scopoletin 51.00±0.02 
scoparone 86.58±0.05 
(+)-catechin >100 
hyperin >100 
cynaroside >100 
vomifoliol 96.64±0.09 
lioxin >100 
syringic acid 29.53±0.19 
galantamine 0.77±0.09 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
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Figure 11.6: AChE inhibition by isolated compounds from Canarium patentinervium Miq. 
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Table 11.4: Growth inhibition of human cancer cell lines by isolated compounds from Canarium patentinervium Miq. 
Compounds Cell line/ GI50 (µg/ml) 
MDA 468 HT-29 MCF-7 HCT 116 
scopoletin 0.09±0.25 0.17±0.05 >2 >2 
scoparone >2 nt nt nt 
(+)-catechin >2 nt nt nt 
hyperin >2 nt nt nt 
cynaroside >2 nt nt nt 
vomifoliol >2 nt nt nt 
lioxin >2 nt nt nt 
doxorubicin 0.04±0.12 0.69±0.06 0.38±0.28 0.65±0.18 
Nt = not tested, Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same letter are not significantly different (P<0.01) according to Tukey multiple comparison test. 
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Figure 11.7a: Effect of scopoletin isolated compounds from Canarium patentinervium Miq. against growth of breast cancer cell line MDA 468 
(GI50 = 0.09 µg/ml) 
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Figure 11.7b: Effect of scopoletin isolated compounds from Canarium patentinervium Miq. against growth of colon carcinoma cell line HT-29 
(GI50 = 0.17 µg/ml) 
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11.3.6 Antiparasitic assay 
 
The antiparasitic activity of the compounds tested is shown in Table 11.6. Compound 
scopoletin was tested against all three parasite amd it was more potent against 
Leishmania donovani (IC50 163.30±0.32 µg/ml) and MIC of >200 µg/ml for both 
Giardia intestinalis and Entamoeba histolytica. Sensitivity of Leishmania donovani is 
then followed by with the presence of lioxin (IC50 211.48±0.32 µg/ml), vomifoliol 
(IC50 302.80±0.33 µg/ml), scoparone (IC50 329.90±0.32 µg/ml) and (+)-catechin (IC50 
478.93±0.28 µg/ml). 
 
 
11.4 Discussion 
 
Of the eight isolated compounds, five were phenolics (hyperin, cynaroside, (+)-
catechin, lioxin and syringic acid), two were coumarins (scopoletin and scoparone) 
and one was a norsesquiterpene with a cyclohexenone ring (vomifoliol). Among the 
phenolics, (+)-catechin is a flavanol, hyperin is a flavonol with a glucosidic moiety 
and cynaroside is a flavone with a glycosidic moiety and two were benzoic acid 
derivatives. The basic skeleton of these groups are shown in Figure 11.2.  
 
Scopoletin possesses interesting activities, in particular, vasorelaxant [309], 
antioxidant [310],antimicrobial [311], anti-inflammatory [312], anti-pyretic [313], 
anti-platelet aggregation [314] and anti-diabetes mellitus properties [252]. In addition, 
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Table 11.5: MIC, MBC and MBC/MIC ratio for isolated compounds from Canarium patentinervium Miq. 
against Staphylococcus aureus ATCC 11632 
 
Compounds 
Concentration (µg/ml) 
MBC/MIC ratio 
MIC MBC 
scopoletin 25.00±0.00 50.00±0.00 2 (+) 
scoparone 50.00±0.00 100.00±0.00 2 (+) 
(+)-catechin 50.00±0.00 >100 nd 
hyperin 50.00±0.00 100.00±0.00 2 (+) 
cynaroside 50.00±0.00 100.00±0.00 2 (+) 
vomifoliol 100.00±0.00 >100 nd 
lioxin 100.00±0.00 >100 nd 
syringic acid 50.00±0.00 100.00±0.00 2 (+) 
 ND: not determined 
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Figure 11.8: Time-kill plot for MSSA ATCC 11632 in presence of scopoletin isolated from Canarium patentinervium Miq. 
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Table 11.6: Antiparasitic values of isolated compounds from Canarium patentinervium Miq. against 
 Leishmania donovani (AG 83) promastigotes and  
 MIC values against Giardia intestinalis and Entamoeba histolytica growing in vitro. 
 
 
Compounds 
IC50 ( (µg/ml) MIC (µg/ml) 
Leishmania donovani Giardia intestinalis Entamoeba histolytica 
scopoletin 163.30±0.32 >200 >200 
scoparone 329.90±0.32 nt nt 
(+)-catechin 478.93±0.28 nt nt 
vomifoliol 302.80±0.33 nt nt 
lioxin 211.48±0.32 nt nt 
Data were obtained from three independent experiments, each performed in triplicates (n=9) and represented as mean ± SD. 
Values with the same letter are not significantly different (P<0.01) according to Tukey multiple comparison test. nt: not tested 
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it exerted neuroprotective [315] and hypotensive [316] activities in addition to 
applications in cardiovascular disease [252], antitumor [317], anti-proliferation and 
antithyroid [318] treatment. Scoparone has been studied for its potential 
pharmacological properties including immunosuppression [319] and vasorelaxation 
[320].  Compound (+)-catechin is reported to induce longevity in the nematode worm 
Caenorhabditis elegans [321], reduces atherosclerotic lesion development in mice 
[322], have opposite effects on glycogen metabolism in isolated rat hepatocytes [323], 
inhibits intestinal tumor formation in mice [324], inhibits the oxidation of low density 
lipoprotein [325] and as an antioxidant [326]. Cynaroside has been reported for 
moderate inhibition of enzymes for the synthesis of thromboxane B2 and leukotriene 
B4 as well as hydrogen peroxide scavenging activity, scavenge reactive oxygen and 
nitrogen species [327] to chelate transition metals, antibacterial [328], antiviral [329] 
and antifungal [330] activity.  
 
Hyperin has been found to have antioxidant activity [331], inhibition of lipid 
peroxidation in rat liver microsomes [332] and protective effects to PC12 cells against 
cytotoxicity induced by hydrogen peroxide and tert-butyl hydroperoxide [333]. Lioxin 
had been reported to exert strong antioxidant (oral protectant) [334], powerful wound 
healing properties [335], protective effects against DNA damage [336] as well as 
antimutagenic [337] and immunostimulating [338] properties. Syringic acid has 
shown to have antioxidant, antibacterial [339] and hepatoprotective [340] activities. 
Vomifoliol have been reported to have weak DPPH activity [341] and  anti-
inflammatory activity by inhibition of TNF-g [341] and plays an important role as an 
endogenous regulator of the stomatal aperture [262]. 
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11.4.1 Antioxidant activity 
 
The antioxidant mechanisms of flavonoids comprise free radical scavenging, but also 
enzyme inhibition/induction, metal chelation, interaction with receptors and   
modulation of gene expression [342]. The direct scavenging of radicals is believed to 
occur in cells, but, to avoid the interference of other mechanisms, this work was 
developed using a cell-free system. The past few decades of structure-activity 
relationships research have generated several consistent lines of evidence supporting 
the role of specific structural components as requisites for antioxidant activity. The 
antioxidant activity of flavonoids and their metabolites in vitro depends upon the 
arrangement of functional groups about the nuclear structure, namely ring A, B and C 
[343]. Consistent with most polyphenolic antioxidants, both the configuration and 
total number of hydroxyl groups substantially influence several mechanisms of 
antioxidant activity. The B-ring hydroxyl configuration is the most significant 
determinant of scavenging of ROS and RNS. A-ring substitution correlates little with 
antioxidant activity [344]. 
 
Some characteristics of flavonoids are important to the antioxidant capacity according 
to the famous three Bors criteria [344] (Figure 11.9): (i) o-dihydroxy structure in the 
B ring kg"c"5Ó6Ó-catechol structure, which confers higher stability to the radical form 
and participates in electron delocalization ; (ii) C2-C3 double bond in conjugation with 
a 4-oxo function in the C ring, responsible for electron delocalization of the aromatic 
nucleus; (iii) 3- and 5-OH groups with 4-oxo function in the A and C rings, required 
for maximum radical scavenging potential. Moreover, an additional criterion could be 
added: (iv) In the absence of o-dihydroxy structure in the B ring, hydroxyl 
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substituents in a catechol structure on the A ring are able to compensate and become a 
larger determinant of flavonoid antiradical activity. 
 
 
Figure 11.9: Structural features of flavonoids with high antioxidant activity. 
Of the three flavonoids, (+)-catechin and hyperin exhibited the most consistent free 
radical scavenging capability across the five antioxidant assay (Table 11.1). Good 
correlation was found between FRAP values and hydroxyl groups and especially the 
catechol moiety and 3-OH [345], explaning the best activity shown by (+)-catechin 
(FRAP value 75.59±0.42 µg/ml). Results in the ABTS and DPPH assay were 
relatively similar as they have the same mechanism of action [53]. Sawai et al. [346] 
have identified the antioxidant mechanism using NMR analytical approaches to 
identify the antioxidative  molecular mechanism in DPPH  assay and found that the B 
ring of (+)-catechin has been changed to a quinone structure as shown in Figure 
11.10. 
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Figure 11.10: (+)-catechin and the corresponding fully oxidized ortho-quinone product 
 
Flavanols, namely here (+)-catechin and flavonol (hyperin) are more effective free 
radical scavengers than flavones (cynaroside) [343], which may be ascribed to the 
greater number of hydroxyl groups and 3-OH to the former two. Plumb and co-
workers  [347] reported that the antioxidant properties of flavonol glycosides from tea 
decreased as the number of glycosidic moieties increased. In addition, glycosylation 
of flavonoids mostly decreases their antioxidant activity. Multiple A-ring methoxy 
groups as seen in cynaroside also reverse the positive effect of a B-ring catechol 
[344]. 
 
Jqygxgt" kp" vjg" く-carotene bleaching assay, which involves lipid peroxidation via 
hydrogen atom transfer (HAT method- section 4.5), hyperin and cynaroside 
outweighed activity of (+)-catechin. Flavonoids with a C2ÎC3 double bond in 
conjugation with a 4-carbonyl group has been known to exhibit lower EC50 values 
(indicative of stronger antioxidant activity) in a microsomal system compared to those 
with saturated heterocycles [344] explaining the lower EC50 values of cynaroside 
(56.38±0.38 µg/ml) and hyperin (32.21±0.35 µg/ml) kp" vjg" く-carotene bleaching 
assay. However, hyperin has a lower EC50 than cynaroside in this assay as the C-3 
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position is an excellent choice for substitution to give the flavonoid an optimum 
lipophilicity [348]. 
 
Between both glycosides, hyperin was superior to cynaroside in all five assays (Table 
11.1) as C-glycosylation in the A-ring (seen in A ring of cynaroside) results in greater 
diminution of activity than 3-glycosylation (seen in hyperin) in the heterocycle [349]. 
Studies have also shown that O-glycosylation at carbon 7, but not carbon 3, weakens 
the antioxidant effect of flavonoids in rat mitochondria [349]. O-glycosylation 
interferes with the coplanarity of the B-ring with the rest of the flavonoid and the 
ability to delocalize electrons [350]. Though glycosides are usually weaker 
antioxidants than aglycones, bioavailability is sometimes enhanced by a glucose 
moiety [349]. The SOD assay involves flavonoids having SOD-like activity and 
inhibition of XOD that produces the free radicals.  Hyperin and (+)-catechin have 
significantly lower IC50 (0.75±0.03 µg/ml and 0.94±0.27 µg/ml respectively) 
compared to SOD enzyme. This is due to the structure arrangement of hyperin as the 
planar flavonoid core (double bond between C-2 and C-3) and the presence of free 
hydroxyl groups at C-5 and C-7 are important prerequisites for this activity [344]. (+)-
catechin has slightly less activity compared to hyperin as it lacks the double bond 
between C-2 and C-3). 
 
Phenolic acids have been investigated for the radical scavenging activity via ABTS 
assay by Rice- Evans [351]. Structure-activity comparisons suggest that antioxidant 
activity of phenolic acids depends on the number and orientation of hydroxyl groups 
relative to the electron-withdrawing CO2H, CH2CO2H, or (CH)2CO2CH functional 
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group [39]. It can be seen that syringic acid has more electron withdrawing groups 
compared to lioxin confirming the lower EC50 in ABTS assay (7.38±0.02 µg/ml). 
 
Between both coumarins, scopoletin exhibited potent antioxidant activity compared to 
scoparone. It had significantly lower EC50 values in ABTS (EC50 1.08±0.03 µg/ml) 
compared to ascorbic acid (EC50 1.57±0.06 µg/ml) and lower values in FRAP assay 
(FRAP value 49.00±0.64 µg/ml) than quercetin (FRAP value 88.16±0.24 µg/ml) and 
ascorbic acid (FRAP value 345.00±0.23 µg/ml). The result is consistent with a 
previous report that the scavenging capacity was higher for coumarin bearing OH 
groups than the methoxy-substituted derivatives [352] as in scoparone. In the SOD 
assay, the SOD-like activity and inhibition of XOD that produces the free radicals 
seemed to be better with scoparone (IC50 48.72±0.02 µg/ml) than scopoletin (IC50 
>100 µg/ml). Reports have stated that a methoxy substituted for 6- OH diminishes 
inhibition potency against XOD [352] as in the result of both coumarins here. This 
further enhances the hypothesis that the H atom of the 6-hydroxyl plays a more 
significant role than the O atom. It also can be observed that perhaps the 7-methoxy 
group in scoparone increases the inhibition activity. 
 
Not much biological data is available on vomifoliol except weak DPPH activity and  
anti-inflammatory activity by inhibition of TNF-g [341]. However in this study, 
though consistent low DPPH activity is seen (EC50 >100 µg/ml), moderate activity in 
noted in ABTS (EC50 560:;ł2026"-i1on+"cpf"rqvgpv"く-carotene bleaching activity was 
noted (EC50 6.85±0.37 µg/ml). 
 
 
  
303 
 
 
11.4.2 Anti-inflammatory activity 
 
All isolated compounds exhibited significantly lower 5-LOX inhibition than positive 
NDGA (IC50 29.21±0.05 µg/ml). Among the five phenolics, syringic acid and hyperin 
had the most potent 5-LOX inhibitory activity (IC50 1.38±0.03 µg/ml and 3.02±0.02 
µg/ml respectively). Hydroxylations at 5, 7, and 4' have also shown to enhance overall 
anti-inflammatory activity in flavonoids [102]. Flavonols were found to be stronger 
inhibitors of 5-LOX than flavones [353], as established in this study with hyperin 
(IC50 3.02±0.02 µg/ml) being superior to cynaroside (IC50 18.12±0.04 µg/ml). 
Although it is difficult to establish structural-activity relationships due to their 
varieties of chemical structures, these inhibitory activities against 5-LOX could 
explain, at least in part, the anti-inflammatory/ antiallergic activities of flavonoids. No 
clinical data showing the relation of flavonoid intake and incidence (severity) of 
inflammatory disorders such as RA and AD was available, although several studies 
demonstrated some inverse correlation of flavonoid intake and incident rate of 
cardiovascular failure [354].  
 
Lipoxygenases (LOXs) also function as prooxidant enzymes that catalyze enzymatic 
lipid peroxidation. Additionally, they are a source of free radicals initiating 
nonenzymatic lipid peroxidation and other oxidative processes involved in the 
formation of atherosclerotic lesions [354]. Consequently, inhibition of LOXs may 
contribute to the universal antioxidant activities of flavonoids. Planar flavonoid 
structure with delocalized electrons achieved by the C2-C3 double bond seems to be a 
prerequisite for inhibitory activity. The following structural features were found to 
enhance the inhibitory potency: (i) presence of a catechol moiety in the B or A ring, 
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(ii) 4-carbonyl group in the C ring [344], thus confirming the results of this study with 
hyperin having more 5-LOX inhibition than (+)-catechin. 
 
However (+)-catechin had a more comprehensive anti-inflammatory activity with dual 
inhibition of 5-LOX (IC50 16.10±0.03 µg/ml) and COX (COX-1; IC50 12.08±0.02 
µg/ml, COX-2; IC50 83.89±0.03 µg/ml). (+)-catechin displayed COX-1 selective 
activity with the COX-1/COX-2 ratio <1 and this confirms previous findings [107]. 
Benzoic acid derivatives, syringic acid exhibited potent 5-LOX inhibition (IC50 
1.38±0.03 µg/ml) and moderate COX-1 inhibition (IC50 34.89±0.02 µg/ml) compared 
to lioxin that had good 5-LOX inhibition (IC50 17.79±0.03 µg/ml) but no COX 
inhibition. Consideration of the structure-activity relationship of phenolic acids on the 
anti-inflammatory action revealed that both C-4 hydroxy and C-3 methoxy radicals of 
the benzoic acid derivatives play an important role in anti-inflammatory activities 
[355]. However the presence of extra methoxy group at C-5 seemed to drastically 
increase the activity as seen in syringic acid. One study reported potent COX-2 
inhibition of syringic acid (IC50 0.40 µg/ml) using cell based study [356] but we 
demonstrated poor COX-2 inhibition in this study. 
 
Both coumarins scopoletin and scoparone were potent inhibitors of 5-LOX recording 
lowest IC50 values (IC50 0.34±0.01 µg/ml and 0.20±0.01 µg/ml respectively).  
Scoparone has slightly lower IC50 than scopoletin as the SAR findings has reported 
that the chloro and methoxy substitution in coumarin ring showed increase anti 5-
LOX activity [357]. Cyclohexenone derivatives are well known lead molecules for the 
treatment of inflammation and autoimmune diseases [358]. The anti-inflamatory 
activity previously reported for vomifoliol were by inhibition of TNF-g [341]. In this 
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study, vomifoliol has exhibited potent 5-LOX inhibition (IC50 8.72±0.02 µg/ml) and 
poor COX inhibition. 
 
 
11.4.3 Anti-acetylcholinesterase activity 
 
 
 
Only the scopoletin, scoparone, vomifoliol and syringic acid showed AChE inhibition 
at IC50 <100 µg/ml. The studies have also shown that naturally occurring as well as 
the chemically synthesised coumarin analogs exhibit potent AChE inhibitory activity 
[359]. Coumarin ring seems to be essential for the optimal activity and its replacement 
with related structural moiety such as chromone is associated with loss of AChE 
inhibitory activity. The substituents at coumarin moiety particularly at 6th and 7th 
position also influence the activity in a significant manner. The presence of electron-
donating groups such as ÎOCH3, Î OH, and ÎNH2 increase the activity and it has 
been generally attributed to increase in lipophilicity of compounds [360]. This might 
explain good activity of scopoletin (IC50 51.00±0.02 µg/ml) and scoparone (IC50 
86.58±0.05 µg/ml) as both have electron donating groups at position 6th and 7th. The 
presence of bulkier substituents at 6th and 7th positions of the coumarin is associated 
with significant loss in AChE inhibitory activity indicating the critical role of 
electronic as well as steric effects in influencing the AChE inhibitory activity [360], 
this explains why scoparone has higher IC50 due to it having bulkier two methoxy 
groups. 
 
Up to date, quite a lot of studies have reported affirmative effects of phenolics in 
neurodegenerative diseases depending upon their antioxidative properties [361]. 
However, there has been a small number of data on AChE inhibitory activities of 
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phenolic compounds. Among the phenolics isolated in this study only syringic acid 
exhibited good AChE inhibition (IC50 29.53±0.19 µg/ml), lowest of all compounds 
tested. The literature concerning the role of phenolic acids and their derivatives in the 
neuroprotection of the CNS is, however, still incomplete. Thus the actual mechanism 
of inhibition needs to be investigated. Cyclohexenone derivatives, vomifoliol had 
moderate AChE inhibition (IC50 96.64±0.09 µg/ml), which is to the best of our 
knowledge the first to be reported. 
 
11.4.4 Antiparasitic activity 
 
Only scopoletin exhibited moderate antileishmanial activity (IC50 163.30±0.32 µg/ml) 
followed by lioxin, vomifoliol, scoparone and (+)-catechin. Poor activity of scopoletin 
was noted against Giardia intestinalis and Entamoeba histolytica while the others 
were not tested against them. Comparing the anti AChE and antiparasitic activity, it 
can be deduced that same compounds seemed active in both assays. Choline is the 
precursor of phosphatidylcholine (PC), a main component of Leishmania 
promastigote membranes [362]. Therefore, inhibition of choline formation may de-
crease Leishmania survival. This hypothesis can be tested by using inhibitors of the 
acetylcholinesterase enzyme (AChE), which catalyzes the hydrolysis of acetylcholine 
to choline and acetic acid, as leishmanicidal compounds. This may identify another 
mechanism of action for leishmanicidal activity [363].  
 
The lactone groups present in coumarins are also present in the structures of 
Annonaceous acetogenins that show leishmanicidal activity [364]. The AChE inhibi-
tory activity of a previous study on scoparone indicates a possible action mechanism 
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d{" fkutwrvkpi" vjg" xkcdknkv{" qh" ngkujocpkcÓu" egnn" ogodtcpgu. There has been a 
hypothesis that the coumarin and scoparone have mechanism of action acting on the 
same pathway as above compounds, resulting in a net negative effects on choline 
uptake by the parasite [363]. Only flavonoid (+)-catechin was tested in this study. 
Flavonoids however, are able to inhibit acetylcholine hydrolysis and interfere in the 
PC due to their low concentration of choline precursor from the host. Nevertheless, 
the leishmanicidal activity of these compounds may be related to their ability to 
chelate iron (Fe), depriving this essential nutrient from the intracellular forms [365].  
 
11.4.5 Anticancer activity 
 
In this study, scopoletin displayed potent anticancer effect against breast cancer cell 
line MDA 468 (GI50 0.09±0.25 µg/ml) and colorectal cancer cell line HT-29 (GI50 
0.17±0.05 µg/ml), the latter being more significant that positive control doxorubicin 
(GI50 0.69±0.06 µg/ml). Previously studies on scopoletin have shown it to inhibit the 
cell proliferation by inducing cell cycle arrest and the increase of apoptosis in human 
prostate tumor cells [366], and it induced apoptosis of HL-60 cells [367]. The ability 
of scopoletin have been said to induce programmed cell death in leukemic cells 
representing a novel and important aspect of the discussion of the anti-tumoral effects 
of various plants containing scopoletin [367]. In this study, scopoletin has shown 
potent growth inhibition of these two cell lines warranting further study. 
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11.4.6 Antibacterial activity 
 
All isolated compounds tested against Staphylococcus aureus ATCC 11632 showed 
bacterial growth inhibition. Scopoletin, scoparone, hyperin, cynaroside and syringic 
acid had bactericidal effect <100 µg/ml. Only scopoletin had bactericidal effect and 
complete kill at MBC 50.00 µg/ml. The antibacterial properties of coumarins were 
first recognised in 1945 when an investigation with dicoumarol was found to inhibit 
the growth of several strains of bacteria. All the methods reported in the study of the 
antibacterial activity of coumarins were disc diffusion methods [368]. It has then been  
suggested that coumarins possess antibacterial activity act selectively against Gram-
positive microorganisms [368]. Free hydroxyl group at position 7 has been shown to 
be important for antibacterial activity [298] as confirming the activity of scopoletin 
that has free 7-OH. 
 
11.4.7 Formulation of scopoletin as a gel 
 
Previously study by Seon et al. [369] have demonstrated scopoletin to inhibit 
tyrosinase kinase with an IC50 of 10.2 µg/ml suggecting its possible use in skin aging 
and preventive activities. Biosynthesis of melanin in animals is normally initiated 
through the oxidation of tyrosine into DOPA by tyrosinase which is the rate limiting 
enzyme in this pathway. The production of abnormal pigmentation such as melasma, 
freckles, senile lentigines, and other forms of melanin hyperpigmentation could be a 
serious aesthetic problem [369]. In this study scopoletin was found to exhibit potent 
antioxidant, anti-inflammatory and antibacterial properties. Scopoletin has been 
studied to have good pharmacokinetics data with good absorption in the stomach and 
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colon of rats [370]. Reported physical properties of scopoletin which passes the 
Lipinsky rule (mass < 500, log鶏 < 5, donor count < 5, and acceptor count < 10), for 
possible lead compound in drug discovery [371] and, in agreement with its potent 
antioxidant power, good anti-inflammatory and antibacterial activity enables it to be 
considered for a formulation for further test and development.  
 
Transdermal drug delivery offers the following advantages over oral administration: 
(1) peak and valley levels in the serum are avoided; (2) first-pass metabolism is 
avoided and the skin metabolism is relatively low; (3) less frequent dosing regimens 
is needed due to the maintenance and longer sustainability of zero-order drug delivery 
and (4) less inter-subject variability occurs [372]. Other advantages listed include 
aspects such as the accessibility of the skin; a relatively large surface area for 
absorption and the fact that it is non-invasive make it more patient compliant [373]. 
Thus, an external formulation suitable for cosmetic use (skin hyperpigmentation, acne 
and wrinkle protection) and for medicinal use as an anti-inflammatory gel was 
derived. The formulation was prepared with aloe vera gel as a base due to the well 
known skin and medicinal properties of aloe [374]. Orange oil was used as studies 
have shown the limonene (moneterpene) content has a high ability to enhance in vitro 
percutaneous transport greater than conventional lipophilic penetration enhancing 
eqorqwpfu" *g0i0." Urcp̶" 42." g-bisabolol, oleic acid) and hydrophilic penetration 
enhancing compounds (e.g., ethanol, polyethylene glycol 600, 1,8-cineole) [375]. 
Further studies on the efficacy of the gel and penetration test are required. 
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11.5 Conclusion 
 
For the first time, eight compounds (scopoletin, scoparone, (+)-catechin, lioxin, 
cynaroside, hyperin, vomifoliol and syringic acid) were isolated from Canarium 
patentinervium Miq. Three of these compounds (vomifoliol, lioxin and syringic acid) 
were isolated for the first time from the genus Canarium. These compounds were then 
subjected to a range of biological assays, all reported for the first time from this plant.  
 
Canarium patentinervium Miq. is a rare plant from the family of Burseraceae and 
genus Canarium found in Asia Pacific region previously recorded for its usage in 
wound healing by the indigenous people of Malaysia. One of the objectives of this 
study was to ascertain the pharmacological and phytochemical aspect for the 
ethnopharmacological usage. Wound healing involves manifold inflammatory 
processes of which notably the massive release of leukotrienes from arachidonic acid 
via the 5-lipoxygenase pathway (5-LOX) and the generation of nitric oxide (NO) from 
inducible nitric oxide synthase (iNOS). Of note, nitric oxide (NO) is a free radical, 
and the generation of cytokines involves a reactive oxygen species (ROS) outburst. 
Therefore, agents able to block the enzymatic activity of 5-LOX and to scavenge free 
radical are of immense interest against inflammatory conditions which englobe not 
only epidermal insults but also neurodegeneration and obesity.  
 
Cells produce superoxide anion (O2&), peroxide anion (HO2&), and hydroxyl ion (HO&) 
as part of the physiological aerobic metabolism which are quickly scavenged by 
cytoplasmic antioxidant defense system. However, in the event of ageing or 
pathologies, the antioxidant defense system is overwhelmed, and cells suffer massive 
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oxidative stress leading eventually to carcinogenesis or apoptosis. In fact, oxidative 
stress is the main causative factor for cholinergic and dopaminergic neurons apoptosis 
hence CF" cpf" RctmkpuqpÓu" fkugcug" *RF+. In addition, there is a growing body of 
evidence that point to the fact that 5-LOX inhibitors are of immense therapeutic 
values. The various isolated secondary metabolites clearly demonstrate various potent 
biological activities that substantiate the ethnopharmacological claim.  
 
Given the aforementioned evidence it is tempting to speculate that Canarium 
patentinervium Miq. represents an exciting scaffold from which to develop leads for 
treatment of neurodegenerative diseases. 
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CHAPTER 12 
GENERAL CONCLUSIONS 
 
The objectives of the study were to: 
 
i. Extraction of leaves and barks of plant with solvents of different 
polarity to obtain crude extract with solvents of different polarity.  
ii. Investigation of the possible secondary metabolite types present in 
the crude extracts of leaves and barks with qualitative 
phytochemical analysis.  
iii. Isolation and identification of the chemical compounds responsible 
for the antibacterial and antioxidant activity in the most active 
extract through bioassay-guided fractionation using liquid-liquid 
extraction or solvent partioning, column chromatography, thin 
layer chromatography (TLC) and nuclear magnetic resonance 
(NMR).  
iv.  Investigation of the antioxidant activity of the crude extracts of 
both leaves and barks using the 2,2-diphenyl-1-picrylhydrazyl 
(DPPH) radical scavenging assay, ferric reducing ability of plasma 
*HTCR+"cuuc{."4.4Ó-Azino-bis(3-ethyl-14 benzthiazoline-6-sulfonic 
cekf+" *CDVU+cuuc{." く-carotene bleaching assay and superoxide 
dismutase assay.  
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v. Investigation of the anti-inflammatory potential of the crude 
extracts against 5-lipoxygenase and cycloxygenase systems in 
vitro.  
vi. Investigation of the anti AChE potential of the crude extracts in 
vitro.  
vii. Investigation of the in vitro antibacterial activity of the crude 
extracts of leaves and barks using the disc diffusion assay and 
determination of minimum inhibitory concentration, minimum 
bactericidal concentration and death kill rate against four ATCC 
bacterial strains namely Gram-positive bacteria Staphylococcus 
aureus, Bacillus cereus, methicillin-resistant Staphylococcus 
aureus and Gram-negative Pseudomonas aeruginosa and ten 
clinical strain bacteria.  
viii. Investigation of the in vitro antifungal activity of the crude extracts 
of leaves and barks using the disc diffusion assay against three 
clinical strain fungi namely, Candida parapsilosis, Candida 
glabrata and Candida albicans. 
ix. Investigation of the anticancer activity of the crude extracts of the 
leaves and barks against human derived cell lines [HCT 116, colon 
cancer cell line and MCF-7 (ER+), MDA 468 (ER-) breast 
carcinoma] using MTT assay.  
x. Investigation of the in vitro anti-parasitic activity of the crude 
extracts of leaves and barks against Leishmania. donovani 
promastigotes, Entamoeba histolytica and Giardia intestinalis. 
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xi. Bioactivity screening of all isolated compounds using the same 
bioassay as mentioned in iii-ix. 
 
The following appropriate conclusions were drawn based on the experimental data 
obtained. 
i. Extraction of samples 
Extraction was done with maceration with solvents of increasing 
polarity.The yield for the hexane, chloroform and ethanol extract of leaves 
were 1.25 %, 1.11 % and 6.45 % respectively. The yield for the hexane, 
chloroform and ethanol extract of barks was 1.04 %, 0.4 % and 2.61 %. 
Crude extracts were kept at -20oC until further use. 
 
ii. Phytochemical analysis 
Phytochemical analysis of Canarium patentinervium Miq. revealed 
presence of tannins and flavonoids  in the ethanol extract of leaves and 
barks. Steroids were detected in the ethanol extract of leaves and all tested 
bark extracts.  Results from our phytochemical analysis revealed that the 
ethanol extract of leaves and barks of Canarium patentinervium Miq. 
accumulate substantial amounts of flavonoids and tannins which could be 
possibly result in antioxidant or antibacterial activity.  
 
iii. Isolation of biologically active compounds 
Eight compounds were isolated for the first time from Canarium 
patentinervium Miq. using various isolation techniques such as TLC, CC, 
HPLC and identified with NMR method. Compounds isolated scopoletin, 
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scoparone, (+)-catechin, hyperin, cynaroside, lioxin and syringic acid were 
phenolics while vomifoliol was a norsesquiterpene with a cyclohexenone 
ring. Lioxin, syringic acid and vomifoliol were isolated from this genus 
Canarium for the first time. 
 
iv. Antioxidant activity 
The ethanol extract of leaves and barks displayed superior antioxidant 
capacities. The EC50 values of the samples were consistently low in SET 
methods (ABTS, DPPH and FRAP assay) superior to standard as opposed 
vq" JCV" ogvjqf" *く-carotene bleaching assay). The present study 
demonstrates that Canarium patentinervium Miq. is a potent source of 
antioxidants that exhibits its antioxidant activity predominantly via the 
SET method. 
 
Compounds (+)-catechin and hyperin exhibited the most consistent free 
radical scavenging capability across the five antioxidant assay. Flavanols, 
namely here (+)-catechin and flavonol (hyperin) are more effective free 
radical scavengers than flavones (cynaroside). Hyperin and (+)-catechin 
have significantly lower IC50 (0.75±0.03 µg/ml and 0.94±0.27 µg/ml 
respectively) compared to SOD enzyme. Between both coumarins, 
scopoletin exhibited potent antioxidant activity compared to scoparone. It 
had significantly lower IC50 values in ABTS (IC50 1.08±0.03 µg/ml) 
compared to ascorbic acid (IC50 1.54±0.03 µg/ml) and lower values in 
FRAP assay (IC50 49.00±0.64 µg/ml) than quercetin (IC50 86.00±0.24 
µg/ml) and ascorbic acid (IC50 347.00±0.23 µg/ml). Vomifoliol displayed 
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low DPPH activity (IC50 >100 µg/ml), moderate activity is noted in ABTS 
(IC50 560:;ł2026" -i1on+" cpf" rqvgpv" く-carotene bleaching activity was 
noted (IC50 6.85±0.37 µg/ml). 
 
 
v. Anti-inflammatory activity 
In view of dual inhibition of 5-LOX and COX activity, the ethanol extract 
of leaves seemed to have moderate inhibition against 5-LOX and good 
inhibition against COX enzymes (selective COX-2). Chloroform extract of 
the bark though had good 5-LOX inhibition but did not have activity 
cickpuv"EQZ"gp¦{ogu"dgnqy"322"たi1on0 
 
In the 5-LOX inhibition assay, all isolated compounds displayed 
significantly lower IC50 compared to positive control NDGA.  Both 
scoparone and scopoletin (IC50 0.20±0.01 µg/ml and 0.34±0.01 µg/ml 
respectively) had the most potent 5-LOX enzyme inhibition (Figure 11.2) 
which was more than eightyfold compared to NDGA (IC50 29.19±0.02 
µg/ml). This was followed by syringic acid (IC50 1.38±0.03 µg/ml), 
hyperin (IC50 3.02±0.02 µg/ml), vomifoliol (IC50 8.72±0.02 µg/ml), (+)-
catechin (IC50 16.10±0.03 µg/ml), lioxin (IC50 17.79±0.03 µg/ml) and 
cynaroside (IC50 18.12±0.04 µg/ml). 
 
vi. Anti AChE activity 
Chloroform extract of the barks displayed the best activity (IC50 = 
::07;ł2036"たi1on+"cu"qrrqugf"vq"icncpvjcokpg"*KE50 ?"2096ł2028"たi1on+0"
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The ethanol extract of barks and leaves follow through with IC50 = 
3:8022ł2037" たi1on" cpf" KE50 ?" 423046ł2037" たi1on" tgurgevkxgn{+0"Jgzcpg"
extracts of bark and leaves and the chloroform extract of leaves had the 
lowest enzyme inhibition activity (IC50 ?" 792022ł202:" たi1on." KE72" ?"
:64022ł2047" たi1on" cpf" KE50 ?" 39:2022ł2046" たi1on" tgurgevkxgn{+0" The 
potency of activity against AChE was BC > BE > LE > BH >LH > LC.  
 
Only 4 compounds showed good to moderate enzyme inhibition namely 
syringic acid (IC50 29.53±0.19 µg/ml), scopoletin (IC50 51.00±0.02 µg/ml), 
scoparone (IC50 86.58±0.05 µg/ml) and vomifoliol (IC50 96.64±0.09 
µg/ml). Rest of the compounds showed poor enzyme inhibition with IC50 
values >100 µg/ml. 
 
vii. Antimicrobial activity 
All crude extracts of Canarium patentinervium Miq. under investigation 
exhibited exceptional concentration-dependent antimicrobial activity 
against both Gram-positive and Gram-negative bacteria. The most 
promising activity was displayed against Gram-positive bacteria 
Staphylococcus aureus, MRSA, Bacillus cereus and Gram-negative 
bacteria and Pseudomonas aeruginosa, Klebsiella sp, Klebsiella 
pneumoniae ESBL and yeast Candida parapsilopsis. The antimicrobial 
activity exhibited by the bark extracts and ethanol extract of leaves against 
MSSA and MRSA indicates exceptional antimicrobial activity. All the 
tested bacterias were susceptible to either bark or leaf extracts. 
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All isolated compounds tested against Staphylococcus aureus ATCC 
11632 showed bacterial growth inhibition. Scopoletin, scoparone, hyperin, 
cynaroside and syringic acid had bactericidal effect <100 µg/ml. Only 
scopoletin had bactericidal effect and complete kill at MBC 50.00 µg/ml. 
 
viii. Antifungal activity 
The most promising activity was displayed against yeast Candida 
parasilopsis. The ethanol extracts and hexane extract of barks also showed 
inhibition against Candida parasilopsis with a cidal and static action 
respectively. 
 
ix. Anticancer activity 
The chloroform and ethanol extract of barks showed good antitumor 
activities with GI50 values of 23.44±0.05 たi1on"cpf"56062±0.21 たi1on0"Vjg"
most susceptible cell lines were found to be the breast cancer cell line, 
MDA 468. 
 
Scopoletin displayed potent anticancer effect against breast cancer cell line 
MDA 468 (GI50 0.09±0.25 µg/ml) and colorectal cancer cell line HT-29 
(GI50 0.17±0.05 µg/ml), the latter being more significant that positive 
control doxorubicin (GI50 0.66±0.60 µg/ml). 
 
x. Anti parasitic activity 
The hexane extract of leaves showed moderate antileishmanial activity 
with IC50 xcnwgu"qh"479062ł2052"たi1on0"Vjku"eqwnf"dg"fwg"vq"guugpvkcn"qknu"
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present in the hexane extracts as shown previously in the family of 
Burseraceae [216]. Only ethanol extracts showed activity against Giardia 
intestinalis and Entamoeba histolytica at concentration of 500 たi1on0"
Other extracts were inactive against these two intestinal parasites. 
 
Scopoletin was tested against all three parasite amd it was more potent 
against Leishmania donovani (IC50 163.30±0.32 µg/ml) and MIC of >200 
µg/ml for both Giardia intestinalis and Entamoeba histolytica. Sensitivity 
of Leishmania donovani is then followed by with the presence of lioxin 
(IC50 211.48±0.32 µg/ml), vomifoliol (IC50 302.80±0.33 µg/ml), scoparone 
(IC50 329.90±0.32 µg/ml) and (+)-catechin (IC50 478.93±0.28 µg/ml). 
 
In Chinese folk medicine, Canarium album (Lour.) Raeusch has been used for 
treatment of various diseases ranging from cardiovascular, gastrointestinal and 
toxicities while Canarium schweinfurthii Engl. has been used by traditional healers as 
a remedy for diabetes mellitus in southern Senegal while in Congo and Central 
African Republic the plant is used in fever, as stimulant, emollient, in post-partum 
pain, constipation, malaria, diarrhoea, sexual infections and rheumatism (Chapter 1) 
to name a few. The fact only 12 % of 75 species of Canarium have been studied for 
their pharmacological activities promises an unopened crypt of various secondary 
metabolites as lead compounds and biological effects that needs to be uncovered and 
investigated. Thus, by using an ethnopharmacological approach, the investigation of 
Canarium patentinervium Miq. a plant from Malaysia that has been used by the orang 
asli (indigenous people) for healing wounds was done. Crude extracts and isolated 
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secondary metabolites were investigated for their various activities.. Three out of 
eight compounds were isolated for the first time from this genus of 75 species 
(Canarium). Six kinds of major biological effects were evident in the crude and 
compounds namely, antioxidant, antibacterial, anti-inflammatory, anti AChE, anti 
parasitic, and anticancer all of which were reported for the first time from this plant. 
This study is therefore a small leap in the field of an important endeavor for the 
discovery of potent biologically active molecules for the treatment of various 
diseases. This discovery also opens forth a pathway where biologically active 
molecules isolated from biosynthesis of plants can now pose as lead molecules in the 
field of synthetic chemistry for drug discovery. 
 
As modern cultures and scientific advances spread around the world, the depth of the 
knowledge store of traditional use still remains crucial. The full significance of the 
indigenous knowledge forfeited may not be realised. It is thus important that the 
knowledge be documented and the traditional use be given some credence through 
modern scientific studies. Canarium patentinervium Miq. is such  an example. 
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CHAPTER 13 
RECOMMENDATIONS FOR FUTURE WORK 
 
This study intends to contribute towards the knowledge base of plant species with 
therapeutic potential. Material for this study was only collected from a single site. To 
account for possible geographical and chemotypic variation material should be 
studied from several populations. 
 
i. Antioxidant activity 
The isolated compounds should be tested for synergistic or antagonistic effect by the 
construction of an isobologram. 
 
ii. Antimicrobial activity 
̋" Kuqncvkqp" cpf" uvtwevwtcn" gnwekfcvkqp" qh" vjg" eqorqwpf1u from the tannin fraction 
responsible for the antimicrobial activity of Canarium patentinervium Miq. should be 
investigated. 
̋"Fgvgtokpcvkqp"qh"u{pgtikuvke."cpvciqpkuvke"or additive effects should be investigated. 
 
iii. Anti-inflammatory Activity 
̋ The actual efficacy of an anti-inflammatory activity needs to be validated by testing 
the isolated bioactive compounds in a cell-based environment (in vitro) and in a 
biological system (in vivo). 
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̋" The effects of these active compounds on the suppression of the COX-2 gene 
expression, requires investigation and clarification. The effectiveness of interaction of 
these extracts and isolated compounds, including the flavonoid derivatives, with other 
pro-inflammatory biochemical pathways may be assessed, and the possible structure-
activity relationships determined. This will provide a better understanding of the 
possible mode of action. 
 
iv. Anti AChE activity 
̋ More secondary metabolites should be isolated and tested in vitro as it may lead to 
the development of novel treatments in the global struggle against neurodegenerative 
diseases. 
̋ All the compounds should also be subjected to cell based study to investigate the 
mechanism of actions. 
 
v. Anticancer 
̋" Vjku" uvwf{" jcu." ykvjqwv" c" foubt, proven the existence of other compound or 
compounds  (besides scopoletin) with potential in vitro anticancer activity in different 
species and extracts of Canarium patentinervium Miq. Activity-guided fractionation, 
isolation and identification of these compounds is imperative and may lead to the 
development of novel treatments in the global struggle against cancer and cancer-
related ailments. 
 
vi. Antiparasitic activity 
̋ More secondary metabolites should be isolated and tested for the efficacy against 
parasitic kill and it should be tested against various clinical strains of parasites. 
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vii. Toxicity 
̋"Yjkng"kpfkigpqwu"Canarium patentinervium Miq. has edible fruit, it is important to 
note that in order to establish a toxicity profile, other cell lines should be investigated 
such as the liver HepG2 cells, as well as in vivo studies. 
 
viii. Phytochemical investigation 
̋" Tgugctej" qp" vjg" pqp-volatile compounds warrant further study. Further analysis 
must be conducted using different detectors and chromatographic techniques such as 
liquid chromatography Î mass spectrometry, to provide a greater insight of the 
phytochemical composition of this species. 
̋" Rncpvu" rtqfweg" c" ykfg" tcpge of secondary metabolites, which may prove to be 
invaluable in development of drugs, flavours, fragrances, dyes, anti-oxidants and 
insecticides. It is thus important to locate and determine the role of these secondary 
metabolites in plants and unravel their biosynthesis.  
 
Finding new leads for drug development, and determining the biosynthesis of such 
products, thus requires a different approach which researchers are developing. 
Metabolomics investigates the end products of cellular functions. The levels of these 
metabolites are viewed as a response of the biological systems to environmental or 
genetic manipulation. The use of metabolomics in plant studies will enable the 
characterisation and differentiation of genotypes and phenotypes based on the levels 
of metabolites, and also aid in the rapid screening of multiple extracts giving an 
exceptionally broad overview of the chemistry. This may also provide a means of 
improving the production of certain metabolites in plants through genetic engineering. 
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APPENDIX A: NMR DATA 
 
Figure A1: 1H NMR spectrum of compound 1 
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Figure A2: 13C NMR spectrum of compound 1 
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Figure A3: 1H NMR spectrum of compound 2 
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Figure A4: 13C NMR spectrum of compound 2 
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Figure A5: 1H NMR spectrum of compound 3 
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Figure A6: 13C NMR spectrum of compound 3 
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Figure A7: 1H NMR spectrum of compound 4 
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Figure A8: 13C NMR spectrum of compound 4 
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Figure A9: 1H NMR spectrum of compound 5 
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Figure A10: 13C NMR spectrum of compound 5 
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Figure A11: 1H NMR spectrum of compound 6 
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Figure A12: 13C NMR spectrum of compound 6 
  
368 
 
 
 
 
 
Figure A13: HMBC spectrum of compound 7 
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Figure A14: COSY spectrum of compound 7 
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Figure A15: 1H NMR spectrum of compound 7 
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Figure A16: 13C NMR spectrum of compound 7 
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Figure A17: 1H NMR spectrum of compound 8 
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Fiigure A18: 13C NMR spectrum of compound 8 
  
374 
 
 
APPENDIX B:  HPLC CHROMATOGRAMS 
 
Figure B1: HPLC chromatogram for compound 6 
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Figure B2: HPLC chromatogram for compound 7 
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Figure B3: HPLC chromatogram for compound 8 
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Six different extracts of Canarium patentinervium Miq. (Burseraceae) leaves and barks were 
screened for their phytochemical composition, and antimicrobial and free radical scavenging 
activities. Among the different extracts tested, the ethanol extract of leaves showed significant 
antimicrobial and radical scavenging activities. The most susceptible micro-organisms were 
found to be Gram-positive bacteria (Staphylococcus aureus, methicillin-resistant Staphylococcus 
aureus or MRSA) and Gram-negative bacteria (Pseudomonas aeruginosa). Phytochemical analysis 
of the extracts revealed that the antimicrobial and the radical scavenging activities are mainly 
due to the presence of tannins and flavonoids. The results obtained suggest that Canarium 
patentinervium 
Miq. could be exploited in the management of various infectious diseases. 
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ABSTRACT 
The genus Canarium L. consists of 75 species of aromatic trees which are found in the rainforests of 
tropical Asia, Africa and the Pacific. The medicinal uses, botany, chemical constituents and 
pharmacological activities are now reviewed. Various compounds are tabulated according to their 
classes their structures are given. Traditionally Canarium L. species have been used to treat a broad 
array of illnesses. Pharmacological actions for Canarium L. as discussed in this review 
include antimicrobial, antioxidant, anti-inflammatory, hepatoprotective and antitumor activity. 
 
Keywords: Canarium L., Burseraceae, antibacterial, antioxidant, pharmacology, secondary 
metabolites 
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Despite increasing resistance among clinically important gram-negative and gram-positive pathogens 
to many common antibacterial agents, many large pharmaceutical companies are showing decreased 
interest in this product area that is so critical to public health. This downturn in antibacterial discovery 
and development, in turn, is leaving us vulnerable to emerging resistance, particularly to recently 
arrived vancomycin-resistant Staphylococcus aureus and multiply resistant, gram-negative bacilli for 
which we do not have adequate antimicrobial therapy in the future. Rainforest plants possess 
therapeutic potential, including antimicrobial activity [1,2]. Therefore, this study is a screening 
program of several extracts from three endemic medicinal plants in Malaysian rainforest which have 
not been fully discovered and investigated for their antimicrobial properties against several Gram-
positive and Gram-negative bacteria strains. These plants included families namely Annonaceae, 
Ebenaceae and Burseraceae. The antibacterial activity of hexane, chloroform and ethanol fractions of 
some parts of Uvaria grandiflora Roxb. (Annonaceae), Diospyros wallichii King & Gamble 
(Ebenaceae) and Canarium patentinervium Miq. (Burseraceae) was determined against Gram-positive 
bacteria Bacillus cereus ATCC10876, Staphylococcus aureus ATCC11632, Methicilin resistant 
Staphylococcus aureus ATCC43300 and Gram- negative bacteria Pseudomonas aeruginosa 
ATCC10145 and Escherichia coli ATCC10536 using the disk diffusion method. Results showed that 
the bark ethanol fraction of U. grandiflora, the fruit hexane fraction of D. wallichii and the leaf ethanol 
fraction of C.patentinervium are active (Table 1). The results indicate that these medicinal herbs can be 
used as active and potent ingredients in the formulation of natural antibacterial products. 
References:  
1- Wiart C (2006) Medicinal Plants of the Asia-Pacific: Drugs from the Future, World Scientific, 
Singapore. 
2. Harvey AL (1999) Trends Pharmacol Sci 20: 196-198. 
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Bioassay guided fractionation of an ethanol extract of leaves of Canarium patentinervium Miq. 
(Burseraceae Kunth.) led to the isolation of scopoletin. The structure of this coumarin was elucidated 
based on spectroscopic methods including nuclear magnetic resonance (NMR-1D and 2D) and mass 
spectrometry. Scopoletin inhibited the enzymatic activity of 5-lipoxygenase and acetyl cholinesterase 
with an IC50 equal to 1.76 ± 0.01 航M and 0.27 ± 0.02mM, respectively, and confronted oxidation in 
the ABTS, DPPH, FRAP, and 紅-carotene bleaching assay with EC50 values equal to 5.62 ± 0.03 航M, 
0.19 ± 0.01 mM, 0.25 ± 0.03mM and 0.65 ± 0.07 mM, respectively. Given the aforementioned 
evidence, it is tempting to speculate that scopoletin represents an exciting scaffold from which to 
develop leads for treatment of neurodegenerative diseases. 
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The barks and leaves extracts of Canarium patentinerviumMiq. (Burseraceae Kunth.) were investigated 
for cyclooxygenase (COX) and 5-lipoxygenase (LOX) inhibition via in vitro models.The 
corresponding antioxidative power of the plant extract was also tested via nonenzyme and enzyme in 
vitro assays.The ethanolic extract of leaves inhibited the enzymatic activity of 5-LOX, COX-1, and 
COX-2 with IC50 equal to 49.66±0.02 航g/mL, 0.60±0.01 航g/mL, and 1.07±0.01 航g/mL, respectively, 
with selective COX-2 activity noted in ethanolic extract of barks with COX-1/COX-2 ratio of 1.22.The 
ethanol extract of barks confronted oxidation in the ABTS, DPPH, and FRAP assay with EC50 values 
equal to 0.93 ± 0.01 航g/mL, 2.33 ± 0.02 航g/mL, and 67.00 ± 0.32 航g/mL, respectively, while the 
ethanol extract of leaves confronted oxidation in 紅-carotene bleaching assay and superoxide dismutase 
(SOD) assay with EC50 value of 6.04 ± 0.02 航g/mL and IC50 value of 3.05 ± 0.01 航g/mL. The ethanol 
extract acts as a dual inhibitor of LOX and COXenzymes with potent antioxidant capacity.The clinical 
significance of these data is quite clear that they support a role for Canarium patentinervium Miq. 
(Burseraceae Kunth.) as a source of lead compounds in the management of inflammatory diseases. 
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